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Abstract 
 
 
 
Four type II toxin-antitoxin (TA) systems were previously identified in 
Burkholderia pseudomallei K96243. Type II TA toxins are able to induce cell 
growth arrest or death by interfering with key processes within the organism. 
BPSS0390-0391 is one of the TA systems previously identified and has 
homology to hicBA system in Acinetobacter baumannii. B. pseudomallei HicA is 
able to cause a reduction in the number of culturable cells after expression in E. 
coli. This study aimed to characterise B. pseudomallei HicA in three ways: by 
inducing expression of HicA in bacterial species other than E. coli, by identifying 
amino acids in HicA involved in toxicity and neutralisation by the antitoxin HicB 
and by examining the interaction of HicA with other TA antitoxins identified 
within B. pseudomallei genome. 
A broad host range plasmid encoding BPSS0390 was transformed into a range 
of Gram negative bacteria including Yersinia pseudotuberculosis IP32953, 
Vibrio vulnificus E64MW, Salmonella enterica serovar Typhimurium SL1344 
and Burkholderia thailandensis E264. Expression of BPSS0390 was toxic in all 
bacterial species tested, despite the presence of antitoxin BPSS0391 
homologues in some species. Unregulated expression in E. coli resulted in the 
appearance of escape mutants encoding non-toxic variants of HicA.  
An alanine scanning mutagenesis study of HicA identified 20 mutants where 
toxicity was abolished despite high levels of expression, but identified no 
mutants that affected TA complex formation. 
Finally an existing co-expression assay was modified to examine interactions 
between HicA and other type II TA antitoxins in B. pseudomallei. The assay 
revealed no interaction between HicA and non-cognate antitoxins and clarified 
the role of IPTG as an inhibitor of PBAD promoter on the arabinose operon. 
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1.0 Toxin-antitoxin (TA) systems: classification, biological 
functions and applications 
TA systems typically consist of a gene pair, where one gene encodes a 
protein toxin and the other a cognate antitoxin. The unstable antitoxin molecule 
is able to counteract or neutralise the more stable toxin or its action. However, if 
production of the antitoxin is stopped, the rapid degradation of the remaining 
antitoxin molecules allows toxin activation. Free toxins are then able to induce 
cell growth arrest or death by targeting key cellular processes (Unterholzner et 
al. 2013). 
Initially identified on plasmids, TA modules prevent plasmid loss at cell 
division though post-segregational killing (PSK) (Ogura & Hiraga 1983). 
Daughter cells that lack the plasmid bearing the TA module experience a rapid 
decrease in antitoxin levels and the activated toxin kills the plasmid-free cell 
(Brantl 2012; Unterholzner et al. 2013). Since then, many chromosomally 
encoded TA systems have been identified and characterised, although their 
biological functions are less clear. 
1.0.1 Classification of TA systems 
It is possible to classify TA systems into six different types, based on the 
antitoxin and its interaction with its cognate toxin (Figure 1.1). All antitoxins 
regulate toxin activity (Brantl & Jahn 2015; Gerdes & Maisonneuve 2012). 
1.0.1.1 Type I TA systems 
In type I systems, the antitoxin is a small antisense RNA molecule that 
binds to toxin-encoding mRNA through base pairing (Yamaguchi et al., 2011). 
The type I gene pair may be either; overlapping and convergently transcribed 
(cis-encoded antisense RNA antitoxin) or located apart and divergently 
transcribed (trans-encoded small RNA) (Brantl 2012; Brantl & Jahn 2015). 
19 
 
Originally identified on plasmids, chromosomal loci have since been discovered 
and may be present in multiple copies in both Gram-positive and Gram-negative 
bacteria. There is some evidence to suggest that the number of copies may be 
linked to the ecological niche of the host (Gerdes et al. 1985; Fozo et al. 2010; 
Fozo 2012). Antitoxins regulate toxin activity by either inhibiting translation of 
the toxin mRNA or promoting toxin mRNA degradation. Inhibition of translation 
may be direct, where the antitoxin binds at a region that overlaps the ribosome 
binding site (RBS) (Escherichia coli symE/SymR)(Kawano et al. 2007), or 
indirect where the antitoxin binds to the Shine-Dalgarno (SD) sequence of 
leader peptides required for translation of the toxin (E. coli  hok/Sok, 
ldrD/RdlD)(Gerdes & Wagner 2007). In E. coli tisB/IstR1 translation of the toxin 
is also indirectly inhibited, as the IstR antitoxin binds upstream of the translation 
initiation region (TIR) at an unstructured ribosome standby site and thus 
prevents ribosomes from binding and sliding into the TIR (Darfeuille et al. 2007). 
Meanwhile, in a different system in Enterococcus faecalis,  antitoxin RNAII and 
fst mRNA interact at different regions located apart and binding results in a 
partial RNA duplex, which improves stability of the mRNA and prevents 
translation (Weaver 2015). 
In all Bacillus subtilis type I systems investigated to date, the antitoxin binds at 
the 3’ end of the toxin mRNA to encourage degradation by endoribonuclease III 
(txpA/RatA, bsrE/SR5)(Durand et al. 2012; Meißner et al. 2016). Interestingly, 
one system, bsrG/SR4, promotes degradation of toxin mRNA and also induces 
a conformational change to block ribosome binding at bsrE RBS. This antitoxin 
has been described as bifunctional (Jahn & Brantl 2013; Brantl & Jahn 2015). 
Several other regulatory principles are used to ensure tight regulation of toxin 
expression. Ribosome binding at the toxin SD site is prevented by molecular 
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base pairing (tisB, shoB, bsrG, txpA) and translation initiation may be reduced 
by the use of unusual start codons. Additionally, txpA and yonT mRNAs have 
“perfect SD sequences” that are thought to effectively recruit but slowly release 
ribosomes. Often, some degree of mRNA processing is required to produce 
translationally competent molecules (hok, tisB, shoB) and toxin genes may only 
be transcribed under certain condition (tisB and symE). Stability of toxin 
transcripts has been observed to be temperature dependent and toxin SymE is 
prone to digestion by Lon protease (Durand et al. 2012; Gerdes & Wagner 
2007; Kawano 2012). 
Toxins are typically small, hydrophobic proteins with transmembrane domains 
capable of inducing membrane pores, impairing ATP synthesis and 
consequently affecting transcription, translation and replication, leading to cell 
death. TisB toxin from E. coli was shown to produce groups of narrow anion-
selective pores in the lipid bilayer, whilst Ldr toxin was able to cause nucleoid 
condensation, affecting purin metabolism and decreasing cAMP levels(Gurnev 
et al. 2012; Kawano 2012). Some toxins are enzymes; RalR cleaves methylated 
and unmethylated DNA, whilst SymE degrades RNA (Guo et al. 2014; Gerdes & 
Wagner 2007) 
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Figure 1.1: Classification of toxin-antitoxin systems. Toxins are coloured 
orange and antitoxins blue; non-toxic activities labelled in black font, and toxic 
activities labelled in grey. TA systems are classified into 6 different types: type I: 
the RNA antitoxin base pairs with toxin mRNA to inhibit translation; type II: both 
toxin and antitoxin are proteins. Under stressful conditions, cellular proteases 
cleave antitoxins; type III: RNase toxin preferentially cleaves antitoxin, 
generating an RNA pseudoknot-toxin complex; type IV: Antitoxin stabilises 
bacterial filaments, antagonising toxin;  type V: the antitoxin GhoS is an RNase 
specific for the toxin ghoT mRNA; type VI: the SocA antitoxin is an adaptor 
protein that binds the SocB toxin to promote its degradation by ClpXP. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Chemical 
Biology, (Page & Peti 2016), Copyright 2016. 
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. 
1.0.1.2 Type II TA systems 
Both the toxin and antitoxin are small proteins. Typically, both genes are 
grouped onto a self-regulated operon with the antitoxin encoding gene 
upstream of the toxin encoding gene, although there are some exceptions, for 
example, the higBA and hicBA modules (Tian et al. 2001; Makarova et al. 
2006). Some three component systems have also been discovered, where the 
third component is either involved in regulating the activity of the promoter, such 
as the ω-ε-ζ system, identified on Streptococcus pyogenes  pSM19035 plasmid, 
where  ω  is the regulatory component (Zielenkiewicz & Cegłowski 2005), or 
enhancing TA complex formation, for example, the pasA/pasB/pasC module 
from plasmid pTF-FC2 from Thiobacillus ferrooxidans, where PasC enhances 
complex formation (Smith & Rawlings 1997). 
The antitoxin binds to the protein to form a protein-protein complex that remains 
inactive in the bacterial cytoplasm whilst conditions are not stressful. 
Autoregulation of transcription of the antitoxin or TA complex controls cellular 
levels of the complex; this process is sometimes augmented by conditional co-
operativity (Gerdes & Maisonneuve 2012; Garcia-Pino et al. 2010). Antitoxins 
are labile and prone to degradation by Lon or Clp family proteases, whilst the 
toxic protein is stabile (Diago-Navarro et al. 2010; Van Melderen et al. 1996). 
Toxins have diverse structures and cellular targets. Type II TA systems will be 
discussed in more detail later. 
1.0.1.3 Type III TA systems 
Similar to type I systems, the antitoxin is a small RNA molecule, which acts by 
binding the toxic protein directly. Two type III systems have been well 
characterised: toxN/ToxI and abiQ/AntiQ. toxN/ToxI system was identified on a 
23 
 
plasmid from Pectobacterium atrosepticum subspecies atroseptica (Fineran et 
al. 2009). Both genes were co-transcribed, with the antitoxin encoding gene 
upstream of the toxin encoding gene and both genes separated by a Rho-
independent transcriptional terminator. Occasional read through of this 
terminator results in an excess of antitoxin. ToxI antitoxin monomers are 
encoded by short tandem repeats that form a pseudoknot after sequence 
specific processing by ToxN, an RNase. Three ToxN proteins are bound by 
three ToxI  monomers to form a complex that inhibits toxin function (Fineran et 
al. 2009; Tim R Blower et al. 2011).  
Despite having only 31% sequence similarity to toxN/ToxI, abiQ/AntiQ has a 
similar gene organisation and the AntiQ is comprised of short tandem repeats 
that form pseudoknots. AbiQ is also an RNAse that cleaves repeats from its 
antitoxin (Samson et al. 2013; Brantl & Jahn 2015). Recent structure based 
homology searches and protein sequence comparisons identified three 
independent type III families, suggesting that this type of TA system is more 
diverse than previously thought (Blower, Short, et al. 2012). 
1.0.1.4 Type IV TA systems 
In this system, the antitoxin is a protein that acts as an antagonist of the toxin 
and does not interact with it directly. In the E. coli yeeU-yeeV (or ctbA-ctbB) 
system, the toxin inhibits polymerisation of cytoskeletal proteins MreB and FtsZ, 
preventing cytoskeletal assembly and altering cell morphology. Antitoxin YeeU  
counteracts YeeV by stabilising MreB and FtsZ polymers (Masuda et al. 2012). 
A second system, cptA-cptB (or ygfX-ygfY) had been described and has similar 
mechanisms and interactions (Masuda et al. 2012). 
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1.0.1.5 Type V systems 
Only one type V system has been characterised to date; ghoST from E. coli. 
The toxin (GhoT) is a small, membrane lytic peptide that causes a ghost cell 
phenotype (cells with damaged membranes), while GhoS is a protein antitoxin 
with sequence specific endoribonuclease activity, which degrades toxin mRNA. 
This prevents translation of the toxin and is the first example of protein antitoxin 
inhibiting toxin expression by mRNA cleavage (Wang et al. 2012). ghoST is also 
the first TA system to be regulated by another TA system. During stress, 
antitoxin GhoS mRNA is degraded by type II toxin MqsR, allowing translation of  
toxin genes, increasing ghost cell formation and persistence (Wang et al. 2014). 
1.0.1.6 Type VI TA system 
A sixth type of TA system has been recently proposed. The SocAB system, 
where both toxin and antitoxin are proteins, was recently identified in 
Caulobacter crescentus. However, the SocA antitoxin promotes degradation of 
the toxin by acting as a ClpXP protease adaptor for the SocB toxin. SocB toxin 
inhibits DNA replication elongation through a direct interaction with a β sliding 
clamp (Aakre et al. 2013; Markovski & Wickner 2013). 
1.0.2 Putative biological roles of TA systems 
Whilst the function of TA systems identified on plasmids is well understood, the 
role of chromosomal TA systems is more enigmatic (Frampton et al. 2012). 
Chromosomal TA systems are thought to be involved in maintaining the integrity 
of DNA, coping with stress and may also be linked to pathogenicity. 
Alternatively, chromosomally encoded TA systems may have no physiological 
function. The antitoxin gene is indispensable for cells carrying the cognate toxin 
gene, demonstrating strong interdependence and suggesting that TA loci act as 
selfish gene elements. Any physiological functions caused  by TA systems may 
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simply be a bi-product of  TA maintenance (Van Melderen & De Bast 2009). A 
description of putative roles of plasmid-borne and chromosomal TA systems is 
given below.  
 
1.0.2.1 Post-segregational killing (PSK) 
TA systems determine plasmid maintenance using PSK. In bacterial cells 
containing a plasmid with TA module, both the toxin and antitoxin will be 
expressed. If this plasmid is not transmitted to daughter cells, depletion of 
antitoxin levels through degradation will activate the more stable toxin. The toxin 
will then inhibit the growth of, or kill, plasmid- free cells, increasing the number 
of plasmid-containing cells within the growing population (Figure 1.2) 
(Unterholzner et al. 2013; Hernández-arriaga et al. 2014). 
 The first TA plasmid maintenance system described was the coupling cell 
division (ccd) type II system, which stabilised plasmid F 10-fold; when cells with 
only a single copy of the plasmid divided, daughter cells containing the plasmid 
were able to continue dividing, while in plasmid-free daughter cells, division was 
arrested after only a few divisions (Ogura & Hiraga 1983; Jaffe et al. 1985) . A 
similar mechanism was also observed when the first type I TA system, hok-sok, 
was identified and found to increase the stability of plasmid R1 by two orders of 
magnitude with no change in copy number (Gerdes et al. 1986). Together, 
these observations established the PSK concept (Hernández-arriaga et al. 
2014). More recently, PSK has been indirectly linked to virulence, for example, 
a pEMB1 plasmid recovered from E. coli isolated from soil, was found to contain 
a β-lactamase gene and a parDE TA system. The TA system enhanced plasmid 
stability in the absence of ampicillin (Lee et al. 2015).  
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PSK eliminates plasmid free cells from the population and increases the 
percentage of plasmid containing cells by vertical transfer (Hernández-arriaga 
et al. 2014). 
An alternative hypothesis suggests that PSK systems have evolved through 
benefitting host plasmids in environments where plasmids have to compete 
during horizontal transfer. A plasmid-encoded parDE PSK system mediated the 
exclusion of an isogenic ΔparDE plasmid, supporting this “competition” 
hypothesis, where the success of PSK systems results from plasmid-plasmid 
competition rather than plasmid-host relationship(Cooper & Heinemann 2000; 
Cooper et al. 2010) (Figure 1.2).  
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Figure 1.2: Advantage conferred by plasmid encoded TA systems. a) 
Vertical transmission increasing plasmid prevalence within a population by PSK. 
PSK+ (with TA system) plasmid is purple. When daughter cells do not inherit a 
plasmid copy, degradation of labile antitoxins by host proteases will free the 
toxin and lead to selective killing of plasmid-free bacteria. b) Horizontal 
transmission, PSK+ (with TA system) plasmid (in purple) and the PSK− (without 
TA system) plasmid (in black) belong to the same incompatibility group and are 
conjugative. Conjugants containing both plasmids are generated but only 
bacteria that maintain PSK+ plasmid will avoid toxin activation. Figure 
reproduced with permission from (Van Melderen & De Bast 2009). 
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1.0.2.2 Stabilisation of mobile genetic elements (MGEs) 
Chromosomally encoded TA modules located with genomic islands could 
stabilise MGEs, using a similar mechanism to TA systems located on plasmids  
(Pandey & Gerdes 2005; Makarova et al. 2011). A 100kb integrative and 
conjugative element (ICE) identified in clinical isolates of Vibrio chlorae and 
termed SXT, was found to contain a type II TA system, mosAT.  Expression 
from the mosAT locus was increased when SXT was excised from the 
chromosome before conjugation but MosA reduced expression from mosAT loci 
when integrated into the chromosome (Wozniak & Waldor 2009). A similar 
mechanism has also been observed in Acidithiobacillus ferrooxidans, where 
four TA systems were found to be exclusive to strains with the active mobile 
element ICEAfe1 and proposed to play a role in ICE maintenance (Bustamante 
et al. 2014). 
Superintergrons (SIs) are large, stable, chromosomal, genetic elements 
containing many gene cassettes, which are integrated by site specific 
recombination. Bioinformatic analysis has revealed that TA loci were found on 
large SIs but not small ones (Van Melderen 2010; Rowe-Magnus et al. 2003). 
Introduction of two TA systems from a Vibrio vulnificus SI into the E. coli 
chromosome was shown to prevent deletion of flanking DNA (Szekeres et al. 
2007), suggesting that TA systems located on MGEs could limit extensive gene 
loss. However, some chromosomally encoded TA systems, for example, dinJ-
yafQ of E. coli K12 and ccdo157 of E. coli O157: H7, could not prevent deletion of 
flanking DNA when inserted into the chromosome, indicating that perhaps 
different systems could have different functions, dependent on their location 
(Szekeres et al. 2007; Wilbaux et al. 2007; Hernández-arriaga et al. 2014). This 
notion is further supported by the observation that 2 higBA systems from V. 
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chlorae are very efficient at stabilising an unstable replicon (Christensen-
Dalsgaard & Gerdes 2006).  
Interestingly, three parDE systems identified in V. chlorae chromosome II were 
found within a SI and showed that chromosomal TA systems might exhibit PSK. 
The three ParE homologues were revealed to degrade chromosome I in V. 
chlorae cells that had lost chromosome II, suggesting that chromosome mis-
segregation encourages ParE mediated killing of aneuploid daughter cells 
(Yuan et al. 2011; Hernández-arriaga et al. 2014).  Chromosome II qualifies as 
a “bona fide” chromosome but replicates like the plasmid/phage P1 and so may 
have evolved from an MGE (Egan et al. 2005; Srivastava & Chattoraj 2007). 
1.0.2.3 Defence against bacteriophages 
The evolutionary arms race between bacteria and bacteriophages has led to 
considerable diversity in defensive strategies and chromosomal TA modules 
have been linked to this. The hok-sok (type I) system from E. coli plasmid R1 
was shown to exclude T4 phages and the mazEF (type II) system provoked 
abortive infection after attack by P1 bacteriophage (Pecota & Wood 1996; 
Hazan & Engelberg-Kulka 2004; Unterholzner et al. 2013).      
The type III toxN/ToxI system was initially identified as it was able to confer 
resistance against bacteriophages (Hernández-arriaga et al. 2014). The ToxN 
toxin acts as a sequence specific endoribonuclease, processing the toxI RNA to 
generate pseudoknots that bind ToxN. After bacteriophage infection, toxI RNA 
was degraded by an unknown mechanism, releasing ToxN, resulting in growth 
arrest of the infected cell, and subsequently preventing replication, and 
propagation of the phage within the bacterial population (Fineran et al. 
2009).Unsurprisingly, some phages have evolved sequences that can 
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neutralise ToxN by mimicking the toxI antitoxin sequence and allowing evasion 
of host defence systems (Blower et al. 2014; Blower, Evans, et al. 2012). 
1.0.2.4 Gene regulation 
There are several examples of TA toxins differentially shaping gene expression 
in bacteria by altering the transcriptome, or creating a specialised ribosome 
(Bertram & Schuster 2014).   
Overexpression of a VapC homologue identified in Mycobacterium smegmatis 
resulted in differential expression of 3% of the genome. Carbohydrate 
metabolism genes showed dramatic downregulation after overexpression of 
VapC, demonstrating how TA systems are able to influence bacterial 
metabolism (McKenzie et al. 2012).  
The endoribonuclease MazF from E. coli cleaves specifically at ACA sequences 
and so when induced, cleaves the bulk of all cellular mRNAs. Subsequently, up 
to 90% of encoded proteins are no longer produced, leading to growth 
impediment (Zhang et al. 2003; Yamaguchi & Inouye 2009).  Unexpectedly, 16S 
rRNA was also processed by MazF, removing the anti-SD sequence to yield 
“stress ribosomes”.  “Stress ribosomes” were able to translate a set of 
leaderless mRNAs with SD sequences that had also been clipped by MazF, 
producing approximately 50 proteins (Vesper et al. 2011). 
YafQ toxin (structurally similar to RelE) associates with the 50S ribosomal 
subunit to cleave selected mRNAs at AAA [AG] consensus sequences. The 
AAA codon is overrepresented at codon +2 in secretory proteins, suggesting 
that expression of YafQ might specifically arrest their translation (Zalucki et al. 
2007). The ribonucleic activity of RelE has also been linked to significant 
changes in the proteome (Korch et al. 2015). 
31 
 
Finally, the MqsRA type II TA system has been shown to regulate expression of 
ghoST type V TA system. MqsR toxin enriches ghoT mRNA in vivo and in vitro 
as the ghoT transcript lacks the primary recognition site of MqsR toxin (Wang et 
al. 2013).  
1.0.2.5 Programmed cell death (PCD) 
PCD is not restricted to multicellular organisms; bacterial communities can 
induce death in part of the population after exposure to various stress 
conditions. Typically, PCD is induced by TA mechanisms in response to 
oxidative stress, exposure to radiation, nutrient deprivation or phage infection 
(Allocati et al. 2015). 
PCD in E. coli is facilitated by the mazEF type II TA system and dependent on a 
quorum-sensing linear pentapeptide named extracellular death factor (EDF). 
The EDF specifically acts on toxin MazF, magnifying its enzymatic activity. 
However, not all groups report this as a universal phenomenon (Christensen et 
al. 2001; Tsilibaris et al. 2007).  Similar results in E. coli have also been 
observed with chpBIK type II system (Hazan & Engelberg-Kulka 2004; Belitsky 
et al. 2011).  
Intriguingly, EDFs have been identified from Gram positive B. subtilis and Gram 
negative Pseudomonas aeruginosa, which were able to trigger mazEF in E. coli. 
This suggests that induction of PCD by EDFs may be used by one bacterial 
species undergoing stressing conditions, to kill a different species in a mixed 
population (Kumar et al. 2013). 
1.0.2.6 Persister cell formation 
Persistence was first described in the 1940s, when a small population of 
persister cells survived treatment with penicillin through dormancy, a different 
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mechanism to traditional antibiotic resistance (Hobby et al. 1942; Bigger 1944). 
The characteristics used to define the persister phenotype are frequently 
updated but persister cells comprise a subpopulation of genetically identical, 
metabolically slow-growing cells, which are tolerant of antibiotics and other 
environmental stresses (Page & Peti 2016).  
The first gene directly associated with persistence was E. coli  hipA encoding 
high persister protein (Hip) A, a kinase that inactivates glutamyl-tRNA 
synthesase (Germain et al. 2013; Kaspy et al. 2013). A hipA variant, hipA7, 
increased persistence ~100 – 1,000- fold as it destabilised the oligomers that 
formed when the HipBA complexes bound to the hipBA operator, rendering the 
toxin more active (Moyed & Bertrand 1983; Schumacher et al. 2015). HipA toxin 
activity was revealed to lead to the ppGpp-mediated activation of type II RNase 
toxins and consequently persistence (Germain et al. 2015). 
While it may not always be possible to elucidate the role of individual TA loci, 
the importance of type II RNase toxins in persistence has been demonstrated 
extensively. Microarray experiments on E. coli persisters revealed that multiple 
type II toxins, especially RNase toxins, were highly upregulated in persisters 
compared to non-persister cells (Keren et al. 2004; Shah et al. 2006). A direct 
role for TA systems was also evidenced by ectopic expression of RNase toxins 
(increases persistence) and the deletion of TA loci (deletion of ten TA systems 
from E. coli resulted in 100-fold reduction in persistence) (Harrison et al. 2009; 
Keren et al. 2004; Kim & Wood 2010; Maisonneuve et al. 2011). Examples of 
the importance of type II TA systems in persistence are not limited to E. coli. 
Recent studies have demonstrated that systematic deletion of individual type II 
TA modules from Salmonella reduced macrophage-induced persisters and 
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highlighted 14 different type II TA systems that were activated once cells were 
phagocytosed (Helaine & Kugelberg 2014). 
Type I toxins have also been linked to persistence. Obg, a GTPase that is 
universally conserved, induced persistence through activation of transcription of 
hokB. Toxin HokB acts to depolarise the bacterial cell membrane, leading to 
persistence. Interestingly, whilst the exact molecular mechanism for hokB 
activation by Obg is unknown, it was found to rely on ppGpp (Verstraeten et al. 
2015). 
Cells entrance into and exit from the persister state is closely linked to TA 
expression. Persister cells are formed when toxin concentration exceeds a 
threshold set by that of its antitoxin concentration (Page & Peti 2016). Levels of 
free toxin within the cell are controlled by toxin sequestration in complexes of 
differing stoichiometry, rather than by gene regulation. If the toxin translation 
rate exceeds twice the antitoxin translation rate, toxins accumulate within cells 
(Figure 1.3) (Gelens et al. 2013).  
Some cells within a population may enter persistence when they experience 
micro-starvation conditions due to local accessibility of nutrients within the 
population. Nutrient deprivation increases the level of alarmone (p)ppGpp, 
activating Lon protease and subsequently resulting in antitoxin degradation. The 
overall result switches the TA ratio from low to high, allowing the newly freed 
toxin to exert its effects (Germain et al. 2015; Maisonneuve & Gerdes 2014; 
Maisonneuve et al. 2013). 
How bacterial cells exit persistence using TA systems is less well characterised. 
One potential mechanism used by type II TA systems is conditional 
cooperativity (Afif et al. 2001; Garcia-Pino et al. 2010). Typically, type II TA loci 
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are transcriptionally autoregulated (Guglielmini & Van Melderen, 2011) and 
antitoxins are able to bind both DNA and their cognate antitoxin. Antitoxins bind 
to one or more operators within the promoter of their TA loci, thus repressing 
transcription. DNA binding is often enhanced when cognate toxins are bound to 
the antitoxin, resulting in a more potent repression of transcription than would 
be observed with the antitoxin alone (Page & Peti 2016; Gotfredsen & Gerdes 
1998; Afif et al. 2001; Garcia-Pino et al. 2010; Overgaard et al. 2009). In the 
Doc/PhD TA system, it was observed that large excesses of toxin de-repressed 
rather than repressed transcription (Magnuson & Yarmolinsky 1998). The switch 
from a repression to a de-repression complex was accompanied by changes in 
oligomerisation states. Similar studies on ccdAB revealed that maximal DNA 
binding (and so repression) was observed when the ratio of CcdB (toxin): CcdA 
(antitoxin) was 1:1. Ratios above 1 abolished DNA binding and enhanced 
transcription (Afif et al. 2001). From these observations, it was suggested that 
under conditions of excess toxin, transcription and translation of both toxin and 
antitoxin would increase, generating a ratio of CcdB:CcdA  that would permit 
cells to exit persistence and grow normally (Page & Peti 2016). Several other 
TA systems have been shown to be regulated by conditional cooperativity: 
relBE, parDE, kid/kis, vapBC and phd/doc (Overgaard et al. 2009; Johnson et 
al. 1996; Monti et al. 2007; Wang et al. 2013; Magnuson & Yarmolinsky 1998). 
The molecular basis of conditional cooperativity has been observed for relBE 
TA system (Figure 1.4). Antitoxin RelB has a weak affinity for its operator, whilst 
the RelB2-RelE complex binds extremely tightly to inhibit transcription from the 
locus. Any further increases in toxin RelE concentration destabilised DNA 
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Figure 1.3: TA systems and persistence. Growing cells are coloured blue and 
the concentration of antitoxin [A] exceeds that of the toxin [T]. The reverse is 
true of persister cells, coloured orange, where the concentration of toxin [T] 
exceeds the antitoxin [A] concentration. To switch phenotypic states, the ratio of 
[T]: [A] has to change. Within a growing population, a small number of cells will 
be in the persister state; exposure to stress, for example, antibiotics or nutrient 
deprivation, activates bacterial proteases, which cleave antitoxins, leaving 
behind an excess of toxin. How cells exit persistence is less well characterised. 
Reprinted by permission from Macmillan Publishers Ltd: Nature chemical 
biology, (Page & Peti 2016), copyright 2016. 
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binding, resulting in an affinity similar to RelB alone (Overgaard et al. 2009; 
Page & Peti 2016). The 3D structure of a RelB2E2 complex reveals why DNA 
binding is not possible (Boggild et al. 2012). Two RelB2E complexes may bind 
the operator with no problems. However, increased concentrations of RelE led 
to formation of RelB2E2 complexes, which cannot bind the operator as the 
additional RelE molecules clash with neighbouring proteins. Failure of the 
complexes to bind both operators at the same time resulted in de-repression of 
the operon and an increase in transcription (Page & Peti 2016). 
The conditional cooperativity hypothesis in TA systems, combined with the 
growth inhibition activity of free toxin molecules explains how TA systems can 
provide the bi-stability necessary to support one actively growing population and 
one dormant population within a single culture (Cataudella et al. 2013; Gelens 
et al. 2013). 
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Figure 1.4: Molecular basis of conditional cooperativity. a) Picture 
illustrating oligomerisation states of TA complexes, their abilities to bind their 
promoters and resulting transcription levels. Gene loci are represented as 
arrows, toxins in orange, antitoxins in blue and promoters in beige. b) In the 
absence of RelE (orange), antitoxin RelB (blue) binds its promoter, which has 
two adjacent operators, with weak affinity. At a 2:1 RelB: RelE ratio, both 
operators are bound by the RelB dimers but only one RelB within the dimer is 
bound to RelE toxin. Increases in concentrations of RelE lead to a 1:1 ratio and 
a RelB-RelE complex that is incompatible with DNA binding as newly bound 
RelE would clash with the adjacent B2E2 dimer. Figure adapted from (Page & 
Peti 2016). 
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1.0.2.7 Biofilms 
A biofilm could be described as a population of microbial cells embedded within 
an extracellular matrix that adheres to both biotic and abiotic surfaces. The 
extracellular matrix is mostly composed of polysaccharides, glycoproteins and 
DNA, which enables adhesion and protects the bacterial cells from the 
surrounding environment. Within a biofilm, the population displays multicellular- 
like behaviour (Stewart & Franklin 2008; Sauer et al. 2007; Martínez & 
Vadyvaloo 2014).   
Biofilms are heavily involved in the majority of human bacterial chronic 
inflammatory and infectious diseases, and pose a serious therapeutic challenge 
(Hall-Stoodley et al. 2004; Barbara & Hayes 2016). Biofilms are also multidrug 
tolerant and are one of the main strategies used by pathogenic bacteria to 
survive against host immune defence (Rybtke et al. 2011). Biofilms are involved 
in recalcitrance of infections due mostly to the presence of persister cells within 
the matrix; upon treatment with antibiotic, the majority of the cells are killed, 
except the persisters. The immune system cannot reach the biofilm-embedded 
cells and so the persisters may then repopulate the biofilm (Lewis 2007; Lewis 
2010).  
Development and formation of biofilms is well-controlled and the transition 
between planktonic and biofilm phases requires precise and well-coordinated 
gene expression (Ren et al. 2004; Wen et al. 2014). In E. coli, biofilm production 
has been shown to be influenced by multiple TA systems (Barbara & Hayes 
2016).  The role of the MqsR-MqsA type II pair was the first identified in biofilm 
formation and is the best documented. Antitoxin MqsA directly inhibits 
expression of RpoS, the master regulator of stress that controls expression of 
up to 10% of genes involved in the response to various different stresses (Wang 
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et al. 2011). MqsA has also been shown to decrease production of CsgD, a 
master regulator that activates expression of several important components of 
the extracellular matrix  (Soo & Wood 2013; Brombacher et al. 2006). Finally, 
MqsA has been linked to increased motility though activation of flhD, a regulator 
of flagella biosynthesis (Barbara & Hayes 2016). Under stressful conditions, 
MqsA is degraded by Lon protease, leading to de-repression of rpoS and csgD, 
and inhibition of flhD, resulting in decreased motility and increased biofilm 
formation (X. Wang et al. 2011). 
 Toxin MqsR has also been linked to the regulation of biofilm production. 
Expression of mqsR is stimulated by autoinducer 2 (AI-2), which controls 
flagellar synthesis, chemotaxis and motility in E. coli  (Ren et al. 2004; Wood 
2009; González Barrios et al. 2006; Barbara & Hayes 2016). MqsR also 
indirectly inhibits synthesis of McbA, preventing production of colonic acid, an 
exopolysaccharide important for formation of the biofilm architecture (González 
Barrios et al. 2006; Zhang et al. 2008; Prigent-Combaret et al. 2000). 
Additionally, MqsR post-transcriptionally regulates GhoST, a  type V system 
that has been linked to early biofilm formation and motility  (Wang et al. 2012). 
The HipBA system has also been shown to influence biofilm formation through 
the production of extracellular DNA (eDNA) required for the biofilm matrix. 
Activation of HipA toxin affects the integrity of E. coli cells and may induce lysis 
of a subpopulation to increase the eDNA concentration (Zhao et al. 2013).  
TA systems have also been implicated in the formation of biofilms in species 
other than E. coli. In Burkholderia cenocepacia, expression of TA modules was 
found to be higher in in untreated sessile cells than in untreated planktonic cells 
and RelE and VapC toxin homologues were found to contribute to biofilm 
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formation (Van Acker et al. 2014). In B. subtilis, TxpA and YqcG toxins were 
found to eliminate defective cells from biofilms to ensure symmetry is 
maintained. Toxin TxpA was also able to act to dissolve and lyse established 
biofilms (Bloom-Ackermann et al. 2016).  
Several TA systems were upregulated in biofilm cells in Treponema denticola, a 
spirochete associated with chronic periodontitis (Mitchell et al. 2010), whilst 
MqsRA from Xylella fastidiosa was found to positively regulate biofilm formation 
and negatively regulate cell movement (Merfa et al. 2016).     
1.0.2.8 Virulence 
TA systems are indirectly involved in virulence through maintenance of MGEs, 
PSK, PCD and persister cell formation. However, TA systems have also been 
described as having a direct impact on the pathogenicity of bacteria, and the 
identification of a correlation between the number of TA modules in the genome 
and the virulence capacity of bacteria, would support this description (Wen et al. 
2014; Georgiades & Raoult 2011).  
The existence of a subpopulation of persister cells is certainly an important 
aspect of the protracted infection caused by Mycobacterium tuberculosis. 
Reawakened persisters from the latent infection trigger recurrent relapses, 
characteristic of the disease (Getahun et al. 2015). However, TA systems have 
also been linked to mycobacterial pathogenesis in other ways. Three TA 
systems, two relBE cassettes and one yefM-yoeB locus are upregulated in 
response to nitrogen starvation and oxidative stress, and down regulated in 
response to hypoxia, all conditions relevant to those prevailing during M. 
tuberculosis infection (Sala et al. 2014; Barbara & Hayes 2016; Korch et al. 
2009; Ramage et al. 2009). Hypoxia also increases expression of one of the 
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many vapBC homologues and a higBA locus (Ramage et al. 2009). 
Nevertheless, deletion of any of these homologues did not affect survival or 
persistence in mice (Singh et al. 2010). Interestingly, although expression of the 
two relBE cassettes and one yefM-yoeB locus could not be detected during the 
early or middle stages of infection, expression of both relE genes, one of the 
relB genes and yoeB gene was apparent in late stage infection (Korch et al. 
2009). Macrophages from the immune system phagocytose infecting microbes 
so expression of TA genes, specifically at the late infection stage, suggests that 
the genes may be involved in bacterial survival in this specific hostile 
environment (Barbara & Hayes 2016). 
In uropathogenic E. coli (UPEC), individual deletions of seven type II TA loci 
revealed that mutants lacking pasTI, were outcompeted by the wild type strain 
in the kidneys, but not the bladder, of a mouse model urinary tract infection 
(UTI) system. Deletion of pasTI also reduced kidney colonisation but not 
gastrointestinal tract colonisation. How the pasTI locus facilitates kidney 
colonisation is not known (Norton & Mulvey 2012). 
Expression of chpBK and mazEF genes was elevated in Leptospirosis 
interrogans within human macrophages compared to bacterial cells in culture 
medium. Mutants lacking either TA module were able to induce late stage 
apoptosis less efficiently than wild type, suggesting that the chpBK and mazEF 
TA loci have roles in cellular necrosis by L. interrogans (Komi et al. 2015). 
Similarly, a VapC  toxin homologue in Rickettsia species has been linked to 
host cell apoptosis. Rickettsia species with multiple type II TA systems promote 
higher levels of host cell apoptosis than species with fewer TA genes (Audoly et 
al. 2011; Socolovschi et al. 2013; Botelho-Nevers et al. 2012).    
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Type I TA loci have also been shown to contribute to pathogenicity. The hok/sok 
locus from E. coli prolonged the lag phase of host cell cultures, allowing cells 
time to adapt before increasing the growth rate at exponential phase. As well as 
increasing propagation of resistance genes and tolerance to β-lactam 
antibiotics, this locus enhanced survival of cells grown at high temperature and 
at a low starting cell density. Finally, the hok/sok locus might complement an 
existing or defective SOS mechanism. All of these effects would enhance the 
ability of pathogenic bacteria to establish infections and so might contribute to 
virulence (Chukwudi & Good 2015). 
1.0.3 Biotechnological and therapeutic applications of TA systems 
Infectious diseases are one of the leading causes of human mortality worldwide 
and increasing antimicrobial resistance threatens effective treatment of bacterial 
diseases (Lee & Lee 2016). TA systems are attractive antibacterial targets as 
they are widely distributed in bacteria but not in eukaryotes. Several strategies 
have been suggested on how TA systems could be exploited for the 
development of novel antibiotic drugs. 
One proposed strategy is to artificially activate the toxin by disrupting TA 
complex formation (Ghafourian et al. 2014; Ghafourian & Raftari 2012; Williams 
& Hergenrother 2008). In type II systems, this would involve using structural and 
biochemical information available on TA complexes to design peptides that 
inhibit interactions at the TA interface. The crystal structure of VapBC30 from M. 
tuberculosis was used to design peptides to mimic the TA interface. Three 
peptides of varying lengths mimicking part of the toxin were tested and two 
were found to increase the ribonuclease activity of VapC (I.-G. Lee et al. 2015). 
Meanwhile, an octapeptide predicted to form an α helix was found to occupy the 
TA binding interface between PemK and PemI from B. anthracis, inhibiting TA 
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complex formation but also decreasing the ribonuclease activity of toxin PemK 
(Chopra et al. 2011). The limited information available on TA protein-protein 
interactions and the size of the TA protein interface present difficulties when 
trying to identify suitable peptides. Care must also be taken to target toxins that 
are effective at mediating cell death, rather than inducing persister cell 
formation and contributing to chronic infection (Lee & Lee 2016).  
In other types of TA systems it is possible to disrupt complex formation using 
antisense RNA that binds to antitoxin encoding mRNA without affecting 
translation of the toxin. One example of this method is the sequestration of type 
I antitoxin Sok-RNA by anti -Sok peptide nucleic acid (PNA) oligomers. The 
oligomers competitively inhibited hok mRNA:: Sok-RNA interactions. In E. coli 
cells harbouring hok/sok, the anti-Sok PNAs were more bactericidal than the 
antibiotic rifampicin and expression resulted in ghost cell formation (Faridani et 
al. 2006). 
A second proposed strategy involves increasing the rate of degradation of 
bound antitoxin by Lon or Clp proteases, resulting in premature release of 
toxins and cell death. Over-expression of Lon protease activates YoeB from its 
complex with YefM and leads to inhibition of global translation and cell death 
(Christensen et al. 2004). Several other antibiotic molecules that bind to activate 
ClpP in other systems have already been identified (Leung et al. 2011; Famulla 
et al. 2016). Biomolecules that are able to bind to the DNA promoter and 
subsequently prevent further transcription would also be of interest. 
Finally, toxin molecules themselves can be treated as potential antimicrobial 
drug candidates. However, the poor oral availability and high costs of 
bioprocessing make this proposal unlikely to be realised (Lee & Lee 2016). 
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Toxins may also be poor choices as potential antimicrobials as several are 
capable of lysing bacterial and eukaryotic cells. The PepA1 type I toxin from 
Staphylococcus aureus was found to lyse bacteria and human erythrocytes, 
though chemical optimisation was able to enhance its antibacterial activity and 
decrease the haemolytic side effects (Sayed et al. 2012; Solecki et al. 2015). 
Toxins may also be difficult to deliver to the site of infection, although 
bacteriophages would be able to deliver toxin genes into specific pathogens 
(Huys et al. 2013). 
PepA1 is not the only toxin capable of targeting eukaryotes. When RelE toxin 
was expressed in a human osteosarcoma cell line, it was able to retard growth 
and cause cell death through apoptosis (Yamamoto et al. 2002). Toxin MazF 
has also been suggested as a suitable candidate for gene therapy as when 
expressed in human embryonic kidney cells that had formed a tumour in mice, it 
was able to make the tumours regress (Shimazu et al. 2014). Zymogenised 
MazF was also able to cleave cells infected with hepatitis C, a prominent cause 
of chronic liver disease (Shapira et al. 2012). Finally, the Kid toxin from E. coli 
has also been repurposed to demonstrate selective killing of oncogenically 
stressed human cells (Preston et al. 2016). 
TA systems have been used in several expression systems as they provide 
plasmid maintenance without the need for antibiotics. The GATEWAY system 
cloning vectors include the kid gene to facilitate cloning. Cloning sites within the 
vectors are designed to disrupt toxin expression when DNA has successfully 
inserted, and cells harbouring plasmids without an insert do not grow (Walhout 
et al. 2000). 
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The Gene Guard system is a plasmid system designed for safety to reduce 
unintentional plasmid propagation in E. coli and B. subtilis and uses toxins ζ or 
Kid in an auxiliary manner to make the vector disadvantageous for strains 
lacking the cognate antitoxin (Wright et al. 2015) . A similar “containment” 
system was developed using the relBE system for Saccharomyces cerevisiae, 
where RelE toxin expression was controlled under lab conditions using a 
glucose-repressible promoter and basal RelB expression (Kristoffersen et al. 
2000). 
Lastly, TA systems have been used to improve yields in microbial production. 
Inducible cell lysis systems, such as PCD, facilitate the release of products from 
cells on an industrial scale, whilst keeping production costs down (Gao et al. 
2013). A novel food grade expression system for B. subtilis was stabilised by 
TA systems, generating a greater biomass and increasing the amount of 
product when compared to expression systems where antibiotics are used  
(Yang et al. 2016). 
   
 1.1 Type II TA systems 
In type II systems the antitoxin is a labile protein (Leplae, Geeraerts, Hallez, et 
al., 2011) capable of neutralising the toxin by sequestering it in a protein-protein 
complex and rendering it post-transcriptionally inactive (Galvani et al. 2001; Lee 
& Lee 2016). However, under stressful environmental conditions (Yamaguchi et 
al. 2011; Kolodkin-Gal & Engelberg-Kulka 2008) the antitoxin is rapidly 
degraded by ATP-dependent proteases, such as those from Clp and Lon 
families (Christensen et al. 2001; Christensen et al. 2004; Lehnherr & 
Yarmolinsky 1995; Diago-Navarro et al. 2013), releasing the toxin and resulting 
in cell growth arrest or death (Yamaguchi et al. 2011; Unterholzner et al. 2013).  
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In response to amino acid starvation, bacteria downregulate synthesis of rRNAs 
and tRNAs by increasing the concentration of the alarmones, tetraphosphate 
(ppGpp) and penta-phosphate (pppGpp). Both ppGpp and pppGpp are 
synthesised by RelA, which is activated by uncharged tRNAs present at the 
ribosomal A-site. Both alarmones also accumulate in response to carbon 
starvation and due instead to the inhibition of SpoT. The increased 
concentration of alarmones directs RNA polymerase towards the synthesis of 
biosynthetic operon mRNAs (rather than stable RNAs) and are bound to RNA 
polymerase and subsequently decrease the half-life of promoter open 
complexes. ppGpp and pppGpp also inhibit exopolyphosphatase (PPX), which 
results in accumulation of polyphosphate (PolyP) , a signalling molecules that 
binds to Lon protease, directing it to degrade available ribosomal proteins to 
generate amino acids for protein synthesis (Gerdes, Christensen & Løbner-
Olesen 2005). 
 
Levels of transcription of the TA system are governed by the differing binding 
stoichiometry of antitoxins and TA complexes and their ability to repress 
transcription; this mechanism is called conditional cooperativity (Lee & Lee 
2016; Page & Peti 2016). 
Antitoxins typically form dimeric proteins and within each monomer, the N-
terminus is usually required for dimerization and the C-terminus for binding the 
toxin. Generally, antitoxins block the catalytic site of the toxin molecule, 
however, as antitoxins are intrinsically disordered and fold upon binding to the 
toxin, this can make it difficult to determine the structure (Lee & Lee 2016). 
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Differing toxic modes of action, sequence homology and structural features 
have allowed type II TA systems to be further classified into families (and sub-
families) (Gerdes, Christensen & Lobner-Olesen 2005; S. J. Park et al. 2013).  
1.1.1 Identification of type II TA systems and confirmation of their 
activity 
Candidate TA systems are often identified initially by bioinformatics, using 
programmes such as RASTA or BLAST (Butt et al. 2013; Jurenaite et al. 2013). 
However, it is still necessary to confirm functionality experimentally, typically by 
over-expression of TA toxins in their native host or E. coli and monitoring 
cultures for growth arrest or cell death (Zheng et al. 2015; Iqbal, Guérout, et al. 
2015). Recently, type II TA systems were identified through shotgun cloning, as 
a functional toxin may only be cloned with its cognate antitoxin. During shotgun 
Sanger sequencing the whole genome is randomly fragmented, ligated into a 
vector and transformed into E. coli. If a toxin is detached from its antitoxin, the 
clone will no longer grow and will not be recovered (Sberro et al. 2013). 
1.1.2 Distribution of type II TA systems 
Type II TA systems are widely distributed and the number  of systems 
present varies greatly, not only between species but also between isolates from 
the same species(Raphaël Leplae et al. 2011)  . On average, bacterial 
chromosomes and plasmids encode 3.8 and 0.4 type II TA systems respectively 
(Goeders & Melderen 2014). Toxin-antitoxin systems are present in nearly all 
free-living prokaryotes (Pandey & Gerdes , 2005) and there is some evidence to 
suggest that the number of TA loci present in an loci present in a genome is 
dependent on the lifestyle of the organism. 
Bioinformatic analysis of 126 complete prokaryote genomes revealed 
that species that appeared to lack TA loci were mostly obligate, host associated 
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parasites or came into close contact with other organisms. Almost all free-living 
bacteria living in changing environments have multiple TA loci, whereas 
bacteria living in constant environments have few (Pandey & Gerdes 2005). 
 This same analysis also determined that the number of TA modules 
within the genome is not directly correlated to its size but rather to the growth 
rate of free living prokaryotes. Both Nitrosomas europea, an obligate 
chemolithotrophic soil organism with 43 TA loci and M. tuberculosis, with over 
30 TA loci (Park et al. 2013), have many TA systems and are both associated 
with low growth rates. In contrast, only two TA loci were identified in M. 
smegmatis the fast growing relative of M. tuberculosis (Pandey & Gerdes 2005).
   
1.1.3 Classification of type II TA systems into families 
Type II TA systems were classified into 14 families based on structural features, 
amino acid sequence similarity of toxins and the assumption that each toxin 
was specifically associated with one antitoxin family (Guglielmini & Van 
Melderen, 2011). Eleven of these families are two component systems and 
three are three component systems (Table 1.1). However, the identification of 
functional ‘hybrid’ systems within genomes, where the toxin is from one family, 
for example, RelE, and the antitoxin from a different family, for example, VapB, 
has led to suggestions that type II TA components should be classified 
separately into superfamilies (Leplae, Geeraerts, Hallez, et al., 2011; 
Anantharaman & Aravind, 2003). Seventeen toxin super-families, their 
representative sequences and activities have been experimentally validated, 
including, RelE/ParE, CcdB/MazF, Zeta, Doc, VapC, HipA, YafO, VapD, RnlA, 
HicA, GinA, GinC, GinD, GinE, GinF, GinG and GinH, but this nomenclature is 
not widely used in the literature at the present (Leplae, et al., 2011). 
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Table 1.1: The fourteen type II TA families in prokaryotes  
TA family 
name 
Toxin Antitoxin Target Cellular 
process 
Ccd CcdB CcdA DNA gyrase Replication 
HicBA HicA HicB RNA cleavage Translation 
HipBA HipA HipB Phosphorylate EF-
Tu 
Translation 
MazEF 
(ChpA) 
MazF 
(ChpAK) 
MazE 
(ChpAI) 
mRNA cleavage Translation 
ParD 
(PemKI) 
Kid (PemK) Kis (PemI) mRNA cleavage Translation 
ParDE ParE ParD DNA gyrase Replication 
Phd-Doc Doc PhD Ribosome Translation 
RelBE 
1 
RelE RelB Ribosome Translation 
VapBC 
(Vag)
2 
VapC VapB Endoribonuclease Unknown 
MosAT MosT MosA Unknown Unknown 
YeeUV YeeV YeeU Unknown Unknown 
ω-ε-ζ ζ ε Phosphotransferase Unknown 
PasABC PasB PasC Unknown Unknown 
PaaR-PaaA-
ParE 
ParE PaaA DNA gyrase Replication 
 
1 
Five subfamilies: RelBE, HigBA, YefM-YoeB, YgiTU(MqsAR) and PrlF-YhaV 
2 
Two subfamilies: YapBC and Bat-Bto. 
Adapted from (S. J. Park et al. 2013). 
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1.1.4 Interactions between type II toxins and their targets 
 
Type II toxins target key cellular processes, including but not limited to 
replication, translation and peptidoglycan synthesis (Yamaguchi et al. 2011; 
Unterholzner et al. 2013). A brief description is given below.   
1.1.4.1 DNA replication 
CcdB and ParE toxins both target DNA gyrase (Miki et al. 1992). DNA gyrase is 
a class II topoisomerase, an enzyme that introduces negative supercoils into 
the DNA using ATP. The enzyme also has double-strand break and re-joining 
activity. CcdB toxin does not generate double stranded breaks by itself but 
inhibits the re-ligation step of DNA gyrase, through binding to the A subunit of 
the molecule and stabilising the resulting complex (Gerdes, Christensen & 
Løbner-Olesen 2005). This generates double stranded breaks (Bernard et al. 
1993) ParE also targets DNA gyrase,  although through a different mechanism 
requiring ATP (S. J. Park et al. 2013).  
1.1.4.2 Ribosome dependent mRNA interferases 
The RelE toxin cleaves ribosomally bound RNA by at the A-site of the ribosome 
and is perhaps the best studied ribosome dependent mRNA interferase 
(Christensen & Gerdes 2003). Cleavage occurs between the second and third 
bases of A-site codons. Cleavage efficiency is also dependent on the codon 
present at the ribosomal site. UAG and UAA codons are cleaved 800- and 100- 
fold, respectively, more efficiently than stop codons (Gerdes, Christensen & 
Lobner-Olesen 2005). 
YoeB, a homologue of RelE, also requires the ribosome for cleavage of mRNA. 
In contrast to RelE, YoeB associates with the 50S ribosomal subunit and 
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cleaves immediately downstream of the initiation codon (Yamaguchi & Park 
2011).  
The HigB toxin binds to the 50S region of the 70S subunit and cleaves A-rich 
sequences in mRNA. Ribonuclease activity is only displayed when HigB is 
associated with the ribosome, but the toxin is able to cut in frame and out of 
frame AAA sequences all of the time (Hurley & Woychik 2009). 
1.1.4.3 Ribosome independent mRNA interferases 
MazF is by far the best studied  RNAse and cleaves mRNA at ACA sequences, 
although characterisation of MazF homologues from have revealed recognition 
sites of 3, 5 or 7 base pairs long (Christensen & Gerdes 2003; Zhang et al. 
2003; Jørgensen et al. 2009; Winther & Gerdes 2011). Unusually, MazF is also 
capable of degrading its own mRNA, suggesting that expression could be 
negatively regulated (Hazan et al. 2004). E. coli ChpBK, a toxin homologous to 
MazF, is a sequence-specific endoribonuclease cleaving single-stranded 
mRNAs at ACA, ACG, and ACU sequences (Belitsky et al. 2011). 
Other ribosome independent mRNAases include HicA and VapC. HicA cleaves 
mRNA and tmRNA at an unknown recognition sequence (Jørgensen et al. 
2009). VapC toxins belong to the PIN-domain family and inhibit translation by 
either cleaving tRNAfMet in the anticodon stem loop, or cleaving mRNA at -
AUA(U/A)-hairpin-G- sequences or by sequence-specific RNA binding (Cook et 
al. 2013). 
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1.1.4.4 Ribosomes    
Doc toxin, from PhD-Doc system, inhibits translation elongation by associating 
with the 30S ribosomal subunit, in the same 16S rRNA region in the ribosome 
as hygromycin B (Liu et al. 2008). 
1.1.4.5 Cell wall formation 
ζ toxin inhibits cell wall formation by phosphorylation of the peptidoglycan 
precursor uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc), inhibiting 
MarA protein, which catalyses the first step in peptidoglycan synthesis 
(Mutschler et al. 2011).  
1.1.4.6 Elongation factor TU (EF-Tu) 
HipA can autophosphorylate itself, subsequently phosphorylating elongation 
factor EF-Tu. EF-Tu is essential for translation as it catalyses aminoacyl-
transfer RNA binding to the ribosome. As GTP is hydrolysed to GDP, EF-Tu 
undergoes a conformational change and so can no longer bind to ribosomes 
(Germain et al. 2013). 
 
1.1.5 Interaction between toxins and antitoxins 
Determination of many TA complexes by X-ray crystallography or NMR 
has revealed many of the protein-protein interactions responsible for complex 
formation. Comparison of these structures has revealed that TA systems, with 
very little sequence homology, share 3D structural homology (S. J. Park et al. 
2013). The structures of antitoxins and TA complexes from E. coli (and one from 
Y. pestis) are depicted in Figure 1.5. 
It is possible to classify type II and type III toxins into 6 different sub-
groups based on structural similarity. The first sub-group consists of members 
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of the Kid family (Kid, MazF, CcdB and YdcE) and act primarily as mRNA 
interferases (except CcdB). These proteins are composed of compact globular 
folds with anti-parallel beta-sheet cores surrounded by α-helices. The second 
sub-group contains RelE, MqsR and YoeB, which have a four β –strand core, 
surrounded by 4 α helices. The other four groups include VapC family, which 
contains a PIN domain consisting of a 3-layer α/βα sandwich around a central 
5- stranded β-sheet, the HipA toxin family which is similar structurally to Ser/Thr 
kinase, the phosphyltransferase ζ toxin and the α-helical Doc toxin ( Blower et 
al. 2011) 
Generally, type II antitoxins have two domains; one for binding its 
cognate toxin and one for binding DNA within its operon (Yamaguchi & Park 
2011). The DNA binding domain may be either a helix-turn-helix (HTH) or a 
ribbon-helix-helix (RHH) and binds to a palindromic sequence within the 
promoter region (Seok et al. 2007; Brown et al. 2004; Fasani & Savageau 
2015).  
Antitoxins bind their cognate toxins though hydrophobic and electrostatic 
interactions, and may interact directly with the active site of the toxin, or 
indirectly by binding elsewhere and causing a conformational change to prevent 
substrate binding. The HipB antitoxin dimer cross contact with the N and C 
terminal domains of toxin HipA to cause HipA to undergo an active and inactive 
conformation (Schumacher et al. 2009) 
Recently, it has been suggested that non-cognate M. tuberculosis TA 
can interact physically and functionally. A spectrum of pair-wise combinations of 
cognate and non-cognate M. tuberculosis toxin-antitoxins using in vivo toxicity 
and rescue experiments, alongside in vitro interaction experiments revealed 
several examples of non-cognate TA association, among different families. This 
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study challenges the “one toxin for one antitoxin” dogma and suggests that 
organisms, including M. tuberculosis, enlist a network of toxin-antitoxin systems 
to alter physiology in response to environmental clues (Zhu et al. 2010). 
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Figure 1.5 Summary of TA complex structures. (a) TA loci in the E. coli genome 
(b) Ribosome-dependent RNase toxins that adopt the microbial RNase fold. (c) 
Ribosome-independent RNase toxins; MqsR does not required the ribosome for activity 
despite the fact it adopts a microbial RNase fold, MazF is a dimer. (d) TA structures. 
Toxins are coloured orange and antitoxins coloured blue. TA systems with a ribosome-
dependent toxin have a blue border (PDB IDs: HigBA, 4MCX47 RelBE, 4FXE51 ; 
DinJYafQ, 4Q2U90 ; YefMYoeB, 2A6Q95 ). MqsRA, which is an RNase with structural 
characteristics of ribosome-dependent toxins but functional characteristics of ribosome-
independent toxins, is bordered in magenta (3HI239). The MazEF system and HicBA 
system from Y. pestis are bordered in orange (4MDX96). The HipAB system, in which 
the toxin is a kinase, is bordered in grey (4YG763, 4P78). cc signifies known regulation 
by conditional cooperativity and no cc, no regulation by conditional cooperativity. (e) 
Structures of other well-studied type II TA systems not present in E. coli: Phd/Doc 
(3K33), CcdBA (3G7Z75), Kid/Kis (1M1F99)), VapBC (3TND73)  Antitoxins coloured 
blue and toxins orange. Figure adapted from Macmillan Publishers Ltd: Nature 
Chemical Biology, (Page & Peti 2016), Copyright 2016. 
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1.1.6 Interactions between type II toxins and TA systems 
Transcriptional cross-activation between different type II TA systems of E. coli 
has been observed. The chromosomal relBEF operon was found to be activated 
by toxins MazF, MqsR, HicA and HipA. Furthermore, expression of the RelE 
toxin in turn induced transcription of several other TA operons. Previously, 
induction of TA operons was shown to depend on Lon protease which is 
activated by polyphosphate accumulation. However, transcriptional cross-
activation was observed in E. coli strains deficient for Lon, ClpP, and HslV 
proteases and polyphosphate kinase (Kasari et al. 2013).  
Additionally, toxins were found to cleave the TA mRNA in vivo, degrading the 
antitoxin-encoding fragments and allowing accumulation of toxin-encoding 
regions. These accumulating fragments can be translated to produce more 
toxin, possibly generating a positive feedback loop, which can fire other TA 
systems, forming a network of mutually activating regulators in bacteria (Kasari 
et al. 2013) 
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1.2 Burkholderia pseudomallei  
Burkholderia pseudomallei is an opportunistic pathogen responsible for the 
disease melioidosis in humans.  
1.2.1 Microbiology  
B. pseudomallei is a Gram negative, non-spore forming, facultatively anaerobic 
rod. It exists in the environment as an opportunistic saprophyte, commonly 
found in tropical areas such as southeast Asia and northern Australia and has 
been isolated from mud, soil and water in endemic areas (Cheng & Currie 
2005).  The organism is able to survive in distilled water for 16 years and in 
desiccated soil for over  70 days (Pumpuang et al. 2011; Larsen et al. 2013; 
Cheng & Currie 2005). B. pseudomallei is also resistant to a large range of 
antibiotics (Schweizer 2012).  
 
1.2.2 Genome 
In the reference strain, B. pseudomallei K96243, the genome consists of two 
complex chromosomes, (chromosome 1 is 4.075Mbp and chromosome 2 is 
3.173 Mbp) and is exceptionally large. The gene content between the two 
chromosomes also differs; core functions, such as those required for cell growth 
and central metabolism are encoded on chromosome 1, whilst accessory 
functions required for adaptation and survival are encoded on chromosome 2. 
The genome of B. pseudomallei K96243 is considered very diverse due to the 
high frequency of recombination associated with GIs. Studies have 
demonstrated that GI insertion is not random and 128 GIs were identified 
across all B. pseudomallei strains examined (Holden et al. 2004). 
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1.2.2.1 Toxin-antitoxin systems and persisters in B. pseudomallei K96243 
 
To date, there is published data on four type II TA systems in B. pseudomallei 
K96243, BPSS0390-BPSS0391, BPSL0174-BPSL0175, BPSS1060-BPSS1061 
and BPSS1583-BPSS1584. Toxin BPSS0390 shared 78% sequence identity 
with HicA from Acinetobacter baumannii and BPLS0175 and BPSS0160 shared 
54% sequence identity from RelE from Klebsiella pneumonia. Toxin BPSS1584 
was found to be homologous to HipA from E. coli. 
Ectopic expression of BPSL0175 (RelE1) or BPSS1060 (RelE2) caused growth 
to cease when expressed in Escherichia coli. In contrast, expression of 
BPSS0390 (HicA) or BPSS1584 (HipA) (in an E. coli ΔhipBA background) 
caused a reduction in the number of culturable bacteria. These toxin induced 
phenotypes were enhanced by an <3kDa extracellular factor that accumulated 
in the spent medium during growth. Expression of the cognate antitoxins 
restored growth and resuscitated cells. Interestingly, in E. coli, an increased 
number of persister cells were observed when hicA was expressed and cultures 
challenged with ciprofloxacin or ceftazidime, whilst removal of this system 
increased susceptibility to ciprofloxacin  
 Site directed mutagenesis identified two key residues within the HicA toxin that 
were essential for toxicity and persistence. This non-toxic variant allowed for 
over-expression and determination of the structure of B. pseudomallei HicA by 
NMR. NMR revealed that HicA forms a RNA binding domain like fold (Butt 
2013; Butt et al. 2014; Butt et al. 2013). 
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1.3 Melioidosis 
B. pseudomallei is the causative agent of melioidosis (Cheng & Currie 2005). 
1.3.1 Overview 
Melioidosis was recently described as “a disease so neglected, it’s missing from 
the WHO list of neglected tropical diseases” (Melioidosis: the most neglected 
tropical disease, 2017). Currently endemic to 45 countries (Figure 1.6), it was 
estimated that there were 165,000 cases with 89,000 fatalities in the year 2015 
(Limmathurotsakul et al. 2016).   
There are three routes of infection: inhalation, ingestion and inoculation (White 
2003; Cheng & Currie 2005), with inoculation considered the major mode of 
acquisition, and paddy field workers especially at risk due to walking through 
mud or surface water with minor foot wounds (Cheng & Currie 2005). In 
humans, ingestion of B. pseudomallei occurs when domestic water supplies are 
not sufficiently chlorinated (Inglis et al. 2000), whilst inhalation of dust (Amadasi 
et al. 2014) or aspiration of contaminated water in near –drowning (Lee et al. 
1985)  can result in infection. Exposure to B. pseudomallei typically results in 
subclinical, symptomatic infections (Currie 2015),  although host risk factors, 
including diabetes mellitus, excessive alcohol intake, chronic lung and kidney 
disease can significantly increase the likelihood of melioidosis developing after 
infection (Cheng & Currie 2005). Other risk factors that can impact disease 
presentation are the size of bacterial load, virulence of bacterial strain and route 
of infection (Currie 2015). 
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Figure 1.6: Geographic location of B. pseudomallei infection from 1910 to 
2014. Green represents a complete consensus on absence of B. pseudomallei, whilst red 
signifies a complete consensus on the presence of B. pseudomallei. Macmillan Publishers Ltd: 
Nature Microbiology, (Limmathurotsakul et al. 2016), Copyright 2016. 
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1.3.2 Clinical presentation 
Pneumonia is the most common presentation of melioidosis, with or without 
bacteraemia, and is involved in approximately half of all cases (Figure 1.7). 
Abscess formation is characteristic of the disease and may occur on a variety of 
organs (White 2003; Wiersinga et al. 2012) Encephalomyelitis, genitourinary 
infection, bone and joint infection or sepsis without an apparent focus may also 
be presented (Cheng & Currie 2005; Currie 2015).   
Mortality rates vary from 14% in Northern Territory Australia (Currie et al. 2010) 
up to 43% in northeast Thailand (Limmathurotsakul et al. 2016) and are 
associated with disease presentation and severity; in Australia patients 
presenting with septic shock had a mortality rate of 50%, compared to a 
mortality rate of 4% for patients that presented with non-septic shock (Currie et 
al. 2010). Mortality is also increased in patients with one or more of the host risk 
factors (Currie et al. 2010). 
Acute melioidosis  has an incubation period of 1-21 days and symptoms of less 
than 2 month duration (Cheng & Currie 2005; Currie et al. 2010). 
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Figure 1.7: Various clinical manifestations of melioidosis. Three routes of 
infection are shown in blue boxes, which link to a natural history of infection (red boxes) 
and to clinical manifestations (white text). Panels show: A: cutaneous melioidosis in a 
healthy host; B: lung abscesses on the chest radiograph of a patient with acute 
melioidosis pneumonia and the corresponding computed tomographic (CT) scan 
(Panel C); D: skin manifestations in a fatal case of disseminated melioidosis; E: splenic 
abscesses on an abdominal CT scan; F: aspirated pus in a patient with prostatic and 
periprostatic abscesses, and G:bscesses on a CT scan from the patient. 
Reproduced with permission from (Wiersinga et al. 2012), Copyright Massachusetts 
Medical Society. 
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1.3.3 Persistent melioidosis 
 
Persistent melioidosis could be defined as disease where B. pseudomallei cells 
have existed in the human host for an extended period of time, whilst avoiding 
removal by antibiotics or by the host immune system. Chronic, latent and 
relapsed melioidosis can all be described as persistent melioidosis.  
Chronic melioidosis, where symptoms have been present for more than two 
months, currently accounts for ~11-12% of all melioidosis presentations in 
clinical areas (Limmathurotsakul et al. 2006; Currie et al. 2010). Latent 
melioidosis indicates that there has been a period of months to years between 
initial infection with B. pseudomallei and presentation of melioidosis; the longest 
recorded latent period is 62 years (Ngauy et al. 2005). Relapsed melioidosis 
occurs when the same strain of B. pseudomallei is involved in recurrent 
infection (Limmathurotsakul et al. 2006). 
B. pseudomallei has previously demonstrated the ability to form persister cells 
(Butt et al. 2014). Substantial evidence suggests that persisters contribute in 
other persistent diseases (Fauvart et al. 2011), and so it is likely that persisters 
contribute to persistent melioidosis. B. pseudomallei persisters in vitro have re-
generated a population of cells after antibiotic mediated death of the majority of 
the population (Butt et al. 2014), suggesting that persisters  in vivo could 
contribute to relapsed melioidosis despite antibiotic treatment. Persister cells 
are also apparent in travellers, who have visited endemic areas but live in non-
endemic regions, and yet present with melioidosis many years later.   
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1.3.4 Diagnosis and treatment 
 
A diagnosis for melioidosis should be considered in febrile patients with a 
predicted risk of occupational or recreational exposure, history of travel to 
endemic areas and patient risk factors, especially diabetes (Currie 2015). 
Positive diagnoses are confirmed by isolation of B. pseudomallei by culture from 
patients’ bodily fluids, including but not limited to blood, urine, pus and swabs 
from a range of sites. Isolation of B. pseudomallei on selective media, such as 
Ashdown’s media, remains the “gold standard” for a positive diagnosis and may 
be coupled with commercial biochemical testing or microscopy (Wuthiekanun et 
al. 1990; Currie 2015; Dance 2014).  
Real time PCR to target the B. pseudomallei type three secretion system gene 
cluster (T3SS-1) (Kaestli et al. 2012) and latex agglutination assays, where a 
range of antibodies detect B. pseudomallei antigens (Amornchai et al. 2007), 
have also been used within a laboratory setting to identify B. pseudomallei. 
Outside the lab, a rapid antigen detection test using a dipstick lateral flow 
immunoassay, containing antibodies that target the capsular polysaccharide of 
B. pseudomallei, is being tested. If successful, this test would allow rapid 
diagnosis at point of care (Houghton et al. 2014; Currie 2015). 
The treatment for melioidosis is currently at least 10 days of intravenous 
ceftazidime (or another 3rd generation cephalosporin, such as carbapenem and 
imipenem,) followed by a 20 week course of oral trimethoprim-sulfomethoazole, 
chloramphenicol and doxycycline (Dance 2014; Currie 2015). Even with this 
treatment regimen, there is still a 10% relapse rate. If the oral treatment is taken 
for less than 8 weeks then the relapse rate is 30% (Chaowagul et al. 1993). 
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1.4 Aims 
 Evaluate toxin BPSS0390 as a potential novel antimicrobial compound, 
 Identify residues or regions in BPSS0390 toxin involved in toxicity and 
BPSS0390-BPSS0391complex formation. 
 Determine if type II TA antitoxins in B. pseudomallei form a co-operative 
network through non-cognate toxin-antitoxin interactions. 
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Chapter 2: Materials and Methods 
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2.1 Bacterial strains and plasmids 
Bacterial strains used in this study are described in Table 2.0. Plasmids used in 
this study are described in Table 2.1. 
2.2 Bacterial storage 
2.2.1 Long term storage 
Bacteria were kept at –80°C in an O ring sealed cryovial for months or years. A 
known volume of overnight culture was mixed with an equal volume of sterile 
50% glycerol before freezing. 
2.2.2 Fridge storage 
For short term storage, E. coli and B. thailandensis strains on LB agar plates 
were kept for up to 2 weeks at 4°C. Vibrio species on LB agar plates were 
stored at room temperature for periods of up to 2 weeks. 
2.3 Bacterial growth 
2.3.1 Culture media 
All bacterial strains were cultured on autoclaved Luria-Bertani (LB) medium 
(product 10638013, Fisher Scientific), aerobically with shaking at 37°C unless 
otherwise specified. Agar plates were LB agar, where 1.5% Bacto-agar number 
2 (product MC006, Lab M) was added.  
Conjugations into B. thailandensis were initially plated onto Brain Heart Infusion 
medium (Table 2.2) and Thiosulfate-citrate-bile salts-sucrose (TCBS) medium 
was used to select for Vibrio species after conjugation (Table 2.3). 
 
 
 
68 
 
Table 2.0: Bacterial strains used 
Bacterial strain Comments Source 
Escherichia  coli K-12 
MG1655 
F
-
 λ
-
 ilvG- rfb-50 rph-1 Laboratory collection 
E. coli DH5α  λpir ΔlacU169(ΦlacZΔM15), 
recA1, endA1, hsdR17, 
thi-1, gyrA96, relA1, λpir 
phage lysogen 
Laboratory collection 
E. coli ΔhipBA:  E. coli MG1655 derivative 
ΔhipBA: Cm
R
 
(Butt 2013) 
E. coli XL-10 Gold endA1 glnV44 recA1 thi-1 
gyrA96 relA1 lac Hte 
Δ(mcrA)183 Δ(mcrCB-
hsdSMR-mrr)173 
tet
R
 F'[proAB lacI
q
ZΔM15 
Tn10(Tet
R
 Amy Cm
R
) 
Stratagene 
Burkholderia 
thailandensis E264 
Environmental isolate. Laboratory collection 
Yersinia 
pseudotuberculosis       
IP32953 
Clinical isolate. Laboratory collection 
Salmonella enterica 
serovar Typhimurium 
SL1344 
Animal isolate Laboratory collection 
Vibrio vulnificus 
E64MW 
Environmental isolate Laboratory collection 
E. coli DH5a 
(pRK2013) 
ΔlacU169(ΦlacZΔM15), 
recA1, endA1, hsdR17, 
thi-1, gyrA96, relA1, 
pRK2013 (KmR oriColE1 
RK2-Mob
+
 RK2-Tra
+
 
Laboratory collection 
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Table 2.1: Plasmids used or created in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
Plasmids Comments Source 
pBAD/his-BPSS0390 Ampicillin
R 
, BPSS0390 
cloned into NcoI and 
HindIII sites. N-terminus 
histidine tag. 
 
(Butt et al. 2013) 
pBAD/his-H24A Ampicillin
R 
, mutated 
BPSS0390 H24A cloned 
into NcoI and HindIII 
sites. N-terminus histidine 
tag. 
(Butt et al. 2013) 
pSCrhaB2 Trimethoprim
R
, with a 
rhamnose inducible 
promoter 
(Cardona & Valvano 
2005) UK Defence 
Science and 
Technology 
Laboratory. 
pSCrhaB2/his-
BPSS0390 
Trimethoprim
R
, with a 
rhamnose inducible 
promoter and BPSS0390 
cloned into NcoI and 
HindIII.  
This study 
pSCrhaB2/his-H24A Trimethoprim
R
, rhamnose 
inducible promoter and 
mutated BPSS0390 H24A 
cloned into NcoI and 
HindIII sites. N-terminus 
histidine tag. 
This study 
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Table 2.2: BHI medium 
Components Per litre 
Brain Heart Infusion 37 g 
dH2O To 1 litre 
 
To make BHI agar plates 1.5% bacto-agar was added before autoclaving. 
 
Table 2.3: TCBS medium 
Components Per litre 
Cholera medium TCBS 88 g 
dH2O To 1 litre 
 
Medium was boiled to dissolve completely. To make TCBS plates 1.5% bacto-
agar was added before boiling. 
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2.3.2 Recovery from freezer storage 
Freezer stocks were removed the freezer, a sterile loop used to remove a small 
amount of frozen culture and inoculated onto the surface of an LB agar plate. 
The inoculated plate was placed in a static 37°C incubator. The freezer stocks 
were returned to the freezer. 
2.3.3 Growth of bacteria for assays 
A single colony was removed from a streak plates and used to inoculate 5ml LB 
in 30ml universal. The culture was incubated at 37°C with 200rpm shaking 
overnight. 
2.4 Growth curve analysis 
Overnight cultures of E. coli harbouring pBAD/his-mutant alleles were diluted to 
an OD590nm of 0.01 in fresh LB with 100 µg/ml ampicillin, before 100µl of the 
diluted culture was placed into individual wells in 96-well plate. Samples were 
loaded in triplicate, three wells were left empty and three were loaded with 
growth media only, as a control. The 96 well plate was incubated overnight at 
37°C, without shaking, in a Softmax Pro-5 Microplate Reader (Versamax), 
programmed to take automated OD590nm reading every 15 minutes.  
2.5 Antibiotics used  
All antibiotics used in this work are shown in table 2.4. Antibiotics supplied by 
Sigma-Aldrich. Antibiotics dissolved in distilled water were filter sterilised using 
a 0.2µm filter (Minisart Sigma-Aldrich) before use. 
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Table 2.4: Antibiotics used and their storage conditions 
 
 
 
 
 
 
 
 
 
 
Antibiotic Stock solution Storage conditions Final concentration in 
culture 
Ampicillin 100 mg/ml in 
water 
-20°C in solution 100 µg/ml 
Gentamicin 100 mg/ml in 
water 
-20°C in solution 100 µg/ml 
Tetracycline 15 mg/ml in 
water 
-20°C in solution 15 µg/ml 
Trimethoprim 50 mg/ml in 
DMSO 
Room temperature in 
solution 
50 µg/ml(or 100 µg/ml  for 
plasmid maintenance in B. 
thailandensis E264 or V. 
vulnificus E64MW) 
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2.6 Competent cells         
2.6.1 Calcium competent cells   
A calcium chloride method was used. 5ml of LB was inoculated with the 
appropriate E. coli strain and incubated with shaking overnight at 37°C. The 
overnight culture was diluted 1:100 into 100ml of fresh LB in a 500ml conical 
flask and grown with shaking until an OD590nm between 0.5-0.7 was reached. 
The culture was poured into pre-chilled Falcon tubes and incubated on ice for 
10 minutes. Cells were pelleted by centrifugation at 3,200 x g for 10 minutes in 
an eppendorf Centrifuge 5810 R chilled to 4°C and the subsequent pellet 
resuspended in 50ml ice cold, sterile 0.1M calcium chloride solution before 
incubation on ice for 30 minutes. Cells were pelleted again and the subsequent 
pellet resuspended in 600µl 0.1M calcium chloride and 300µl sterile 50% 
glycerol then aliquoted and stored at –80°C. 
 
2.6.2 Electrocompetent cells  
An overnight culture of the desired transformant strain was diluted 1:100 into 
100ml of fresh LB in a 500ml conical flask and grown with shaking until an 
OD590nm between 0.5-0.8 was reached. The culture was poured into pre-chilled 
Falcon tubes and incubated on ice for 10 minutes. Cells were pelleted by 
centrifugation at 3,200 x g for 10 minutes in an eppendorf Centrifuge 5810 R 
chilled to 4°C and the subsequent pellet resuspended in 50ml ice cold, sterile 
water. Cells were pelleted as described previously before resuspension in 25ml 
ice cold, sterile water before centrifugation again and resuspension in 5ml ice 
cold, 10% glycerol. Cells were pelleted a final time and aliquoted before storage 
at –80°C.      
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2.7 Transformation  
2.7.1 Heat Shock 
An aliquot of calcium chloride competent cells was thawed on ice and up to 2µl 
of purified plasmid (up to 500 ng of DNA) or an entire ligation reaction added. 
The sample was incubated on ice for 30 minutes before a heat shock at 42°C 
for exactly 90 seconds, then returned to ice for 2 minutes before 900µl of room 
temperature LB added. Cells were recovered at 37°C with shaking for 1 hour. 
After this, 100µl was plated on selective LB agar plates. The remainder of the 
sample was pelleted by centrifugation (eppendorf Centrifuge 5424, 17,000 x g) 
before resuspension in 100µl of fresh LB and plated onto selective media. 
When the plasmid transformed was pBAD/his-BPSS0390 or pSCrhaB2/his-
BPSS0390 glucose (final concentration 2% (w/v)) was added to the recovery 
media and selective LB agar plates. 
2.7.2 Electroporation 
A 100µl aliquot of electrocompetent cells was thawed on ice and up to 500 ng of 
extracted plasmid added before the samples were transferred to pre-chilled 
electroporation cuvettes. A Bio-Rad MicroPulser was used to electroporate the 
cells with 2kV. Immediately after electroporation 1ml of LB broth was added the 
cuvette, then transferred to a 1.5ml Eppendorf and the cells allowed to recover 
aerobically with shaking for 1 hour. 100µl of cell suspension was spread onto 
selective LB agar plates. When the plasmid was pBAD/his-BPSS0390 or 
pSCrhaB2/his-BPSS0390  glucose (final concentration 2% (w/v)) was added to 
the recovery media and selective LB agar plates. 
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2.7.3. Conjugation into V. vulnificus E64MW 
E. coli DH5α harbouring either pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-
H24A was used as the donor strain. E. coli DH5α harbouring pRK2013 was 
used as a helper. The recipient was V. vulnificus E64MW. Cultures of the 
helper, donor and recipient strains were grown in LB media with the appropriate 
antibiotic selection at 37°C with shaking overnight. The next day, 1ml of each 
culture was transferred into 1.5ml Eppendorf tubes and cells isolated by 
centrifugation at 8,000 x g in an eppendorf Centrifuge 5424. The supernatant 
was removed, and the cells resuspended in 1ml of sterile PBS before 
centrifugation again as described.  Supernatant was removed and the donor 
and helper strains resuspended in 200μl of LB without antibiotic. 100μl of donor 
and helper were then added to the cell pellet of the recipient strain and re-
suspended to make a conjugation mix. 100μl of the mixed bacterial culture was 
then added to an LB plate and left as a pool for plasmid exchange. 100μl of 
donor, recipient and helper strain were also plated as controls. Plates were 
incubated at 37oC in an upright position overnight in a static incubator.  The 
next day the lawns of bacteria on the test and control plates were scraped off of 
the plate using a loop and resuspended in 1ml volumes of PBS in Eppendorf 
tubes. 100μl volumes were then plated onto TCBS plates containing 50 µg/ml 
trimethoprim.  These plates were incubated for 2-3 days at 37oC for colonies to 
grow. Colonies were then re-streaked onto LB trimethoprim to confirm that they 
were conjugants.    
2.7.4 Conjugation into B. thailandensis E264 
E. coli DH5α harbouring either pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-
H24A was used as the donor strain. E. coli DH5α harbouring pRK2013 was 
used as a helper. The recipient was B. thailandensis E264. Cultures of the 
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helper, donor and recipient strains were grown in LB media with the appropriate 
antibiotic selection at 37°C with shaking overnight. The next day, 1ml of each 
culture was transferred into 1.5ml Eppendorf tubes and cells isolated by 
centrifugation at 8,000 x g in an eppendorf Centrifuge 5424. The supernatant 
was removed, and the cells resuspended in 1ml of sterile PBS before 
centrifugation again as described.  Supernatant was removed and the donor 
and helper strains resuspended in 200μl of LB without antibiotic. 100μl of donor 
and helper were then added to the cell pellet of the recipient strain and re-
suspended to make a conjugation mix. 100μl of the mixed bacterial culture was 
then added to a BHI agar plate and left as a pool for plasmid exchange. 100μl of 
donor, recipient and helper strain were also plated as controls. Plates were 
incubated at 37oC in an upright position overnight in a static incubator.  The 
next day the lawns of bacteria on the test and control plates were scraped off of 
the plate using a loop and resuspended in 1ml volumes of LB in Eppendorf 
tubes. 100μl volumes were then plated onto LB plates containing 100 µg/ml 
trimethoprim and 100 µg/ml gentamicin.  These plates were incubated for 2-3 
days at 37oC for colonies to grow. Colonies were then re-streaked onto LB 
trimethoprim to confirm that they were conjugants.   
2.8 Toxicity assays  
2.8.1 Toxicity assays with E. coli harbouring pBAD/his cloned toxin 
genes or cloned mutant toxin genes 
E. coli strains carrying pBAD/his cloned toxins or mutated toxins were 
inoculated into 5ml of LB containing 100 µg/ml ampicillin and a final 
concentration of 2% (w/v) glucose and grown overnight at 37oC, 200rpm. 
Cultures were then diluted 1:100 into 50ml fresh LB in a 250ml conical flask and 
supplemented with fresh antibiotic. Cultures were grown at 37oC in a shaking 
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incubator at 200rpm until reaching an OD590nm of ~0.1 and 5ml volumes of 
culture were aliquoted into 30ml universal tubes. To induce gene expression 
from the PBAD promoter arabinose was added to a final concentration of 0.2% 
(w/v). To repress expression glucose was added to a final concentration of 
0.2% (w/v) glucose. Cultures were returned to the 37oC incubator and grown for 
a further 3 hours taking samples every hour measuring the OD590nm and 
determining CFU counts. Alternatively, the CFU was determined after 0 and 2 
hours and the fold change in CFU counts was calculated. OD590nm was 
measured using a spectrophotometer blanked with LB. CFU was determined by 
serial diluting cultures in LB in a 96 well plate and spot plating onto LB-ampicillin 
(100 µg/ml) glucose plates. Plates were incubated at 37oC overnight in a static 
incubator. 
2.8.2 Toxin expression in B. thailandensis, V. vulnificus and Y. 
pseudotuberculosis 
Bacterial strains carrying pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-H24A 
were inoculated into 5ml of LB containing trimethoprim (100 µg/ml for B. 
thailandensis and V. vulnificus and 50 µg/ml for Y. pseudotuberculosis) and a 
final concentration of 2% (w/v) glucose and grown overnight at 37oC, 200rpm. 
Cultures were then diluted 1:100 into 50ml fresh LB in a 250ml conical flask and 
supplemented with fresh antibiotic. Cultures were grown at 37oC in a shaking 
incubator at 200rpm until reaching an OD590nm of ~0.1 and 5ml volumes of 
culture were aliquoted into 30ml universal tubes. To induce gene expression 
rhamnose was added to a final concentration of 0.5% (w/v). To repress 
expression glucose was added to a final concentration of 0.5% (w/v). Cultures 
were returned to the 37oC incubator and grown for a further 3 hours taking 
samples every hour measuring the OD590nm and determining CFU counts. 
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OD590nm was measured using a spectrophotometer blanked with LB. CFU was 
determined by serial diluting cultures in LB in a 96 well plate and spot plating 
onto LB-trimethoprim (100 µg/ml for B. thailandensis and V. vulnificus and 50 
µg/ml for Y. pseudotuberculosis) and glucose (2%(w/v)) plates. Plates were 
incubated at 37oC overnight in a static incubator. 
2.8.3 Toxin expression in E. coli and S. Typhiumurium  
Bacterial strains carrying pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-H24A 
were inoculated into 5ml of LB containing trimethoprim (50 µg/ml) and a final 
concentration of 2% (w/v) glucose and grown overnight at 37oC, 200rpm. 
Cultures were then diluted 1:100 into 50ml fresh LB in a 250ml conical flask and 
supplemented with fresh antibiotic. Cultures were grown at 37oC in a shaking 
incubator at 200rpm until reaching an OD590nm of ~0.1 and 5ml volumes of 
culture were aliquoted into 30ml universal tubes. To induce gene expression 
rhamnose was added to a final concentration of 0.2% (w/v). To repress 
expression glucose was added to a final concentration of 0.2% (w/v). Cultures 
were returned to the 37oC incubator and grown for a further 3 hours taking 
samples every hour measuring the OD590nm and determining CFU counts. 
OD590nm was measured using a spectrophotometer blanked with LB. CFU was 
determined by serial diluting cultures in LB in a 96 well plate and spot plating 
onto LB-trimethoprim (50 µg/ml) and glucose (2% (w/v)) plates. Plates were 
incubated at 37oC overnight in a static incubator. 
 
2.9 Co-expression assays 
E. coli harbouring pBAD cloned toxin or mutant toxin and pME6032 cloned 
antitoxin were inoculated into 5ml LB supplemented with 15 µg/ml tetracycline, 
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100 µg/ml ampicillin and a final concentration of 2% (w/v) glucose  and grown 
overnight at 37oC, 200rpm. The following day the culture was diluted 1:100 in 
50ml of fresh LB in a 250ml conical flask and supplemented with fresh ampicillin 
and tetracycline at the same concentration. Cultures were grown at 37oC, 
200rpm until reaching an OD590nm of ~0.1. Cultures were then aliquoted into 3 
x 5ml volumes in 30ml universal tubes supplemented with 0.2% (w/v) glucose or 
0.2% (w/v) arabinose or 0.2% (w/v) arabinose and 1mM IPTG. Cultures were 
returned to the incubator and samples were taken after 2 hours, or hourly for 
three hours, for measurement of OD590nm by spectrophotometry and CFU 
determination by serial dilutions in 96 well plates. Cells were spot plated onto 
LB ampicillin tetracycline glucose (2% (w/v)) plates and incubated overnight at 
37oC. 
2.10 Preparation of samples for Scanning Electron Microscopy 
(SEM) 
Samples were taken at T0 (before addition of inducer/repressor), T1 (one hour 
post induction/repression) and T3 (three hours post induction/repression) from 
cultures expressing BPSS0390 or BPSS0390 H24A The 1ml samples were 
centrifuged at 4°C for 5 minutes and the supernatant discarded. Samples were 
then washed three times in 1 x PBS before resuspension in 0.1M phosphate 
buffer or distilled, sterile water before pipetting onto grids, fixing for 1 hour using 
osmium tetroxide and dehydrated using ethanol. Grids were viewed using a 
Hitachi S3200N SEM-EDS. 
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2.11 DNA extraction 
2.11.1 Extraction of digested DNA fragments and plasmids from 
agarose gel  
Successfully digested fragments and/ or plasmids were excised from the 
agarose gel after electrophoresis using a scalpel and each piece of gel placed 
into an individual 1.5ml Eppendorf tube. Agarose gel pieces were weighed 
before a ThermoScientific Gel Extraction kit was used according to 
manufacturer’s protocol to purify the DNA.   
2.11.2 Plasmid extraction     
Plasmid DNA was extracted from an overnight culture of bacteria (typical 
volume of 5ml) using a ThermoScientific GeneJET Plasmid Miniprep Kit 
according to manufacturer’s instructions.   
2.12 DNA amplification by Polymerase Chain Reaction (PCR) 
 A Biometra T Professional TRIO Thermocycler was used to amplify DNA by 
PCR following the variations on the programme listed in Table 2.4. All reactions 
used either Failsafe (Cambio) or Hot Star Taq (Qiagen) polymerase and had a 
final volume of either 20µl or 50µl with buffers and concentrations used 
according to the manufacturer’s protocol.    
2.12.1 Boilate preparation for colony PCR  
To confirm the presence of a clone or to identify V. vulnificus or B. thailandensis 
after conjugation a colony boilate was used. A single colony was resuspended 
in 100 µl of distilled water and boiled for 5 minutes at 95°C using a Stuart Block 
heater. Alternatively, 1ml of overnight culture was pelleted by centrifugation 
(eppendorf Centrifuge 5424, 17,000 x g), washed in 1ml sterile 1xPBS and re-
centrifuged to pellet the cells. The cells were then resuspended in 100µl of 
distilled water and boiled for 5 minutes at 95°C using a Stuart Block heater. 
81 
 
Boiling ruptured cells and released DNA. The boilate was centrifuged to pellet 
the boiled cells (eppendorf Centrifuge 5424, 17,000 x g) and the supernatant 
used in PCRs as a source of bacterial DNA. 
2.13 PCR purification  
GeneJET PCR Purification Kit was used according to manufacturer’s 
instructions. DNA was eluted into EB or nuclease free water.  
2.14 Agarose gel electrophoresis   
Gel electrophoresis was used to separate DNA fragments generated by PCR or 
required for cloning. Samples were mixed with 6 x Loading dye (Thermo 
Scientific) and loaded into gels made from 1% (w/v) agarose dissolved in 1 x 
Tris-acetate-EDTA (TAE) with Midori Green Advanced DNA stain (Nippon 
Genetics Europe GmbH) added for band visualisation. Gels were also loaded 
with DNA molecular marker; 5µl 1 kb Plus DNA ladder (Thermo Scientific) was 
used. A  Bio-Rad PowerPac power supply was used to electrophorese the gel 
for 45 minutes at 90V. Gels were visualised with UV light using a BioRad Gel 
Documentation Unit and QuantityOne software.    
2.15 Determining DNA concentration  
DNA concentration was determined by loading 2µl of sample onto a Thermo 
Scientific NanoDrop 1000 spectrophotometer with ND1000 software and 
following the procedure provided by the manufacturers. The machine was 
washed with water, before loading the sample. 
 
2.16 Digestion of DNA using restriction enzymes 
Plasmid DNA was digested using High Fidelity enzymes provided by NEB in a 
final reaction volume of 50µl (Table 2.5). Reactions also contained the 
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appropriate buffer as recommended by the manufacturer. Digests were 
incubated at 37°C overnight. The entire reaction was then electrophoresed the 
following day. 
2.17 Ligations   
All ligation reactions had a final volume of 15μl and contained 1μl of T4 DNA 
ligase (NEB) and 1.5μl of ligation buffer. Each reaction also contained 150 ng of 
digested vector DNA but the amount of digested insert varied; it was calculated 
using the formula described below: 
Amount of insert (ng) =amount of vector (ng) x (Size of insert (kb)/ size of vector 
(kb)) x molar ratio (insert/vector) 
 A molar ratio of 4:1 was used and nuclease free water added to bring the final 
volume to 15µl. Reactions were incubated overnight at 15°C.   
2.18 pGEM-T-Easy cloning  
The gateway vector used was pGEM-T-Easy (Promega). Cloning was carried 
out as instructed by manufacturers. In summary, this involved incubating the 
PCR product with the gateway vector and T4 ligase at room temperature before 
transformation of the resulting ligated plasmid/PCR product into calcium 
competent cells. Blue/white screening was used to detect positive colonies by 
plating onto X-galactose and IPTG containing plates. White colonies were 
screened for presence of insert either by colony PCR. 
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Table 2.4: Table showing generic programme used for PCR 
Number of cycles Stage Temperature (°C) Time (seconds) 
1 Initial denaturation 95 60 
25-35 Denaturation 95 30 
25-35 Annealing 55-72 60 
25-35 Extension 72 60 
1 Final extension 72 600 
1 Final hold 4 ∞ 
 
 
Table 2.5: Contents of 50 µl restriction digest 
Component Volume or amount added 
Buffer 5µl 
Enzyme 1µl 
DNA 0.5 µg 
Nuclease-free water Up to final volume of 50µl 
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2.19 Sequencing of plasmid DNA 
Source Bioscience was used to determine the sequence of plasmids. Samples 
were diluted to a concentration of 100 ng/µl and sent with appropriate specific 
primers. Resulting DNA sequences were downloaded and aligned with 
reference sequences using Clone Manager. When unknown nucleotides, ‘N’, or 
inconsistencies were present in the text output, the automated chromatogram 
was examined at the corresponding position. If there was a well formed, evenly 
spaced, tall, clean peak at that position, with little to no baseline noise then that 
was taken as the nucleotide for that position. 
 
2.20 Site directed mutagenesis   
Primers for site directed mutagenesis were designed on the Agilent website and 
synthesised by Eurofins MWG. Primers contained the base pair(s) substitution 
needed to encode the amino acid change. Site directed mutagenesis was 
carried out on the histidine tagged BPSS0390 toxin DNA as per manufacturer’s 
instructions and using the Quick-change lightning kit. In summary, this involved 
the synthesis of forward and reverse mutant plasmid DNA strands using the 
designed primers, pBAD/his-BPSS0390 as a template and a pfu-based 
polymerase. DpnI was subsequently used to digest the parental non-mutant 
methylated DNA before transformation of the mutant plasmid into XL10-gold 
ultracompetent cells, for nick repair and replication, by heat shock in the 
presence of β-mercaptoethanol. Transformants were plated onto LB ampicillin 
(100 µg/ml) glucose (2%(w/v)) plates and grown overnight at 37oC. Colonies 
were then picked and plasmid DNA was re-isolated using the Qiagen miniprep 
kit as previously described and sent for sequencing to confirm that the 
appropriate nucleotides were mutated. 
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2.21 SDS-Polyacrylamide gel electrophoresis (PAGE)  
For detection of protein, 1 ml sample was taken from a culture, centrifuged and 
either lysed using BugBuster, lysozyme and benzonase or resuspended in 20µl 
of 4 x SDS loading before boiling at  95oC for 5 minutes in a heat block before 
loading. Novex NuPAGE 12% Bis-Tris gels (Life Technologies) were used. A 
total of 20μl of protein preparation were loaded into each well of the gel. 5μl of a 
protein ladder was loaded for size comparison. For the majority of gels the 
Protein perfect 10kDa-225kDa marker (Novagen) was used. Gels were run in 1 
x MES or MOPS buffer at 180V for 35minutes or until the protein reached the 
bottom of the gel. After the gel was run it was washed in de-ionised water 
before staining with simply blue protein stain (Invitrogen). The protein gel was 
incubated with approximately 20ml of Simply Blue stain and microwaved in 30 
second intervals until protein bands were visible. Following staining the gel was 
washed with de-ionised water 3 times and then incubated on a rocker in 100ml 
de-ionised water overnight to de-stain the gel.     
2.22 Western blots 
Protein samples were boiled, loaded and run on gels as previously described. 
After gel electrophoresis the gel was removed from its cast and washed twice in 
approximately 20ml of deionised water. The gel was then placed onto a 
nitrocellulose membrane using the iBlot dry blotting system (Invitrogen). The 
protein was blotted onto the appropriate membrane for 5-7 minutes using 20-
23V. The membrane was then transferred to 30ml of a 3% (w/v) BSA solution 
dissolved in TBST (Tris buffer saline 1% Tween) which was used as a blocking 
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agent. The membrane was incubated in this solution overnight at 4oC. The next 
day the solution was removed.  The anti-Xpress epitope antibody (Invitrogen) 
was diluted 1:5000 in 15ml of 3% (w/v) BSA dissolved in TBST and added to 
the membrane, incubating for 1 hour at room temperature on a rocker. 
Following this incubation step, the BSA and antibody mix was discarded and 
then 20ml of TBST was added to wash and incubated on a rocker for 10 
minutes before discarding. This washing process was repeated 3 times. A 
secondary IR Dye ® 800 CW Goat anti-mouse antibody was then diluted 
1:10,000 in 10ml of fresh 3% (w/v) BSA dissolved in TBST and incubated with 
the membrane for a further hour. The wash steps in TBST were repeated as 
described above. Protein on the membrane was detected using Odyssey ® CLx 
Imaging system and Image Studio software. 
2.23 Primer design 
Primers (excluding those for site-directed mutagenesis) were designed by 
examining the regions upstream and downstream of the desired sequence in 
Artemis and suitable areas chosen that would allow the primer to have a GC 
clamp at the 3’ end and no long repetitive sequences. Clone Manager was used 
to check that primers had similar Tm and no undesired homology to parent 
DNA. 
2.23.1 Primers designed for site directed mutagenesis 
Primers were designed using the Agilent QuickChange Primer design tool. For 
primer list please see Appendix. 
 
87 
 
2.24 Statistical analysis 
When comparing two values, an unpaired, parametric t-test assuming equal 
variance was used. For three or more values a one-way ANOVA with Dunnett’s 
post test (comparing experimental groups with a control) was used.  
The null hypothesis was rejected and a significant difference concluded, if the 
significance probability was less than or equal to 0.05. 
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Chapter 3: Over-expression and host 
specificity of toxin gene BPSS0390 
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3.0 Introduction  
The emerging antimicrobial resistance of many pathogenic bacteria 
threatens effective treatment of bacterial infections, a leading cause of human 
mortality worldwide (Chan et al. 2015; Lee & Lee 2016). The search for novel 
antimicrobial candidates has recently highlighted how TA systems could be 
exploited, including using toxin molecules as potential antimicrobials 
(Unterholzner et al. 2013; Lee & Lee 2016).  
Expression of TA toxin HicA in E. coli has been shown to induce cell 
growth arrest through cleavage of mRNA at an unknown specificity residue 
(Jørgensen et al. 2009). Similarly, expression of BPSS0390 (B. pseudomallei 
HicA) in E. coli resulted in a rapid decrease in the number of culturable cells 
after induction (Butt et al. 2013). This suggests that BPSS0390 might have the 
potential to be active in a broad range of bacteria and could be exploited as a 
novel bacteriostatic and bactericidal compound.  
Current studies and BSAC guidelines for testing of potential antimicrobial 
compounds state the minimum bactericidal concentration (MBC) of the novel 
compound as the lowest concentration of an agent that causes ≥ 3 log reduction 
in surviving cells within 24 hours of treatment (Schlievert et al. 2013; Peterson & 
Shanholtzer 1992). To investigate if BPSS0390 might meet these guidelines I 
decided to induce ectopic expression of the toxin from a broad host range 
plasmid in a range of Gram negative pathogenic bacteria and monitor patterns 
of growth inhibition. Using a range of pathogenic bacteria also allowed 
determination of the host specificity of BPSS0390.  
Three of the bacterial species chosen had genomic homologues to B. 
pseudomallei HicB; it was hoped that induction of ectopic BPSS0390 
90 
 
expression in these species might results in a neutralisation phenotype and 
allow for identification of critical residues involved in toxin-antitoxin complex 
formation. The selection of bacterial species was limited as species chosen had 
to be readily available within the lab, possess the correct antibiotic sensitivity to 
facilitate use of the plasmid and grow relatively quickly. 
 
3.1 Hypothesis 
 Toxin BPSS0390 is toxic in a range of bacterial species. 
 
3.1.1 Objectives 
 To induce expression of  B. pseudomallei toxin BPSS0390 in range of 
different bacterial species  
 To evaluate toxin BPSS0390 as a potential antimicrobial compound. 
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3.2 Results 
3.2.1 Generation of construct pBAD/his-BPSS0390 containing the 
native HicA sequence 
Previously reported data (Butt et al. 2013) used construct pBAD/his-
BPSS0390 where BPSS0390 gene was cloned into pBAD under the control of 
the arabinose promoter, for HicA toxin expression. Unfortunately, when this 
construct re-isolated for use in this study is was found to contain mutations so it 
was necessary re-generate the construct pBAD/his-BPSS0390.  
3.2.1.1 Cloning native BPSS0390 sequence directly into pBAD/his 
PCR was used to amplify BPSS0390 from genomic B. pseudomallei 
K96423 DNA. Both the PCR product insert and pBAD/his vector were treated 
with NcoI and HindIII before ligation. The ligation was recovered into E. coli 
DH5α. A screening PCR was used to identify clones containing the BPSS0390 
insert and seven constructs isolated and sent for nucleotide sequencing (Figure 
3.1). 
Sequencing analysis revealed that all of the constructs tested contained 
mutations within the hicA gene. Mutations included S3L, K42E, S23G, P41L, 
I47M and deletion of nucleotides that caused frame shift mutations in the gene. 
3.2.1.2 Cloning native BPSS0390 sequence into a holding vector. 
  PCR was used to amplify BPSS0390 from genomic B. pseudomallei 
K96423 DNA and the resulting product was mixed with a TA cloning vector 
(pGEM T-easy). The ligation was recovered into E. coli DH5α. A screening PCR 
was used to identify clones where the pGEM T-easy contained the BPSS0390 
insert and three plasmids were extracted and nucleotide sequenced (Figure 
3.2). Analysis of the sequencing data revealed that all of the constructs  
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Figure 3.1: Sequencing data from cloning to attempt to generate 
pBAD/his-BPSS0390. The sequences of BPSS0390 cloned into plasmid pBAD are 
shown as BPSS0390_2 to BPSS0390_8. FASTA sequence for gene BPSS0390 is at 
the top as a reference sequence. Clustal consensus is the consensus sequence of all 
sequences shown in the figure. Sequences were aligned using ClustalW and image 
generated using BioEdit. 
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Figure 3.2: Sequencing data from cloning to attempt to generate pGEM-
BPSS0390. The sequences of BPSS0390 cloned into pGEM plasmid are shown as 
pGEM1, pGEM2 and pGEM10. FASTA sequence for BPSS0390 is used as a 
reference. Clustal consensus is the consensus sequence of all sequences shown in the 
figure. Sequences were aligned using ClustalW and image generated using BioEdit. 
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contained mutations within the hicA gene sequence; two containing H25Y and 
one with L35P. 
3.2.1.3 Site directed mutagenesis of pBAD/his-BPSS0390 P41L 
As it was not possible to generate pBAD/his-BPSS0390 with an authentic hicA 
sequence, an Agilent QuikChange Lightning Site Directed Mutagenesis Kit was 
used to revert pBAD/his-BPSS0390 P41L back to the hicA wild type sequence. 
Initial attempts using the recommended annealing temperature of 68°C failed. 
However, once the annealing and elongation temperatures were increased to 
70°C, construct pBAD/his-BPSS0390 was successfully generated and the 
sequence confirmed (Figure 3.3). The required increase in annealing and 
elongation temperatures for the PCR step may be due to the high GC content of 
the native sequence and mutagenic primers. 
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Figure 3.3: Sequencing data from site directed mutagenesis to revert 
pBAD/his-BPSS0390 P41L to pBAD/his-BPSS0390. FASTA_BPSS0390 - wild 
type sequence; pBAD/his-0390 - the sequence of BPSS0390 after reversion of P41L 
mutation;  BPSS0390_P41L - sequence of BPSS0390 cloned into pBAD containing the 
P41L mutation (template for site-directed mutagenesis); Clustal consensus- consensus 
of all sequences shown. Sequences aligned using CLUSTALW and figure generated 
with BioEdit. 
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3.2.2 Induction of Expression of B. pseudomallei toxin gene 
BPSS0390 in wild type E. coli   
Construct pBAD/his-BPSS0390 was transformed into wild type E. coli MG1655.  
An overnight culture of E. coli  pBAD/his-BPSS0390 was then used to inoculate 
LB supplemented with ampicillin (100 µg/ml) and the culture incubated at 37°C 
with shaking until early log phase was reached (OD 590  ~ 0.1) . The culture was 
split and either toxin expression induced (addition of arabinose to a final 
concentration of 0.2% (w/v) arabinose) or repressed (addition of glucose to a 
final concentration of 0.2% (w/v)). The optical density (OD) of the cultures was 
monitored every hour, for three hours (Figure 3.4a). The colony forming units 
(CFU) were also measured every hour by serially diluting samples in a 96- well 
plate in LB before plating onto LB ampicillin plates for CFU counts the following 
day (Figure 3.4b). 
The addition of glucose to culture permitted E. coli cells to grow, as 
demonstrated by the increase in OD and increase in the number of culturable 
cells. However, when toxin expression was induced there was a decrease in the 
number of culturable cells after three hours. Despite this, the OD of the 
arabinose-supplemented culture continued to increase, although a reduced 
growth rate was observed when compared to the glucose control. 
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Figure 3.4: Effect of induction of BPSS0390 expression on E. coli MG1655: 
a) OD590 over three hours following induction (addition of arabinose to a final 
concentration of 0.2% (w/v)) or repression (addition of glucose to a final concentration 
of 0.2% (w/v)) of toxin expression at T0.  b) Number of culturable cells (CFU/ ml) after 
plating samples onto LB agar monitored every hour for three hours after toxin 
induction/repression at T0. Data is the average of three biological repeats and error 
bars represent SEM. 
 
 
a) 
b) 
0 1 2 3
0 .1
1
1 0
T im e  (h o u rs )
O
D
5
9
0
n
m
0 .2  %  g lu c o s e
0 .2  %  a ra b in o s e
0 1 2 3
1 0 5
1 0 6
1 0 7
1 0 8
1 0 9
1 0 1 0
T im e  (h o u rs )
C
F
U
/m
l
0 .2  %  g lu c o s e
0 .2  %  a ra b in o s e
b) 
98 
 
3.2.2.1 Induction of toxin expression using different concentrations of 
inducer. 
An overnight culture of E. coli MG1655 pBAD/his-BPSS0390 was used to 
inoculate LB supplemented with ampicillin (100 µg/ml)  and the culture 
incubated at 37°C with shaking until early log phase (OD 590 ~0.1) . The culture 
was split and arabinose added (to a final concentration of 0.002% or 0.02% or 
0.2% or 2% (w/v)) to induce toxin expression or glucose (final concentration of 
0.2% (w/v)) added to repress toxin expression. Optical density and CFU were 
then measured hourly for 3 hours (Figure 3.5). 
Addition of glucose permitted E. coli cells to continue growing; both the OD and 
number of culturable cells increased. Addition of final concentration of 0.002% 
(w/v) arabinose resulted in a reduced growth rate but the number of culturable 
cells increased. Increasing the final concentration of arabinose 10-fold to 0.02% 
(w/v) resulted in a reduced growth rate and the number of culturable cells 
becoming static. Increasing the final concentration of arabinose to 2% (w/v) 
resulted in immediate bacteriostasis followed by a decrease in culturable cells 
after 2 hours. 
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Figure 3.5:  Effect of addition of different concentrations of inducer 
arabinose on a) optical density or b) number of culturable cells. Addition of 
arabinose to a higher final concentration reduced the growth rate. Adding arabinose to 
a final concentration higher than 0.2% (w/v) resulted in a decrease in the number of 
culturable cells, whilst adding only arabinose to a final concentration of 0.02% (w/v) led 
to bacteriostasis. Data shows mean of three biological repeats and error bars represent 
SEM. 
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3.2.2.2 Identification of mutated residues in gene BPSS0390 within 
construct pBAD/his-BPSS0390 
Induction of toxin expression in E. coli harbouring pBAD/his-BPSS0390 
in an early log phase culture did not reproducibly result in a decrease in 
culturable cells (Figure 3.5a). In some cultures, after induction of toxin 
expression at T0, the number of culturable cells continued to increase similar to 
the glucose-repressed control cultures. 
  When this different phenotype was observed, the pBAD/his-BPSS0390 
plasmids were isolated from cultures and nucleotide sequenced. Comparison 
against the wild type BPSS0390 sequence revealed a mutation, resulting in a 
premature stop codon at position 31 in place of a lysine. (Figure 3.5b) 
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Figure 3.6: Abolished toxicity phenotype observed after induction of 
expression from toxin gene BPSS0390 K31*.a) Example of a culture where the 
induction of toxin expression by addition of arabinose to a final concentration of 0.2% 
(w/v) did not result in the number of culturable cells decreasing. Data shows mean of 
two biological repeats and error bars represent SEM. b) Sequence alignment showing 
K31* mutation. FASTA_BPSS0390 - wild type sequence; BPSS0390 K31*- sequence 
of BPSS0390 containing K31* mutation and isolated from cultures where the toxic 
phenotype was lost. Consensus sequence is consensus of sequences displayed. 
ClustalW used to align sequences and BioEdit used to generate image. 
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3.2.2.3 Monitoring stability of gene BPSS0390 after prolonged induction of 
toxin expression 
An overnight culture of E. coli MG1655 harbouring  pBAD/his-BPSS0390 
was used to inoculate (1:100) LB media supplemented with ampicillin (100 
µg/ml) , which was grown until early log phase (OD590nm ~0.1). At this time either 
arabinose was added to a final concentration of 0.2% (w/v) to induce toxin 
expression or glucose to a final concentration of 0.2% (w/v) was added to 
repress toxin expression (Figure 3.7). Optical density and CFU were then 
measured hourly for 3 hours and cultures were then incubated at 37°C for a 
further 21 hours (a total of 24 hours).  Samples for sequencing were taken after 
3 hours and after 24 hours. These samples were plated onto LB ampicillin agar 
plates and incubated overnight. The following day, single colonies were picked 
at random from each plate and used to inoculate an overnight containing 
ampicillin (100 µg/ml) and glucose (2% (w/v)). The pBAD/his-BPSS0390 
construct was isolated from this overnight and sent for nucleotide sequencing. 
Ten constructs were sent for sequencing from both three hours after and 
24 hours after toxin expression or repression.  None of the twenty constructs 
isolated after glucose repression of the toxin contained any mutations. Of the 
twenty constructs isolated after toxin induction, one had a mutation that 
changed the amino acid sequence; after three hours of expression there was a 
substitution of the histidine residue at position 29 with a proline. 
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Figure 3.7: Monitoring stability of toxin gene BPSS0390: a) OD590 over three 
hours following induction (addition of arabinose to a final concentration of 0.2% (w/v) or 
repression (addition of glucose to a final concentration of 0.2% (w/v)) of toxin gene 
BPSS0390 at T0; b) Culturability (CFU/ml) monitored every hour for three hours after 
toxin induction/repression at T0. Data represents one biological repeat and error bars 
represent SEM; c) schematic overview of sampling time points during the stability 
monitoring experiment. Blue lines indicate the time at which a sample was taken for 
analysis. 
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3.3. Induction of expression of toxin BPSS0390 in a range of 
bacterial species 
3.3.1 Generation of suitable broad host range plasmids 
pSCrhaB2/his-BPSS0390 and pSCrhaB2/H24A 
To investigate whether the induction of ectopic expression of BPSS0390 
caused growth arrest in a range of bacteria species it was first necessary to 
clone the BPSS0390 gene into a broad host range construct capable of 
replication within many different Gram negative species. Plasmid  pSCrhaB2 
was chosen; it is a broad host range vector with a rhamnose inducible promoter, 
Prha and a dihyrdofolate reductase gene encoding trimethoprim resistance 
(Cardona & Valvano 2005). 
A DNA fragment encoding histidine tagged BPSS0390 (BPSS0390/his) 
was released from pBAD/his-BPSS0390 by restriction digestion with NcoI and 
HindIII. The digest was electrophoresed in an agarose gel and visualised under 
UV light. The appropriate band was cut out and the DNA extracted. The vector 
pSCrhaB2 was also restriction digested with NcoI and HindIII, electrophoresed 
and the linearised DNA extracted from the gel. The digested DNA fragment 
encoding BPSS0390/his was ligated into digested pSCrhaB2 and recovered 
into E. coli DH5α.  A colony screening PCR was used to identify clones 
containing BPSS0390/his. 5ml overnight cultures of LB supplemented with 
trimethoprim (50 µg/ml) and glucose (final concentration 2% (w/v)) were 
inoculated with single colonies. Glycerol stocks were generated using 0.5ml of 
the overnight culture and the plasmid extracted from the remaining 4.5ml of 
culture. Nucleotide sequencing was used to confirm that the BPSS0390 gene 
was intact and unmutated. 
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A control was required to ensure that any phenotypes observed were 
due to toxin expression only. A previously characterised mutation within 
BPSS0390, where a histidine residue at position 24 was deliberately mutated to 
an alanine, abolished toxicity completely (Butt et al. 2014). This mutated gene, 
BPSS0390 H24A was released from pBAD/his-H24A by restriction digestion 
and ligated into pSCrhaB2 as described above to generate pSCrhaB2/his-H24A  
before recovery in E. coli DH5α. Nucleotide sequencing was used to confirm 
that the desired mutation was present. 
 
3.3.2 Induction of expression of BPSS0390 from pSCrhaB2/his-
BPSS0390 in E. coli MG1655 
Plasmids pSCrhaB2/his-BPSS0390 and pSCrhaB2/his-H24A were 
transformed into E. coli MG1655 by electroporation. After electroporation, cells 
were recovered in LB supplemented with glucose (final concentration 2% (w/v)) 
and plated onto LB agar supplemented with glucose (final concentration 2% 
(w/v)) and trimethoprim (50 µg/ml). Overnight cultures in LB supplemented with 
trimethoprim (50 µg/ml) and glucose (final concentration 2% (w/v)) were 
inoculated using transformant single colonies. After culturing overnight, glycerol 
stocks were generated using 0.5ml of the overnight culture and the plasmid 
extracted from the remaining 4.5ml of culture. Nucleotide sequencing was used 
to confirm that the BPSS0390 gene was intact and unmutated. 
Overnight cultures in LB supplemented with glucose (final concentration 
2% (w/v)) and trimethoprim (final concentration 50 µg/ml) of E. coli MG1655 
harbouring either pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-H24A were used 
to inoculate (1:100) fresh LB media supplemented with trimethoprim and grown 
until early log phase (OD 590 nm ~ 0.1). The cultures were split before addition of 
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either rhamnose (final concentration 0.2% (w/v) to induce toxin expression) or 
glucose (final concentration 0.2% (w/v) to repress toxin expression). The optical 
density and number of culturable cells was monitored hourly, for three hours for 
E. coli pSCrhaB2/his-BPSS0390 (Figure 3.8a, b) and E. coli pSCrhaB2/his-
H24A (Figure 3.8c, d). 
Induction of expression from pSCrhaB2/his-BPSS0390 resulted in a 
reduced growth rate and a rapid decrease in the number of culturable cells 
whilst the addition of glucose permitted cell growth. The growth of E. coli 
possessing pSCrhaB2/his-H24A was similar in cultures to which either 
rhamnose or glucose was added.  
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Figure 3.8: Effects of induction or repression of expression of BPSS0390 
or BPSS0390 H24A from pSCrhaB2/his-BPSS0390 and pSCrhaB2/his-
H24A in E. coli MG1655: a) Growth over three hours following induction (0.2% (w/v) 
rhamnose) or repression (0.2% (w/v) glucose) of BPSS0390; b) Profile showing change 
in number of culturable cells after induction or repression of toxin expression at T0; c) 
Growth over three hours following induction (0.2% (w/v) rhamnose) or repression (0.2% 
(w/v) glucose) of expression of non-toxic mutant BPSS0390 H24A; d) Profile showing 
change in number of culturable cells after induction or repression of non-toxic control 
H24A at T0. Each graph shows mean of two biological replicates and error bars 
represent SEM. 
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3.3.2.1. Induction of toxin expression in E. coli using different 
concentrations of rhamnose. 
Overnight cultures of E. coli MG1655 harbouring either pSCrhaB2/his-
BPSS0390 or pSCrhaB2/his-H24A that had been supplemented with glucose 
(final concentration 2% (w/v) and trimethoprim 50 µg/ml) were used to inoculate 
(1:100)  fresh LB media supplemented with trimethoprim (50 µg/ml) and grown 
until early log phase (OD 590 nm ~ 0.1) was reached. The culture was split and 
different concentrations of rhamnose (0.002%, 0.02%, 0.2% or 2% ((w/v) final 
concentrations)) were added to induce toxin expression or glucose (final 
concentration 2% (w/v)) was added to repress. Optical density and CFU were 
measured hourly for 3 hours (Figure 3.9). 
When glucose was added the cells continued to grow, as demonstrated by the 
increase in OD and increase in number of culturable cells. The addition of 
rhamnose reduced the growth rate and decreased the number of culturable 
cells at three hours. However, 0.002% and 0.02% (w/v) rhamnose resulted in 
the number of culturable cells increasing initially at a similar rate to the glucose 
repressed control, before declining after one hour. Adding a final concentration 
of 2% rhamnose resulted in a decrease in the number of culturable cells, very 
similar to the profile observed when a final concentration of 0.2% (w/v) 
rhamnose was added (Figure 3.9a). 
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Figure 3.9: Effect of different concentrations of rhamnose or glucose on a) 
optical density and b) culturable cells. Cultures of E. coli MG1655 harbouring  
pSCrhaB2/his-BPSS0390 were cultured in the presence of the final concentrations of 
rhamnose or glucose indicated.  Any addition of rhamnose resulted in a decreased 
growth rate and a decrease in culturable cells over time. Data shows mean of two 
biological repeats and error bars represent SEM. 
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3.3.3 Expression of BPSS0390 in Salmonella enterica serovar 
Typhimurium SL1344  
Salmonella enterica subspecies are associated with a variety of intestinal 
diseases in a broad range of hosts. S. enterica serovar Typhimurium infection in 
humans results in salmonellosis, whilst infection in mice is frequently used as 
an animal model for systemic typhoid in humans (Northen et al. 2010). 
A BLASTp alignment comparing the protein sequence of B. pseudomallei 
K96243 HicB against all available non-redundant protein sequences available 
for S. Typhimurium SL1344 was conducted and no significant similarity was 
found. 
S. Typhimurium was screened for any trimethoprim resistance by 
streaking onto LB agar only, LB agar supplemented with trimethoprim (50 
µg/ml) or LB agar supplemented with trimethoprim (100 µg/ml). Growth was 
only observed on the LB agar only plate indicating that S. Typhimurium SL1344 
did not harbour any pre-existing trimethoprim resistance. 
Constructs pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-H24A were 
transformed into S. Typhimurium by electroporation, cells were recovered in LB 
broth supplemented with glucose (final concentration 2% (w/v)) and plated onto 
LB agar with glucose (final concentration 2% (w/v))  and trimethoprim (50 
µg/ml). Overnight cultures of LB containing trimethoprim (50 µg/ml) and glucose 
(final concentration 2% (w/v)) were inoculated using single colonies recovered 
after the electroporation. The following day, glycerol stocks were created using 
0.5ml of the overnight cultures and plasmids extracted from the remaining 4.5ml 
of cultures. Nucleotide sequencing was used to confirm that the native 
BPSS0390 gene in pSCrhaB2/his-BPSS0390 did not contain any mutations and 
that the expected mutation was present in pSCrhaB2/H24A. 
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Overnight cultures of S.Typhimurium harbouring either pSCrhaB2/his-
BPSS0390 or pSCrhaB2/his-H24A, which had been supplemented with glucose 
(final concentration 2% (w/v) and trimethoprim at final concentration 50 µg/ml)  
overnight were used to inoculate (1:100)  fresh LB media supplemented with 
trimethoprim (50 µg/ml)  and grown until early log phase (OD 590 nm ~ 0.1) was 
reached. The cultures were split before addition of either rhamnose to a final 
concentration of 0.2% (w/v) (to induce toxin expression) or glucose to a final 
concentration of  0.2% (w/v)  (to repress toxin expression). The optical density 
and number of culturable cells was monitored for three hours (Figure 3.10). 
The addition of glucose or rhamnose did not affect the growth of 
S.Typhimurium harbouring BPSS0390 H24A. However, the induction of toxin 
BPSS0390 expression resulted in a rapid decrease of almost 10,000 culturable 
cells and a greatly reduced growth rate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
 
 
 
 
 
 
  
  
 
 
 
Figure 3.10: Induction of toxin expression in S. Typhimurium SL1344. 
Growth over three hours following induction (0.2% (w/v) rhamnose) or repression (0.2% 
(w/v) glucose) of BPSS0390. a) OD590nm b) culturable cells; or induction (0.2% (w/v) 
rhamnose) or repression (0.2% (w/v) glucose) of BPSS0390 H24A c) OD590nm d) 
culturable cells. Each graph shows mean of three biological replicates and error bars 
represent SEM. 
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3.3.4. Induction of expression of BPSS0390 in species with partial 
HicB (BPSS0391) homologues 
3.3.4.1 Selection of suitable bacterial species with partial HicB 
homologues 
A BLASTp search of B. pseudomallei BPSS0391 against all non-redundant 
protein sequences was carried out and a distance tree of the results (Figure 
3.11) used to identify bacteria from different classes that were readily available 
within the lab. Species were also chosen to have to have HicB homologues with 
less than 50% identity when compared to B. pseudomallei antitoxin; it was 
hoped that toxin expression in such a species might give rise to a partial 
neutralisation phenotype and identify critical residues in HicB involved in toxin-
antitoxin complex formation. 
Four species, Yersinia pseudotuberculosis IP32952, Vibrio vulnificus E64MW, 
Pseudomonas aeruginosa PA01 and Pseudomonas syringae were identified by 
this method and along with B. thailandensis were tested for trimethoprim 
resistance (Table 3.1). 
Both P. aeruginosa and P. syringae were resistant to trimethoprim at 100 µg/ml 
and so were not investigated further. Induction of ectopic toxin expression was 
carried out in Yersinia pseudotuberculosis, Vibrio vulnificus and B. 
thailandensis. 
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Figure 3.11: Distance tree of results of BLASTp of B. 
pseudomallei BPSS0391 against all non-redundant 
protein sequences. A BLASTp search of B. pseudomallei BPSS0391 against 
all non-redundant protein sequences was carried out, proteins with a less than 
50% amino acid identity were selected. Distance tree generated using BLASTp 
with Fast Minimum Evolution tree method. 
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Table 3.1: Trimethoprim sensitivity of selected species. Species were 
streaked onto agar indicated, incubated at 37°C and growth recorded 24 hours 
later. 
Species % amino acid 
identity of 
HicB 
homologue 
Growth on 
LB agar 
only 
Growth on 
LB agar with 
trimethopri
m (50 µg/ml) 
Growth on LB 
agar with 
trimethoprim 
(100 µg/ml) 
Yersinia pseudotuberculosis 
IP32953 
28  X X 
Vibrio vulnificus E64MW 40  X X 
Pseudomonas aeruginosa PA01 41    
Pseudomonas syringae 44    
Burkholderia thailandensis E264 99  X X 
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3.3.4.2 Induction of expression of toxin BPSS0390 in  Y 
.pseudotuberculosis IP32953 
Y. pseudotuberculosis is a Gram negative bacterium known to cause fever, 
abdominal pain and diarrhoea in humans (Laukkanen et al. 2008; Jalava et al. 
2006). Typically foodborne, Y. pseudotuberculosis infection is linked to the 
consumption of raw or undercooked pork or dairy products (Laukkanen et al. 
2008) or  contaminated food. For example, raw grated carrots were linked to an 
outbreak in May 2003 (Jalava et al. 2006). Zoonotic infection has also been 
reported; typically from livestock or family pets (Tertti et al. 1984).Y. 
pseudotuberculosis is closely related to Y. pestis, the causative agent of plague 
(Rasmussen et al. 2016).  
A BLASTp search revealed that Y. pseudotuberculosis contained a protein with 
28% amino acid sequence identity homology to HicB from B. pseudomallei 
(Figure 3.12a). Plasmids pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-H24A 
were transformed into Y. pseudotuberculosis IP32953 by electroporation. Cells 
were resuspended in LB broth with 2% (w/v) glucose then plated onto LB agar 
plates with glucose and trimethoprim (50 µg/ml). Successful transformants were 
used to inoculate overnight cultures of LB again supplemented with 
trimethoprim (50 µg/ml) and glucose (2% (w/v)).  Sequencing confirmed that 
both genes inside the constructs were intact.  
Overnight cultures containing either pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-
H24A, which had been supplemented with glucose (final concentration 2% (w/v) 
and trimethoprim at final concentration 50 µg/ml) overnight, were used to 
inoculate (1:100) fresh LB broth supplemented with trimethoprim (50 µg/ml). 
Cultures were grown until early log phase was reached; split and either a final 
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concentration of 0.5% (w/v) rhamnose (to induce toxin expression) or a final 
concentration of 0.5% (w/v) glucose (to repress toxin expression) added. The 
optical density and number of culturable cells was monitored hourly, for three 
hours (Figure 3.12). 
Induction of toxin expression resulted in a rapid decrease in the number of 
culturable cells after three hours and also a reduced growth rate assessed by 
change in OD590nm. Glucose repression of the toxin gene and induction of 
expression/repression of the non-toxic control allowed cells to grow. 
Unfortunately, the viability data showing the change in the number of culturable 
cells after induction or repression of non-toxic BPSS0390 H24A protein 
expression was lost and so is absent from this study. However, the growth 
profile after induction or repression of BPSS0390 H24A expression 
demonstrates that both the OD590 continues to increase at a similar rate 
regardless of addition of inducer (0.5% (w/v) rhamnose) or repressor (0.5% 
(w/v) glucose). 
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Figure 3.12: Toxin expression in Y. pseudotuberculosis: a) Alignment of B. 
pseudomallei HicB with the Y. pseudotuberculosis homologue. The consensus 
symbols: * denotes a single, fully conserved residue, : indicates conservation between 
groups of strongly similar properties and . marks conservation between groups of 
weakly similar properties. b) Growth profile after HicA expression (0.5% (w/v) 
rhamnose) or repression (0.5% (w/v) glucose) c) Change in culturable cells after 
expression (0.5% (w/v) rhamnose) or repression (0.5%  (w/v) glucose) of BPSS0390 d) 
Growth profile of cells after expression (0.5% (w/v)  rhamnose) or repression (0.5%  
(w/v) glucose) of the non-toxic mutant protein BPSS0390 H24A. CFU data is absent. 
Data shown is average of two biological replicates and error bars represent SEM. 
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3.3.4.3 Induction of expression of toxin BPSS0390 in V. vulnificus E64MW 
V. vulnificus is frequently found in estuaries and shellfish; indeed it is the 
leading cause of all shellfish related deaths in the USA (Oliver & Bockian 1995) 
It is capable of causing two severe, though distinct syndromes dependent on 
the route of infection; either primary septicaemia or necrotizing wounds (Strom 
& Paranjpye 2000). Increasing temperatures due to climate change have been 
linked to new outbreaks and so this organism of increasing interest (Wu et al. 
2015; Paz et al. 2007). 
Conjugation was used to transform plasmids pSCrhaB2/his-BPSS0390 or 
pSCrhaB2/his-H24A into V. vulnificus. Donor E. coli DH5α was mixed with 
recipient V. vulnificus and an E. coli  helper strain harbouring plasmid pRK2013 
and plated onto a non-selective LB agar plate. Following incubation overnight at 
37°C, growth was scraped off and plated onto LB agar plates supplemented 
with 2% (w/v) glucose and 100 µg/ml trimethoprim for another overnight 
incubation.  The next day growth was replated on TCBS plates containing 100 
µg/µl trimethoprim and resultant green colonies were patched. A screening PCR 
was used to ensure the colonies were V. vulnificus and nucleotide sequencing 
confirmed that the transformed constructs contained no undesired mutations. 
Overnight cultures containing either pSCrhaB2/his-BPSS0390 or pSCrhaB2/his-
H24A, which had been supplemented with glucose (2% (w/v) and trimethoprim 
at final concentration 50 µg/ml)  overnight, were used to inoculate (1:100) fresh 
LB broth supplemented with trimethoprim 100 µg/ml. Cultures were grown until 
early log phase (OD590nm ~ 0.1)   was reached, before splitting  and adding 
either a final concentration of 0.5% (w/v) rhamnose (to induce toxin expression) 
or a final concentration of 0.5% (w/v) glucose (to repress toxin expression). The 
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optical density and number of culturable cells was monitored for three hours 
(Figure 3.13) 
 
Induction of toxin expression in V. vulnificus by addition of rhamnose resulted in 
a 3 log decrease in culturable cells after just 3 hours. This was accompanied by 
a decreased growth rate when compared to glucose controls. When glucose 
was added or expression of the non-toxic protein was induced, cells were able 
to continue growing. 
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Figure 3.13: Induction of toxin expression in V. vulnificus: a) alignment of B. 
pseudomallei HicB with the homologue in V. vulnificus. The consensus symbols: * 
denotes a single, fully conserved residue, : indicates conservation between groups of 
strongly similar properties and . marks conservation between groups of weakly similar 
properties.; b) Profile showing change in OD after induction of expression (0.5% (w/v) 
rhamnose) or repression (0.5% (w/v)  glucose) of the toxin and matching culturable cell 
counts; c). d) Profile showing change in OD after induction of expression (0.5% (w/v)  
rhamnose) or  repression (0.5%  (w/v) glucose) of the non-toxic control and matching 
culturable cell numbers e). Data shown is average of two biological repeats and error 
bars represent SEM. 
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3.3.4.4 Induction of expression of toxin BPSS0390 in B. thailandensis 
E264 
B. thailandensis is closely related to B. pseudomallei and has a homologue of 
HicB with 99% amino acid identity. Only a single residue is different; at position 
55 there is an aspartic acid rather than a glutamic acid (Figure 3.14a).  
Plasmids pSCrhaB2/his-BPSS0390 or pSCrhaB2/H24A were conjugated into B. 
thailandensis. Donor E. coli  DH5α harbouring the appropriate pSCrhaB2 
construct was mixed with recipient B. thailandensis and an E. coli  helper strain 
harbouring plasmid pRK2013 before plating onto BHI agar and incubation 
overnight at 37°C. The following day the growth was replated onto selective LB 
agar plates containing trimethoprim (100 µg/ml) and gentamicin to kill any 
surviving E. coli strains. A colony PCR was used to confirm resultant colonies 
were B. thailandensis and plasmids were extracted for sequencing. 
B. thailandensis overnight cultures that had been supplemented with glucose 
(2% (w/v)) overnight were used to inoculate fresh LB broth supplemented with 
trimethoprim (100 µg/ml). Cultures were grown until early log phase and then 
split. Either a final concentration of 0.5% (w/v) rhamnose (to induce toxin 
expression) or 0.5% (w/v) glucose (to repress toxin expression) was added. The 
optical density and number of culturable cells was monitored hourly, for three 
hours (Figure 3.14). 
 
Induction of expression of toxin BPSS0390 (addition of rhamnose) in B. 
thailandensis resulted in a reduced growth rate when compared to a glucose 
control. Addition of rhamnose also results in a small decrease in culturable cells 
before bacteriostasis occurs. Both glucose repressed controls and non-toxic 
controls had no noticeable effect on growth rate or culturable cell numbers. 
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Figure 3.14: Induction of toxin expression in B. thailandensis: a) Alignment 
of HicB with its B. thailandensis homologue. The consensus symbols: * denotes a 
single, fully conserved residue, : indicates conservation between groups of strongly 
similar properties and . marks conservation between groups of weakly similar 
properties. b) Graph showing the changing optical density after induction of expression 
(0.5% (w/v) rhamnose) or repression (0.5% (w/v) glucose) of toxin BPSS0390. c) 
Change in culturable cells after induction of expression (0.5% (w/v) rhamnose) of toxin 
compared to a  control where glucose was added. d) Changes in optical density after 
induction of expression (0.5% (w/v) rhamnose) or repression (0.5% (w/v) glucose) of 
non-toxic HicA control. e) Graph showing changes in culturable cell numbers after 
induction of expression (0.5% (w/v) rhamnose) or repression (0.5% (w/v) glucose) of 
non-toxic HicA control. 
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3.3.4.4.1 Induction of toxin BPSS0390 expression in B. thailandensis using 
different concentrations of rhamnose. 
As described above B. thailandensis overnight cultures that had been 
supplemented with glucose and trimethoprim at final concentration 50 µg/ml   
overnight were used to inoculate fresh LB broth supplemented with trimethoprim 
(100 µg/ml). Cultures were grown until early log phase and then split and 
different concentrations of rhamnose added to induce toxin expression. There 
was a glucose control to repress toxin expression. Optical density and CFU 
were measured every hour (Figure 3.15a and b) 
Addition of glucose allowed the cells to continue growing. Addition to a final 
concentration of 0.002% (w/v) rhamnose also allowed the cells to grow and so 
did likely not induce any/sufficient toxin expression. Once 0.02% and 0.2% (w/v) 
rhamnose (final concentration) was added the culturable cell counts became 
bacteriostatic, although the OD continued to increase. A concentration of 2% 
(w/v) rhamnose resulted in a small decrease in the number of cells and a 
noticeable decrease in growth rate.  
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Figure 3.15: Effect of different concentrations of rhamnose (induction of 
toxin BPSS0390 expression) on a) optical density and b) culturable cells. 
Different concentrations of rhamnose showed different effects. The highest 
concentration of rhamnose results in a decrease in culturable cells, whilst a final 
concentration of 0.02% and 0.2% rhamnose result in bacteriostatic culturable cell 
counts but an increase in growth profile observed by OD. Data shows mean of two 
biological repeats and error bars represent SEM. 
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3.3.4.4.2 Changes in cell size or shape after induction of BPSS0390 toxin 
expression in B. thailandensis. 
To determine if the lack of correlation between OD and culturable cell counts, 
i.e., why the OD continues to increase after induction of toxin expression, 
despite a rapid decrease in culturable cells, may be due to changes in cell 
morphology or size, a preliminary electron microscopy experiment was carried 
out.  
An overnight culture of B. thailandensis harbouring pSCrhaB2/his-BPSS0390 
that had been supplemented with glucose (2% (w/v)) and trimethoprim at final 
concentration 50 µg/ ml was used to inoculate fresh LB broth supplemented 
with trimethoprim (100 µg/ ml). Cultures were grown until early log phase and 
then split. Either 0.5% (w/v) rhamnose (to induce toxin expression) or 0.5% 
(w/v) glucose (to repress toxin expression) was added. Samples were taken at 
T0 (before addition of inducer/repressor), T1 (one hour post 
induction/repression) and T3 (three hours post induction/repression) from both 
cultures. The 1ml samples were centrifuged at 4°C for 5 minutes and the 
supernatant discarded. Samples were then washed three times in 1 x PBS 
before resuspension in 0.1M phosphate buffer or distilled, sterile water before 
fixing onto grids ready for imaging (Figures 3.16, 3.17).  
There was no visible difference between cells before and after induction of toxin 
expression. Neither was there any difference between cells where toxin 
expression had been repressed or induced. 
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Figure 3.16: Monitoring changes in size or shape of B. thailandensis cells 
after induction of expression of BPSS0390. Scale bars are 2µm. Samples were 
fixed using glutaraldehyde and phosphate buffer before sputter coating. a) Image taken 
at T0, before induction or repression of expression; b) image taken 1 hour after 
rhamnose induction of expression; c) image taken 1 hour after glucose repression of 
expression; d) image taken 3 hours after rhamnose induction of expression; e) image 
taken 3 hours after glucose repression of expression. 
 
 
a) 
b) c) 
d) e) 
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Figure 3.17: Monitoring changes in size or shape of B. thailandensis cells 
after induction of expression of BPSS0390. Scale bars are 1µm.Samples were 
fixed using glutaraldehyde and phosphate buffer before sputter coating. a) Image taken 
at T0, before induction or repression of expression; b) image taken 1 hour after 
rhamnose induction of expression; c) image taken 1 hour after glucose repression of 
expression; d) image taken 3 hours after rhamnose induction of expression; e) image 
taken 3 hours after glucose repression of expression. 
 
 
a) 
e) d) 
c) b) 
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3.4 Discussion. 
It is necessary to confirm functionality of TA toxins experimentally, typically by 
over-expression of toxins in their native host or E. coli (Zheng et al. 2015; Iqbal, 
Guérout, et al. 2015). Frequently the putative toxin is cloned into pBAD 
expression plasmids as their expression is considered to be strictly controlled 
and reliable (Jurenaite et al. 2013; Hino et al. 2014; Qiu et al. 2008; Khlebnikov 
et al. 2001). However, expression of BPSS0390 from construct pBAD/his-
BPSS0390 did not always result in toxicity. When expression was not tightly 
regulated, by repression with glucose, mutations appeared in BPSS0390 that 
abolished protein function. The predominant mutation was K31*, a premature 
stop codon at position 31 that abolished toxicity. Nucleotide sequencing of hicA 
revealed that a single point mutation, where a nucleotide substitution begat a 
codon change from AAG (lysine) to TAG (stop). Within the double-stranded 
RNA-binding domain like fold of HicA, residue 31 is located with the β2-β3 loop. 
Its function is unclear but it is not thought to be involved in the hydrophobic 
core, or catalysis or binding of substrate antitoxin (Butt et al. 2014). To prevent 
formation of escape mutants, all media used for growing overnights was 
subsequently supplemented with 2% (w/v) glucose, to tightly repress toxin 
expression.  
Induction of expression of BPSS0390 in all of the bacterial species tested 
resulted in a decrease in the number of culturable cells. In some species this 
decrease was very dramatic; expression in S. Typhimurium, which lacks a HicB 
homologue, resulted in a 4 log decrease in the number of culturable cells over 
the three hour time course. Despite the presence of homologues with limited 
sequence homology to HicB in Y. pseudotuberculosis and V. vulnificus, 
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induction of expression of BPSS0390 resulted in a 2 log and 3 log decrease in 
culturable cells respectively. However, even with the recorded decrease in 
culturable cells, confirmation of expression of the toxin was never checked, 
despite the presence of a hexahistidine tag, which would have facilitated 
Western blotting. The hypothesis that toxin BPSS0390 is toxic in a range of 
bacterial species cannot be entirely supported as expression of the toxin in the 
species tested was not demonstrated; addition of rhamnose to cultures of E. coli 
or Y. pseudotuberculosis or V. vulnificus or S. Typhimurium or B. thailandensis  
harbouring pSCrhaB2/his-BPSS0390 resulted in a decrease of culturable cells. 
The observation of the toxic phenotype suggests that toxin expression was 
induced in response to the addition of rhamnose, but does not prove it. In future 
work, expression studies must contain confirmation of expression of BPSS0390 
after induction, either through Western blotting or by quantitative real time PCR, 
regardless of a toxic phenotype. .  
It is difficult to extrapolate information on residues that are critical to 
HicBA complex formation from this data. Without quantitative data of expression 
levels of toxin BPSS0390 it was not possible to determine if different levels of 
expression of toxin BPSS0390 in different bacterial species could account for 
the log differences in decrease in culturable cells, rather than partial 
neutralisation by the native HicB homologue. 
The HicB homologue identified in B. thailandensis E264 showed 99% 
amino acid identity with the B. pseudomallei K96423 BPSS0391, with a 
substitution of aspartic acid in place of a glutamic acid at residue 55. Despite 
having a homologue with almost identical amino acid identity, induction of 
BPSS0390 expression in B. thailandensis resulted in small decrease in 
culturable cells before the counts became static, suggesting that HicB 
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homologue was only able to partially neutralise BPSS0390. Plasmid pSCrhaB2 
has a backbone originally derived from pMLBAD and so has a high copy 
number (Cardona & Valvano 2005) compared to the single chromosomal copy 
of the HicB homologue. This discrepancy in numbers would lead to a large 
excess of toxin molecules and could explain the bacteriostatic phenotype 
observed in B. thailandensis. Future work could confirm this by using real time 
PCR to confirm expression of the HicB homologue under the conditions of the 
expression study.  
This work has demonstrated that when the concentration of the inducer 
was increased, a progressive decrease in growth was measured, indicating 
dose-dependency. Perhaps more interesting is the difference in the patterns of 
growth measured by changes in OD590 and the number of culturable cells. The 
highest concentration of inducer tested lead to a reduction in culturable cells, 
yet the OD590 continued to rise albeit at a reduced rate over the course of the 
experiment. This observation indicates that whilst an increasing proportion of 
the cells became non-culturable on agar, some retained the ability to grow and 
divide even 2 hours after induction of BPSS0390 expression. Optical density is 
affected by changes in cell size and shape as these alter light scattering 
(Najafpour 2007). Changes in morphology and clumping and clustering of cells 
are characteristics previously observed in viable but non-culturable cells of Y. 
pestis (Pawlowski et al. 2011). and expression of putative V. parahaemolyticus 
TA toxins in E. coli resulted in a filamentous cell shape (Hino et al. 2014). 
However, SEM of B.thailandensis cells expressing BPSS0390 revealed no 
obvious change in size or shape. Future work could include choosing a bacterial 
species where a greater decrease in culturable cells was observed after 
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induction of toxin expression and examining live cells, or using Gram staining to 
look for filamenting or clumping. 
The potential “dose-dependency” of toxicity, coupled with the apparent 
lack of host specificity and toxic activity of B. pseudomallei HicA in all of the 
bacterial species tested, might suggest that B. pseudomallei HicA is a potential 
antimicrobial compound. However, ectopic expression of B. pseudomallei HicA 
toxin in B. pseudomallei has been demonstrated to increase the number of 
persister cells tolerant to ciprofloxacin and ceftazidime (Butt et al. 2014). 
Persister cells are believed to play a role in many chronic or persistent 
infectious diseases, including tuberculosis caused by M. tuberculosis and lung 
infections caused by P. aeruginosa (Getahun et al. 2015; Fauvart et al. 2011). 
Expression of toxin molecules has also been linked to biofilm formation and 
increased virulence within host bacteria (Van Acker et al. 2014; Sala et al. 2014; 
for more details please see sections 1.0.2.6-1.0.2.8) and when type II toxins are 
expressed in eukaryotic cells, cell death is induced through apoptosis apoptosis 
(Yamamoto et al. 2002; Shapira et al. 2012) .  
Increasing the formation of persister cells, biofilms and increasing 
virulence, whilst potentially killing host eukaryotic cells are not desirable 
qualities in a novel antimicrobial and so whilst induction of expression of 
BPSS0390 was able to reduce the number culturable cells, it may also have 
had or may have undesirable side effects that would make the remaining 
bacteria more difficult to eradicate.   
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4.  Identification of residues in HicA 
involved in toxicity and complex formation 
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4.0 Introduction 
Protein toxin BPSS0390 (Figure 4.1) is able to cause growth cell arrest, a 
reduction in CFU and induce persister formation when expressed in E. coli and 
is neutralised when co-expressed with its antitoxin BPSS0391 (Butt et al. 2013). 
BPSS0390 shares sequence identity with E. coli  HicA toxin, a translation 
independent mRNA interferase with an unknown mechanism of action and 
unidentified recognition motif (Jørgensen et al. 2009).    
A previous site-directed mutagenesis study identified two residues, His24 
and Gly22 as important for toxicity. The BPSS0390 H24A mutant was not toxic 
and so could be overexpressed, purified and its structure solved by NMR 
(Figure 4.1). BPSS0390 H24A consists of a double-stranded RNA-binding 
domain (dsRBD) fold, with a triple-stranded β-sheet and two α helices packed 
against one face  (Butt et al. 2014). dsRBDs are small proteins able to bind to 
double-stranded RNA (dsRNA) (Masliah et al. 2013). Determining the structure 
of BPSS0390 allowed some insight into the structural and catalytic roles of 
amino acids conserved across HicA family proteins. 
The first crystal structure of a TA complex from the HicAB family (HicA3-
HicB3 TA system in Yersinia pestis) revealed a binding interface that completely 
occluded the catalytic site of HicA3 and packed the α2 helix of HicA3 against 
the β-sheet of HicB3, which was stabilised by both hydrophobic and polar 
interactions. No specific residues were mentioned (Bibi-Triki et al. 2014). 
A systemic alanine scanning mutagenesis, where each individual amino 
acid in a protein is mutated, allows identification of residues involved in catalysis 
and binding and mutants can be screened for loss of function. 
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Figure 4.1: The amino acid sequence of BPSS0390 and the structure of 
BPSS0390 H24A as determined by NMR. a) Sequence of BPSS0390 showing 
all 59 amino acids. Image generated using BioEdit. b) Structure of BPSS0390 
H24A, with the secondary structures, termini and residue Gly22 labelled. Image 
generating using PyMol, PDB 4C26.  
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4.1 Aim 
Identify residues or regions in BPSS0390 toxin involved in toxicity and 
BPSS0390-BPSS0391complex formation. 
. 
4.2 Identification of conserved residues in BPSS0390  
A sequence alignment of 25 diverse dsRNB domains revealed a consensus 
sequence of conserved residues, within the domain, which were critical for 
protein folding or double-stranded RNA binding and had been validated 
experimentally (Masliah et al. 2013). To identify residues or regions of 
BPSS0390 that might be critical for toxicity or antitoxin binding, a sequence 
alignment was performed. The protein sequence of BPSS0390 was BLASTp 
searched against NCBI. The top matching 100 sequences (E value less than < 
0.001) were aligned using CLUSTALW with BPSS0390 as the reference 
sequence. BioEdit was then used to identify residues conserved in 75 or more 
of the 100 sequences (greater than 75%). (Table 4.1). 
39 residues were conserved in 75 or more of the protein sequences. These 
residues were distributed throughout the molecule: 4 in α1 helix, 2 in the α1-β1 
loop, 5 in β1-β2 loop, 3 in β2 sheet, 4 in β2-β3 loop, 4 in β3 sheet, 8 in β3- α2 
loop, 7 in α2 helix, 2 at the N-terminus and none in β1 sheet. 6 residues were 
conserved in all 100 proteins, including three histidines (one is H24). The 
histidine at position 24 has previously been shown to be critical for toxicity (Butt 
et al. 2014). 
As the conserved residues were scattered through the molecule I decided that 
the best way to investigate the contribution of each residue to toxicity was to 
perform alanine scanning mutagenesis. Alanine was chosen for the scanning 
mutagenesis as it has no side chain beyond its β-carbon; it can be incorporated 
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without altering the main chain conformation. This ensures that any changes 
observed are likely to be due to the loss of the side chain of the substituted 
amino acid. 
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Table 4.1: Table to show most conserved residues across 100 proteins 
with homology to BPSS0390. BPSS0390 sequence was BLASTp searched 
against NCBI and the first 100 sequences that gave a significant E-value of 
<0.001 chosen and aligned against BPSS0390 using BioEdit and CLUSTALW. 
 
% Homologous 
proteins where 
residue  conserved 
Residue in 
BPSS0390 
Location in 
BPSS0390 
molecule 
100 W15  α1-β1 loop 
G22 β1-β2 loop 
H24  β1-β2 loop 
H29 β2-β3 loop 
H40 β3- α2 loop 
A57 α2 helix 
99 T37 β3 sheet 
P39 β3 sheet 
P41 β3- α2 loop 
T49 α2 helix 
I53 α2 helix 
98 G34 β2-β3 loop 
V36 β3 sheet 
S3 N terminus 
S23 β1-β2 loop 
97 G14 α1-β1 loop 
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96 H25  β2 sheet 
S52 α2 helix 
K55 α2 helix 
95 K31  β2-β3 loop 
K43 β3- α2 loop 
93 D44 β3- α2 loop 
L45 β3- α2 loop 
K42 β3- α2 loop 
92 P46 β3- α2 loop 
91 F27 β2 sheet 
89 D13  α1 helix 
86 M1 N terminus 
R19 β1-β2 loop 
83 P30 β2-β3 loop 
80 V18 β1-β2 loop 
79 
 
L35 β3 sheet 
V50 α2 helix 
78 L59 α2 helix 
77 H26  β2 sheet 
76 L6 α1 helix 
L10 α1 helix 
75 I7 α1 helix 
G48 β3- α2 loop 
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4.3 Results  
 
4.3.1 Generation of mutated pBAD/his-BPSS0390 constructs 
An Agilent QuikChange Lightning Site Directed Mutagenesis Kit and mutagenic 
primers were used to individually mutate each of 58 residues to an alanine 
except for A57, which was mutated to a glycine. 
The newly synthesised plasmid DNA was transformed into ultracompetent E. 
coli and transformants recovered onto LB agar with ampicillin (100 µg/ml) and 
glucose (2% (w/v)). Plasmid DNA was extracted from three colonies and sent 
for nucleotide sequencing to confirm that the desired mutation was present. 
 
4.3.1.3 Repeated attempts at mutagenesis 
Despite three repeated attempts it was not possible to generate mutant 
BPSS0390 Q54A. A new primer pair was designed and residue Q54 was 
successfully mutated to a glycine, generating construct pBAD/his-BPSS0390 
Q54G. 
4.3.2 Screening BPSS0390 mutants for changes in toxicity 
4.3.2.1 Toxicity assays 
The constructs were transformed into E. coli MG1655 ΔhipBA and 
transformants plated onto LB agar with ampicillin (100 µg/ml) and glucose (2% 
w/v). E. coli MG1655 ΔhipBA harbouring mutated BPSS0390 constructs were 
grown to OD590 0.1 and supplemented with a final concentration of 0.2% (w/v) 
arabinose to induce gene expression for two hours. It was not possible to test 
all 57 mutants in a single toxicity assay and so mutants were split into 6 groups 
of 8-12 different mutants. Two controls were used. One was the previously 
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described non-toxic mutant H24A, which was expressed in E. coli MG1655 
ΔhipBA from pBAD plasmid (negative control). The second control was wild 
type BPSS0390, expressed from pBAD (positive control).  Colony forming units 
(CFU) were measured before induction of expression with arabinose and  two 
hours after induction of expression by serially diluting samples in a 96- well 
plate in LB and plating onto LB ampicillin (100 µg/ml) glucose (2% (w/v)) plates 
for CFU counts the following day. The fold change in CFU after two hours 
(T2/T0) was calculated (Figure 4.2).  
In the first group (a) tested,  E. coli MG1655 ΔhipBA harbouring pBAD/his-
BPSS0390 H24A demonstrated over a 10 fold increase in the number of 
culturable cells after two hours incubation, whilst cells harbouring pBAD/his-
BPSS0390 had over 10 fold decrease in the number of culturable cells after two 
hours incubation. E. coli MG1655 ΔhipBA expressing P46A or I53A showed a 
more than 100 fold decrease in culturable cells. Cells expressing H40A, G14A 
and T37A also demonstrated decreased culturable cells after two hours 
incubation. However, E. coli MG1655 ΔhipBA  expressing either S3A or T49A 
increased more than 10 fold two hours after incubation, cells harbouring W15A, 
P41A or D44A also increased after two hours incubation, similar to the H24A 
non-toxic control.  
In the second group (b), E. coli MG1655 ΔhipBA harbouring pBAD/his-
BPSS0390 demonstrated a 100 fold decrease in culturable cells after two hours 
incubation. However, E. coli MG1655 ΔhipBA harbouring pBAD/his-BPSS0390 
H24A demonstrated a 10 fold increase in the number of culturable cells after 
two hours incubation. Cells expressing K5A, L6A, R8A, M9A, E11A, E12A, D13, 
R16, I17A or V18A all showed decreases in the number of culturable cells after 
two hours incubation, similar to the BPSS0390 control. In contrast, E. coli 
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MG1655 ΔhipBA expressing I7A or L10A increased in culturable cells after 
incubation, similar to the H24A control. 
In the third group (c), E. coli MG1655 ΔhipBA harbouring pBAD/his-BPSS0390 
demonstrated a 1000 fold decrease in culturable cells after two hours 
incubation, whilst cells expressing H24A showed a 10 fold increase in culturable 
cells after two hours incubation. E. coli MG1655 ΔhipBA expressing S23A, 
H26A, V36A, G54G or G58A had a decrease in culturable cells after two hours, 
similar to the BPSS0390 control. In contrast, cells harbouring pBAD/his, 
pBAD/his-BPSS0390 T21A or pBAD/his-BPSS0390 H29A showed increased 
numbers of culturable cells after two hours incubation, similar to the H24A 
control. 
In the fourth group (d), E. coli expressing BPSS0390 showed a more than 10 
fold decrease in culturable cells after two hours incubation, whereas expression 
of H24A resulted in a more than 10 fold increase in culturable cells. Similarly to 
cells expressing H24A, cells expressing K31A, K32A, G34A or V38A had an 
increased number of culturable cells after two hours incubation. Cells 
expressing K28A, P30A, P33A, L35A, P39A or K42 showed a decrease in the 
number of culturable cells, like the BPSS0390 control. 
The toxin control in the fifth group (e), where E. coli MG1655 ΔhipBA expressed 
BPSS0390, showed a 100 fold decrease in culturable cells after two hours 
incubation. Cells expressing G48A, V50A, K51A, K55A or L59A, also showed a 
decrease in the number of culturable cells after two hours expression. However, 
cells expressing S52, S56A or A57G demonstrated an increase in the number 
of culturable cells, similar to the non-toxic H24A, where expression resulted in a 
100 fold increase in the number of culturable cells after two hours incubation. 
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In the final group (f), E. coli MG1655 ΔhipBA expressing BPSS0390 
demonstrated a 100 fold decrease in the number of culturable cells after two 
hours incubation, whereas cells expressing H24A demonstrated a 100 fold 
increase in the number of culturable cells after two hours. Increased   
fold change CFU were also observed after two hours incubation in cells 
expressing R19A, G22A, F27A and L45A. Cells expressing N2A, S4A, V20A, 
H25A, K43A or I47A showed a decrease in the fold change of culturable cells 
after two hours of incubation. 
In total, expression of 20 of the mutants resulted in cell growth, suggesting that 
either toxicity was abolished or that there was no expression of the mutant 
allele. These mutants were S3A, I7A, L10A, W15A, R19A, T21A, G22A, F27A, 
H29A, K31A, K32A, G34A, V38A, P41A, D44A, L45A, T49A, S52A, S56A and 
A57G.  Out of the remaining 57 mutants, expression of 22 of the mutants 
resulted in a similar or greater decrease in fold change CFU compared to the 
toxic BPSS0390 control, whilst expression from 15 mutants resulted in a 
reduced fold change in CFU compared to BPSS0390.   
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Figure 4.2: Fold change in CFU after expression of BPSS0390 mutants two 
hours. E. coli MG1655 ΔhipBA harbouring either pBAD/his-BPSS0390, or pBAD/his-
BPSS0390 H24A or BPSS0390 mutant gene cloned into pBAD/his was grown to OD590 0.1 
before induction of expression (0.2% (w/v) arabinose). CFU counts were determined by plating 
cells onto LB ampicillin (100 µg/ml) glucose (2% (w/v)). Six groups labelled a-f. Data shown are 
an average of three biological repeats and error bars shown SEM. 
a) 
d) 
b) 
c) 
e) f) 
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4.3.2.2 Normalising toxicity data 
To determine if increases or decreases in toxicity of mutants were significantly 
different compared to the wild type BPSS0390 control it was necessary to 
normalise fold change CFU (T2/T0) for each mutant against its BPSS0390 
control.  
For each group (a-f) the mean fold change in CFU after induction of expression 
of BPSS0390 for two hours was plotted as 100% toxicity whilst the mean fold 
change in CFU after induction of expression of BPSS0390 H24A mutant for two 
hours was plotted as 0% toxicity. A linear trend line was added (Figure 4.3). 
Each replicate of fold change in CFU was taken as x value and the equation of 
the linear trend line used to generate percentage toxicity. The mean of the 
percentage toxicity for each BPSS0390 mutant was plotted. The percentage for 
BPSS0390 and H24A mutant represents mean of all replicates across all six 
groups (Figure 4.4).  
Inducing expression of 29 of the mutant alleles demonstrated no change or an 
apparent increase in toxicity compared to wild type BPSS0390, whilst 28 of the 
mutants expressed had a reduced toxicity compared to wild type BPSS0390. 
The H24A mutant had the lowest toxicity. 
 One-way ANOVA analysis revealed that the percentage toxicity of the H24A 
control, empty pBAD control and 14 BPSS0390 mutants were statistically 
significantly different from the percentage toxicity of BPSS0390 (p<0.05, 1 way 
ANOVA Dunnett post-test) (Figure 4.5). 
All the mutants identified using one-way ANOVA were mutants that had been 
previously identified as their expression permitted cell growth. None of the 
mutants with increased toxicity were significantly different from BPSS0390. 
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Figure 4.3:  Mean fold change in CFU (T2/ T0) against toxicity. Each graph has 
the mean fold change in CFU after two hours of expression of BPSS0390 plotted with 100% 
toxicity and the mean fold change in CFU after two hours of expression of H24A plotted as 0% 
toxicity. A linear trend line was added and the equation generated used to convert fold change 
CFU for each replicate to % toxicity. Each graph corresponds to the graphs (a-f) in Figure 4.2.
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Figure 4.4: Percentage toxicity of each mutant expressed. Percentage toxicity was calculated using 
equation of the trend line on the graph of toxicity against fold change in CFU of each group. The fold change in CFU 
(T2/T0) was taken as x in the equation. Data shown are mean of three biological repeats and error bars represent SEM.  
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Figure 4.5: Mutants with significantly different toxicity to BPSS0390. The mean 
percentage toxicity for each mutant was analysed using one way ANOVA (Dunnett’s post-test) with 
BPSS0390 as the reference strain. Data shown average of three biological replicates and error bars 
represent SEM. * = p≤ 0.05, ** = p≤ 0.01, *** = p≤0.001, **** = p ≤ 0.0001 after one way ANOVA 
(Dunnett’s post-test)) against BPSS0390.   
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4.4 Further characterisation of BPSS0390 mutants 
4.4.1 Effect of BPSS0390 mutations on growth 
4.4.1.1 Growth curves of E. coli MG1655 ΔhipBA pBAD/his-BPSS0390 and E. 
coli MG1655 ΔhipBA pBAD/his-BPSS0390 H24A 
Overnight cultures of E. coli MG1655 ΔhipBA harbouring pBAD/his-BPSS0390 
(encoding native toxin) or pBAD/his-BPSS0390 H24A (encoding non-toxic mutant) 
were diluted to an OD590 of 0.01 and 100µl placed into individual wells in a 96-well 
plate. The plate and cultures were incubated at 37°C overnight and automated 
readings of the optical density of the culture in each well taken every 15 minutes 
(Figure 4.6). 
E. coli MG1655 ΔhipBA harbouring pBAD/his-BPSS0390 grew more slowly 
through exponential phase and reached a lower OD once in stationary phase than E. 
coli harbouring pBAD/his-BPSS0390 H24A.  An unpaired t-test comparing the 
growth of the two strains at 24 hours revealed that the growth of E. coli BPSS0390  
H24A was significantly different ( p≤ 0.001) to the growth of the strain harbouring 
BPSS0390  (Figure 4.6). This suggests that mutations in BPSS0390 do have an 
effect on bacterial growth. 
To determine if other mutations in BPSS0390 affected growth, overnight 
cultures expressing the mutants were diluted to an OD590 of 0.01 and 100µl placed 
into individual wells in a 96-well plate.  E. coli harbouring pBAD/his with either 
BPSS0390 (native toxin) or H24A (non-toxic mutant) were grown and diluted in 
parallel as controls.  The plate and cultures were incubated at 37°C overnight and 
readings of the optical density taken every 15 minutes. It was not possible to test all 
57 mutants in a single 96-well plate and so mutants were split into 6 groups (a-f). 
The OD590 of each culture at 24 hours was plotted (Figure 4.7).   
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Figure 4.6: Analysis of growth of E. coli MG1655 ΔhipBA pBAD/his-BPSS0390 
and E. coli MG1655 ΔhipBA pBAD/his-BPSS0390 H24A. a) OD590nm reading taken 
every 15 minutes to generate growth curves. Data shown is average of three biological replicates and 
error bars represent SEM.  b) Comparison of OD measurement for both strains at 24 hours. Unpaired 
t-test determined that E. coli MG1655 ΔhipBA pBAD/his-BPSS0390 H24A is significantly different. **** 
= p≤ 0.0001. Data shown is average of three biological repeats and error bars represent SEM. 
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All cultures of E. coli MG1655 ΔhipBA harbouring a pBAD/his cloned BPSS0390 
alanine substitution mutant grew to a higher OD at 24 hours that the cultures of E. 
coli MG1655 ΔhipBA pBAD/his-BPSS0390, except E. coli MG1655 ΔhipBA pBAD/his 
harbouring D13A, S4A and V50A, which have percentage toxicity similar or greater 
than BPSS0390. 
A one way ANOVA (Dunnett’s post-test) found that the growth of  40 of the E. 
coli pBAD/his mutant alleles at 24 hours was significantly different from the growth of 
E. coli expressing BPSS0390 at 24 hours. All the E. coli BPSS0390 H24A controls 
for each group and E. coli harbouring pBAD were also statistically significant from 
the control harbouring pBAD/his-BPSS0390. 
Seventeen of the 40 cultures statistically significantly different from the E.coli 
harbouring pBAD/his-BPSS0390, harboured plasmids encoding alanine substitution 
mutants that also abolished BPSS0390 toxicity (S3A, W15A, I7A, L10A, K32A, 
G34A, V38A, R19A, G22A, F27A, L45A, S52A, S56A, A57G, T21A and H29A). Ten 
of the 40 cultures harboured plasmids encoding alanine substitution mutants with 
lower percentage toxicity that BPSS0390 (107.065%), (Table 4.2). Together, the 10 
mutants with a lower percentage toxicity, plus the 17 mutants with abolished function 
suggest that mutants with reduced percentage toxicity permit more growth after 24 
hours than wild type BPSS0390. 
Interestingly, the remaining 13 cultures that were significantly different from E. 
coli harbouring pBAD/his-BPSS0390 , harboured plasmids encoding mutants with a 
higher percentage toxicity than BPSS0390 (Table 4.3). This might suggest that the 
increased toxicity of these mutants does not directly affect growth of the host cells 
(when there is no expression induced). It could be that these mutants show 
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increased percentage toxicity as more protein is produced in response to induction of 
expression. 
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Figure 4.7: Analysis of growth of cultures of E. coli MG1655 ΔhipBA pBAD/his 
harbouring alanine substitution mutants. The final OD590 at 24 hours was analysed using 
one way ANOVA (Dunnett’s post-test) with BPSS0390 as the reference strain. Data shown average of 
three biological replicates and error bars represent SEM. * = p≤ 0.05, ** = p≤ 0.01, *** = p≤0.001, **** 
= p ≤ 0.0001 after one way ANOVA (Dunnett’s post-test)) against BPSS0390.   
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Table 4.2: Table to show the alanine substitution mutants with a lesser toxicity 
than BPSS0390, encoded by the plasmids harboured by cultures that 
reached a statistically significantly higher OD590 at 24 hours than 
cultures harbouring plasmids that encoded BPSS0390 only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutant Toxicity % 
T37A 68.6167 
P46A 89.8333 
V18A 56.2667 
V20A 106.033 
K55A 89.3667 
G58A 72.5 
L59A 80.35 
H26A 103.017 
V36A 90.35 
Q54G 79.8 
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Table 4.3: Table to show the alanine substitution mutants with a greater 
toxicity than BPSS0390, encoded by the plasmids harboured by cultures 
that reached a statistically significantly higher OD590 at 24 hours than 
cultures harbouring plasmids that encoded BPSS0390 only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutant Toxicity % 
I53A 137.625 
L6A 134.667 
R8A 128.617 
L17A 107 
K28A 130.133 
L35A 139.367 
P39A 139.867 
K42A 114.9 
N2A 111.483 
H25A 118.817 
K43A 123.8 
K51A 108.45 
I47A 122.867 
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4.4.2 Monitoring expression of BPSS0390 mutant proteins 
4.4.2.1 Quantifying protein expression through Western blotting 
To determine if different BPSS0390 mutants produced different quantities of protein, 
it was necessary to calculate the relative concentration of protein detected for each 
mutant on Western blots. To do this a standard curve was generated using H24A 
mutant. 
A culture of E. coli MG1655 ΔhipBA pBAD/his-BPSS0390 H24A was grown to an 
OD590 0.1 and a final concentration of 0.2% (w/v) arabinose added to induce 
expression. The culture was incubated for a further two hours before a 1 ml sample 
was taken, centrifuged and lysed using BugBuster, lysozyme and benzonase. The 
cell lysate was serially diluted, loaded onto an SDS-PAGE gel and electrophoresed 
before a Western blot was carried out. For the Western blot, an anti-Xpress 1° 
antibody, which was specific against the Xpress epitope in the N-terminus 
hexahistidine tag, was used. The secondary antibody used was IR Dye ® 800 CW 
Goat anti-Mouse IgG. The signal intensity of each band was measured using 
Odyssey software and plotted against theoretical concentration of the protein at each 
dilution (Figure 4.8). The graph was fitted with a linear trend line. The equation of this 
trend line was multiplied against the signal intensity (x) of each band detected on the 
Western blot, i.e. (=0.3268*signal intensity)-2.6406), for each mutant to generate the 
calculated relative concentration (Figure 4.8).  
All of the mutants had a greater calculated relative concentration than BPSS0390 
control. One way ANOVA (Dunnett’s post-test) using the BPSS0390 strain as the 
reference, identified 27 mutants as having statistically significantly different 
concentrations. The non-toxic H24A control mutant was also statistically significantly 
different to the BPSS0390 control. 
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Five of the mutants identified as significantly different (bars coloured yellow) had an 
increased percentage toxicity and an increased OD590  at 24 hours when compared 
to BPSS0390 control (Table 4.2); the residues were L6A, R8A, L35A, I53 and N2A. 
This could suggest that the increase in percentage toxicity of these mutants is due to 
an increase in the relative concentration of protein in response to induction of 
expression. In contrast, four of the mutants identified as significantly different (bars 
coloured light blue) have a decreased percentage toxicity and an increased OD590 at 
24 hours when compared to BPSS0390 control (Table 4.2); V36A, H26A, P46A and 
K55. 
Eleven of the mutants identified as significantly different from expression of wild type 
BPSS0390, were mutants where expression of the mutant permitted cell growth 
(bars coloured purple). Mutation of S3 (N-terminus), I7, L10 (α1 helix), F27 (β2 
strand) H29, K31, K32 and G34 (β2-β3 loop) or S52, S56 and A57 (α2 helix) resulted 
in significantly increased relative calculated concentration.  
The remaining mutants identified by the one way ANOVA were K5A, M9A, E11A, 
D13A, P30A, P33A and G48A. 
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Figure 4.8: Quantifying protein expression through Western blotting. A prepared protein sample of BPSS0390 H24A was serially diluted 
before a) Western blotting. Diluted samples were loaded onto SDS-PAGE gel highest to lowest concentration, (lane 3-7), before electrophoresis. Protein on 
the gel was transferred to a nitrocellulose membrane, before blocking and treatment with primary and secondary antibody. The signal intensity was measured 
y = 0.3268x - 2.6406 
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for each band and b) plotted against the theoretical concentration of each dilution (so undiluted 100%, diluted once 50% etc.).   A linear trend line was added 
the equation used to calculate the relative concentration of each BPSS0390 mutant protein; c) Example of a Western blot showing prepared protein samples 
of BPSSS0390 mutants: P46A (lane 2), I47A (lane 3), G48A (lane 4), T49A (lane 5), V50A (lane 6), K51A (lane 7), S52A (lane 8), I53A (lane 9), Q54G (lane 
10), K55A (lane 11), S56A (lane 12), H24A (lane 13) and BPSS0390 (unmutated, lane 14). On this example image the signal intensity of K55A, S56A, H24A 
and BPSS0390 has been measured using Odyssey Image Studio software. This value was then used to determine the calculated relative concentration using 
the equation of the linear trend line from graph b).
160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Calculated relative concentration of mutant protein after expression for two hours. Cultures of E. coli MG1655 ΔhipBA 
harbouring mutants were grown to OD590 of 0.1 and expression induced by 0.2% (w/v) arabinose. The cultures were incubated for a further two hours before 
samples were taken, and pelleted by centrifugation. Cells were resuspended in SDS-loading dye, boiled and electrophoresed through a SDS PAGE gel 
before transfer to a nitrocellulose membrane and blotting. The signal intensity of each band was multiplied by the equation generated by the standard curve to 
generate a calculated relative concentration. Bars coloured purple represent residues where alanine substitution abolishes toxicity. Bars coloured light blue 
represent residues where mutants with lower percentage toxicity (than BPSS0390) demonstrate significantly increased growth compared to BPSS0390. Bars 
coloured yellow represent mutants with increased percentage toxicity (compared to BPSS0390) and significantly increased growth at 24 hours. Data shown 
are the average of two biological repeats. Error bars show SEM. **** = p≤0.0001, *** = p ≤0.001, ** = p≤ 0.01, * = p≤ 0.05, following a one way ANOVA 
(Dunnett’s post-test) using the BPSS0390 strain as a reference.
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4.5 Description of BPSS0390 mutants where expression resulted in 
cell growth 
Induction of expression of 20 of the mutants resulted in cell growth, suggesting that 
either there was no expression of the mutant allele or that the mutation prevented 
the toxicity of BPSS0390. Western blotting revealed that all of the mutants in the 
study had greater levels of expression, i.e. had a greater calculated relative 
concentration, than wild type BPSS0390. This implies that the mutations described 
below (organised by location) may have affected residues that are critical for either 
the structure or function of the protein.  Toxin BPSS0390 forms a double stranded 
RNA binding (dsRNB) domain like fold, with two α helices packed against one face of 
a triple β sheet (Figure 4.10)  
4.5.1 Residues at the N-terminus  
4.5.1.1 Serine 3 
This polar residue has not previously been identified as critical for function in either 
dsRBD-like domains or HicA. It was 98% conserved (Table 4.1). The N-terminus is 
mobile- NMR analysis revealed that it occupies different conformations in different 
states (Figure 4.10). 
4.5.2 Residues located in α1 helix 
4.5.2.1 Isoleucine 7 
This large, Cβ branched, hydrophobic amino acid has not been previously attributed 
to the hydrophobic core (Butt et al. 2014) but analysis of relative solvent accessibility 
suggests that the residue is buried in structure and that its side chain points towards 
the core  (Figure 4.11). This isoleucine was conserved in 75% of the BPSS0390 
protein homologues (Table 4.1).  This residue may be critical for protein structure. 
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4.5.2.2 Leucine 10 
This large, hydrophobic, non-polar amino acid  has previously been identified as part 
of the hydrophobic core (Butt et al. 2014). Its side chain points into the core and 
analysis of its relative solvent activity suggest it is buried (data not shown) (Figure 
4.11). Leucine was 76% conserved across BPSS0390 protein homologues (Table 
4.1). This residue may be critical for protein structure. 
4.5.3 Residues located on the α1- β1 loop   
4.5.3.1 Tryptophan 15 
Conserved across all BPSS0390 homologues, this residue has its indole portion 
orientated towards the hydrophobic core (Figure 4.11). It has previously been 
assigned to the hydrophobic core (Butt et al. 2014). This residue may be critical for 
protein structure. 
4.5.4 Residues located on the β1-β2 loop 
This loop region was suggested to be involved in substrate catalysis. His24, a 
residue previously identified as critical to BPSS0390 toxicity is located here (Butt et 
al. 2014). 
4.5.4.1 Arginine 19 
This basic, positively charged amino acid was conserved in 86 of 100 proteins with 
homology to BPSS0390. The positive charge might be important for RNA binding 
(Figure 4.12). 
4.5.4.2 Threonine 21 
Threonine 21 was conserved in less than 75% of proteins homologous to 
BPSS0390. It is polar and Cβ branched; the bulky side chain limits conformations, 
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suggesting that this residue might be important for maintaining structure of the active 
site (Figure 4.12). 
4.5.4.3 Glycine 22 
Glycine 22 was conserved across all 100 homologues; its hydrogen atom side chain  
may offer the flexibility needed for the active site to change conformation (Yan & Sun 
Qing 1997) (Figure 4.12). 
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Figure 4.10:  Structure of BPSS0390. a) Structure of the BPSS0390 (H24A) protein showing 
the dsRNB domain like fold with two α helices packed against one face of a triple β sheet. The 
secondary structure elements and surface are indicated. The N-terminus is coloured blue and the C-
terminus coloured red. Residues -6 to 1 are omitted from all images as they are unstructured.  b) 
Structure of the BPSS0390 (H24A) protein with serine 3 indicated in sticks, shown in two different 
states. Black is used to indicate the location of the H24A substitution. PyMol was used to generate the 
images (PDB code 4C26). 
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Figure 4.11: Location of residues in α1 helix and α1 - β1 loop of BPSS03390 
where alanine substitution abolished toxicity. Sticks indicate the location of a) Ile7, b) 
Leu10, and c) Trp15. The side chains of the indicated residues point towards the core of the protein. 
Black at the N terminus of β2 sheet indicates the location of the H24A mutation. PyMol was used to 
generate the images (PDB code 4C26). 
 
 
 
 
 
a) 
c) 
b) 
166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Location of residues in β1-β2 loop and β2 strand of BPSS03390 
where alanine substitution abolished toxicity. a) Sticks indicate Arg19, Thr21 and Gly22, 
located on the β1-β2 loop immediately prior to the H24A substitution (marked in black). b) Sticks 
indicate Arg19, Thr21 and Gly22, located on the β1-β2 loop immediately prior to the H24A substitution 
(marked in black), image has been rotated. c) Sticks indicate location of Phe27 within the β2 sheet, 
showing side chain situated in the hydrophobic core. . PyMol was used to generate the images (PDB 
code 4C26). 
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4.5.5 Residues located in β2 strand 
4.5.5.1 Phenylalanine 27 
Phenylalanine 27  is an aromatic and hydrophobic residue previously identified in the 
hydrophobic core (Butt et al. 2014) , Phe27 may be also be indirectly involved as 
aromatic residues may help to main a positive charge on molecule. F27 was 91% 
conserved across BPSS0390 protein homologues (Figure 4.12). 
4.5.6 Residues located in β2-β3 loop 
This loop is located at the opposite end of the molecule from the proposed catalytic 
site. 
4.5.6.1 Histidine 29 
Found in all 100 proteins with homology to BPSS0390, the histidine imidazole 
functional group may play a role in catalysis as its pKa of 6 allows the amino acid to 
act as either a general acid or a base during catalysis depending on pH of active 
site. However, given its location, it may instead be important for folding and 
stabilising of the β sheet. A distance of 1.9 Å between the CO of His29 and the NH of 
Lys31 suggests that would be possible for a hydrogen bond to form, generating a γ 
turn (Figure 4.13). 
4.5.6.2 Lysine 31 
This amino acid (95% conservation) has a positively charged side chain, which can 
be used for binding to negatively charged molecules, such as RNA. Interestingly this 
and its adjacent Lys32 residue are the only lysines identified as critical for toxicity. 
May be part (i+2) of a γ turn (Figure 4.13). 
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 4.5.6.3 Lysine 32  
Lysine 32 was not conserved in 75 or more proteins homologous to BPSS0390. 
Along with Lys31 was identified as critical for toxicity and the positively charged side 
chain might interact with negatively charged RNA. The CO of Lys32 is 1.9 Å apart 
from NH of Gly34, suggesting that there might be hydrogen bonding stabilising the 
turn and the β sheet (Figure 4.13). 
4.5.6.4 Glycine 34  
Glycine 34 was conserved in 98 of the 100 proteins homologous to BPSS0390 and 
its NH group is only 1.9 Å from the CO of Lys32, suggesting that hydrogen bonding 
might be present (Figure 4.13). 
4.5.7 Residue located in β3 strand 
4.5.7.1 Valine 38 
Valine 38 was not conserved in 75 or more of the 100 proteins homologous to 
BPSS0390. This Cβ –branched hydrophobic residue has previously been assigned 
to the hydrophobic core (Butt et al. 2014). Solvent accessibility analysis suggests 
that the residue is buried (data not shown)   and structural analysis suggests that its 
side chain points into the hydrophobic core (Figure 4.14). This residue may be 
critical for protein structure. 
4.5.8 Residues located in β3-α2 loop 
NMR analysis suggests that this loop occupies multiple conformations in solution 
and may be involved in catalysis or binding of RNA substrate (Butt et al. 2014). 
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4.5.8.1 Proline 41 
This imino acid was conserved in 99% of proteins homologous to BPSS0390. Proline 
is able to contribute to turns and kinks in the protein as its amino group is part of the 
cyclical ring of atoms and is conformationally rigid. (Figure 4.14) 
4.5.8.2 Aspartic acid 44  
This residue has an acidic side chain and was conserved in 93% proteins 
homologous to BPSS0390. Role is not clear as is negatively charged at physiological 
pH. (Figure 4.14). 
4.5.8.3 Leucine 45   
This hydrophobic residue was 93% conserved. Analysis of its relative solvent activity 
suggested it was buried (data not shown). It may be involved in protein structure and 
RNA substrate recognition (Figure 4.14).  
4.5.8.4 Threonine 49 
This polar, Cβ branched amino acid has limited conformations due to the bulky side 
chain and so might be important for maintenance of structure (Figure 4.15). Analysis 
of relative solvent accessibility suggests that the residue is buried within the structure 
(data not shown).  T49 was 99% conserved across 100 proteins with homology to 
BPSS0390. 
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Figure 4.13: Location of residues in the β2-β3 loop of BPSS03390 where 
alanine substitution abolished toxicity. Structure of the β2-β3 loop of BPSS0390 (H24A). 
a) Sticks indicate His29, Lys 31, Lys 32 and Gly34.  b) Dashes indicate distance between His29 (CO) 
and Lys31 (NH) and Lys 32 (NH) and Gly34 (CO) is calculated to be 1.9 Å, suggesting that hydrogen 
bonding is possible. c) and d) Lys 31 and Lys32 have different conformations in different states and 
are only two lysines critical for toxicity.  e) Sticks represent all lysine residues present in BPSS0390. 
PyMol was used to generate the images (PDB code 4C26). 
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4.5.9 Residues located in α2 helix 
4.5.9.1 Serine 52 and Serine 56 
Serine 52 was 96% conserved across proteins homologous to BPSS0390, whilst 
Serine 56 was less than 75% conserved. These polar residues are located in the α2 
helix, suggesting that the residues might be importance for structure. (Figure 4.15). 
4.5.9.2 Alanine 57 
Alanine 57 was previously identified as part of the hydrophobic core, which suggests 
it might have a structural role (Butt et al. 2014) This residue was conserved in all 100 
homologues of BPSS0390 (Figure 4.15). 
4.5.10 Summary of residues where alanine substitution abolished 
toxicity 
Twenty residues were identified; four residues were not 75% conserved across 
protein homologues of BPSS0390: Thr21, Lys32, Val38 and Ser52. Six residues 
were identified as contributing to the hydrophobic core (Figure 4.16). 
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Figure 4.14: Location of residues in the β3 strand and β3-α2 loop of 
BPSS03390 where alanine substitution abolished toxicity. a) Sticks indicate position 
of Val38. b) Sticks indicate Pro41, Asp44 and Leu45. c) Sticks indicate Pro41, Asp44 and Leu45 in a 
different conformation indicating movement in different states. PyMol was used to generate the 
images (PDB code 4C26). 
a) 
b) 
c) 
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Figure 4.15: Location of residues in the β3-α2 loop and α2 helix of BPSS03390 
where alanine substitution abolished toxicity. a) Sticks indicate Thr49. b) Sticks 
indicate Ser52 and Ser56 within helix. c) Sticks indicate Ala57, with the methyl side 
chains orientated towards the core of the protein. PyMol was used to generate the 
images (PDB code 4C26). 
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Figure 4.16: Location of residues believed to contribute to the hydrophobic 
core of BPSS0390 (H24A). a), b) Sticks indicate Ile7, Leu10, Trp15, Phe 27, Val38 
and Ala57, with side chains orientated towards the core of the protein. PyMol was 
used to generate the images (PDB code 4C26).
a) 
b) 
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4.6 Identification of BPSS0390 residues involved in binding 
antitoxin BPSS0391 
Bibi-Triki et al. (2014) solved the structure HicA3-HicB3 complex, from a HicAB 
homologue in Yersinia pestis. Crystallisation was only possible after the C-terminus 
of HicB3 had been cleaved off, revealing that the HicA3-HicB3 complex formed a 
heterohexamer with α2 helix of HicA3 packed against the βsheet of HicB, and HicB3 
α1 helix covering one face of the βsheet of HicA3 (Figure 4.17), burying the active 
site required for RNA degradation (Bibi-Triki et al. 2014).  
4.6.1 Co-expression of BPSS0390 mutants with antitoxin BPSS0391 
Mutants N2A, S4A, K5A, L6A, R8A, E11A, E12A, D13A, R16A, L17A, V18A, V20A, 
S23A, H25A, H26A, P30A,P33A, L35A, V36A, T37A, P39A, H40A, K42A, K43A, 
P46A, I47A, G48A, V50A, K51A, I 53A, G56A, A57G, G58A and L59A were all 
tested to determine if the mutated residues played a role in antitoxin binding. It was 
only possible to test BPSS0390 mutants that retained toxicity. 
Competent E. coli MG1655 ΔhipBA  harbouring pME6032-BPSS0391  were 
transformed with pBAD/his containing a mutated BPSS0390 allele and transformants 
recovered onto LB ampicillin (100 µg/ml)  tetracycline (15 µg/ml)  glucose (2%(w/v)) 
plates. An untransformed E. coli MG1655 ΔhipBA harbouring pME6032-BPSS0391   
control was also plated onto LB ampicillin (100 µg/ml) tetracycline (15 µg/ml) glucose 
(2% (w/v)) plates.  
Plates inoculated with un-transformed E. coli MG1655 ΔhipBA harbouring pME6032-
BPSS0391 had no growth, whilst plates inoculated with transformed E. coli MG1655 
ΔhipBA harbouring pME6032-BPSS0391 and pBAD/his-BPSS0390 mutant 
constructs had over 60 colonies.       
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Cultures of E. coli MG1655 ΔhipBA harbouring pME6032-BPSS0391 and pBAD/his-
BPSS0390 mutant constructs were grown to OD590 0.1 before induction of 
expression of mutant BPSS0390 toxin (0.2% (w/v) arabinose) and of antitoxin 
BPSS0391 (1mM IPTG) for 2 hours.  The fold change in CFU after two hours (T2/T0) 
was calculated (Figure 4.18). A negative control, where E. coli MG1655 ΔhipBA 
harbouring pBAD/his-BPSS0390 and empty pME6032, with no cloned antitoxin was 
used. 
E. coli MG1655 ΔhipBA expressing both BPSS0390 and BPSS0391 had an almost 
10 fold increase in CFU counts whilst strains expressing only BPSS0390 and no 
antitoxin showed a 1000 fold decrease in the number of culturable cells.  Co-
expression of BPSS0390 mutants S4A, L6A, R8A and P30A with BPSS0391 
resulted in over a 10 fold increase in the number of culturable cells. Co-expression of 
BPSS0391 with mutants R16A, L17A, V18A, V20A, S23A and H25A also permitted 
cell growth. Cell growth was also observed when BPSS0391 was co-expressed with 
BPSS0390 mutants P33A, V36A, T37A, P39A, H40A, K42, K43, P46A, I47A, G48A, 
V50A, K51A, I53A, G58A and L59A. However, co-expression of mutants N2A, E11A, 
E12A and D13A with BPSS0391 resulted in a decrease in fold change CFU.  
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Figure 4.17: Structure of HicA3-HicB3 from Y. pestis. a) HicA3-HicB3-N terminus 
tetrameric complex. Red indicates the HicA3 toxin subunits, whilst HicB3 subunits are shown in 
green. b) HicA3 α2 helix packs against the βsheet of HicB. HicB3 α1 helix covers on face of the 
βsheet of HicA3, burying the histidine (indicated by black sticks) required for RNase activity.(Bibi-Triki 
et al. 2014). PyMol used to generate images. (PDB 4p78).
a) 
b) 
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Figure 4.18: Fold change in CFU after co-expression of BPSS0390 mutants with antitoxin BPSS0391 for two hours. E. coli 
MG1655 ΔhipBA harbouring either pBAD/his-BPSS0390 or BPSS0390 mutant gene cloned into pBAD/his was grown to OD590 0.1 before induction of toxin 
expression (0.2% (w/v) arabinose) and antitoxin expression (1mM IPTG). Data shown are an average of three biological repeats and error bars shown SEM.
a) b) 
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4.6.2 Comparison of fold change in CFU after BPSS0390 mutant 
expression and after co-expression of BPSS0390 mutants and 
BPSS0391. 
It was not possible to normalise the co-expression data as the toxicity of each 
BPSS0390 mutant differed. To determine if decrease in fold change in CFU 
observed after co-expression of N2A, E11A, E12A and D13A with BPSS0391 
warranted further investigation, it was necessary to compare existing data; change in 
CFU after BPSS0390 mutant only expression (for 2 hours, blue bars) against the 
change in CFU after co-expression BPSS0390 mutants and BPSS0391 (for 2 hours, 
red bars) (Figure 4.19).  
After expression of BPSS0390 for two hours, an almost 100 fold decrease in fold 
change in CFU was observed, whilst co-expression of BPSS0390 and BPSS0391 for 
two hours resulted in an increase fold change CFU. Co-expression of BPSS0391 
and N2A, E11A, E12A or D13A for two hours resulted in a decrease in fold change 
CFU. However, expression of N2A or E12A for two hours resulted in a decrease in 
CFU of over 10 fold, whilst expression of E11A and D13A resulted in an over 100 
fold decrease in the number of culturable cells (Figure 4.20). A ratio of fold change 
CFU after co-expression of N2A, E11A, E12A or D13A with BPSS0391 against fold 
change CFU after expression of N2A, E11A, E12A or D13A was positive (Figure 
4.20), indicating that BPSS0391 was in fact able to neutralise BPSS0390 mutants  
N2A, E11A, E12A and D13A. 
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Figure 4.19: Comparison of change in CFU after BPSS0390 mutant expression for 2 hours and after co-expression of 
BPSS0390 mutants and BPSS0391 for 2 hours. a) Change in CFU after BPSS0390 mutant expression indicated in blue and change in CFU after 
co-expression of BPSS0390 mutant and antitoxin BPSS0391 in red. Data shown is average of three biological repeats and error bars represent SEM. b) Ratio 
of fold change CFU after co-expression: fold change CFU after BPSS0390 mutant expression.
b) 
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4.7 Discussion 
Most of the type II TA toxins characterised to date act as translation inhibitors 
by targeting the stability of RNA through an array of diverse mechanisms and 
structures (Unterholzner et al. 2013; Yamaguchi & Inouye 2009). Toxins in the 
RelE superfamily have a four β –strand core, surrounded by 4 α helices and 
cleavage of the mRNA occurs at the ribosomal A-site (Li et al. 2009; 
Christensen & Gerdes 2003). In contrast, VapC toxins contain a PIN domain, 
which consists of a 3-layer α/βα sandwich around a central 5- stranded β-sheet, 
which is able to bind Mg2+ or Mn2+  at the active sites and typically cleaves 
initiator tRNAfMet  (although there is some evidence that VapC may target mRNA 
in a site specific manner) (Hamilton et al. 2014; Lee et al. 2015; Cook et al. 
2013). Meanwhile, both Kid and MazF proteins cleave mRNA independently of 
the ribosome and have compact globular folds with a core β barrel, conserved 
β-strands on a large loop and a C-terminal α helix (Cook et al. 2013). Despite 
the similarities in structure, Kid toxin preferentially cleaves RNA at UA(A/C) 
triplets (Hargreaves et al. 2002; Muñoz-Gómez et al. 2005), whilst the 
recognition motif of MazF toxins varies in both length and sequence in different 
bacterial species (Cook et al. 2013; Unterholzner et al. 2013). Protein 
BPSS0390 has homology to HicA, a TA toxin that acts as an mRNA interferase, 
capable of cleaving free mRNA independently of the ribosome but with no 
obvious consensus recognition motif (Jørgensen et al. 2009). The structure of 
BPSS0390 H24A was determined by NMR to form a dsRBD-like domain fold, a 
structure not previously attributed to a TA toxin (Butt et al. 2014) and perhaps 
suggests that this toxin cleaves mRNA  in the area of double-stranded (ds) 
regions (Bibi-Triki et al. 2014). 
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First identified as a conserved domain in 1992, dsRBD are small protein 
domains (65-70 amino acids) that adopt an αβββα fold, with two α-helices 
packed against a three stranded β- sheet (Johnston et al. 1992; Masliah et al. 
2013; Drusin et al. 2016). Important for many cellular processes in both 
eukaryotes and prokaryotes, the dsRBD is one of the most abundant RNA 
binding domains and its interaction with dsRNA is well characterised (Maris et 
al. 2005; Drusin et al. 2016).  
In solution dsRNA forms an A-form double helix, with two grooves. The minor 
groove is wide and shallow with the edge of bases easily accessible, while the 
major groove is deep and narrow, which hinders access to bases. The width of 
these grooves and the 2’OH functional groups on the ribose sugars in the minor 
groove, allow the dsRBD to discriminate between dsDNA and dsRNA (Saenger 
1984; Dickerson et al. 1982).  
High resolution structures of various dsRBDs in complex with dsRNA have 
revealed that three separate regions are required for recognition of dsRNA. 
(Ryter & Schultz 1998; Ramos et al. 2000; Gan et al. 2006; Gan et al. 2008; 
Gan et al. 2005; Blaszczyk et al. 2004; Z. Wang et al. 2011; Wu et al. 2004; 
Stefl et al. 2010; Huang et al. 2009; Yang et al. 2010; Masliah et al. 2013). 
Systemic mutational analysis of various dsRBDs also identified the same three 
regions and conserved residues that may be involved in dsRNA binding (Green 
& Mathews 1992; Green et al. 1995; Bycroft et al. 1995; Ramos et al. 2000; 
McMillan et al. 1995; Patel et al. 1996; Masliah et al. 2013). The three regions 
identified were: region 1 located at the N-terminus of the protein in helix α1, 
region 2 located in the β1-β2 loop and region 3 located at the N-terminal of α2 
helix. 
183 
 
Expression of twenty mutants, S3A, I7A, L10A, W15A, R19A, T21A, G22A, 
F27A, H29A, K31A, K32A, G34A, V38A, P41A, D44A, L45A, T49A, S52A, 
S56A and A57G, permitted cell growth. Quantification of protein expression 
levels by Western blotting determined that expression levels for all substitution 
mutants were higher than the BPSS0390 control. These twenty mutants are 
interesting as they have no function despite being expressed. This suggests 
that the residues mutated are critical for function, either indirectly, through 
maintenance of structure and correct protein folding, or directly, because they 
are involved in binding or catalysing RNA.  
Alanine substitution of three amino acids, Arg19, Thr21, Gly22 (excluding the 
previously identified His24) located on the β1-β2 loop of BPSS0390, abolished 
toxicity.  The β1-β2 loop of canonical dsRBDs is thought to interact with the 
minor groove, one turn away from the minor groove interacting with region 1. 
Typically, this loop is six residues long and features the conserved amino acid 
motif GPxHxx, where both the histidine and glycine residues are absolutely 
required for function, whilst the proline residue is not essential (Masliah et al. 
2013; Stefl et al. 2010). Structural resolution of many dsRBDs revealed that the 
carbonyl group of the peptide backbone of the histidine formed a hydrogen 
bond to the 2’OH group on one strand, while the imidazole portion stacked onto 
a ribose to make a hydrogen bond to the 2’OH group of the previous ribose on 
the other strand (Stefl et al. 2010; Z. Wang et al. 2011; Ryter & Schultz 1998). 
The residue immediately preceding the histidine has also been shown to bind 
dsRNA; the peptide backbone carbonyl group contacts the edge of a base, in 
the dsRBD1 of protein Hyponastic Leaves 1 (HYP1), the residue was a serine 
that formed a hydrogen bond with N3 of a guanine (Rasia et al. 2010).  In some 
ways, this description describes the β1-β2 loop of BPSS0390. Both His24 and 
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Gly22 are critical to toxicity and NMR spectra indicate that this loop of six 
residues has increased local dynamics (Butt et al. 2014). However, the amino 
acid sequence does not contain the GPxHxx motif (amino acid sequence is 
RVTGSH). In fact, the sequence of the β1-β2 loop more closely resembles the 
Rx4-6H motif (where x is any amino acid and 4-6 indicates the number of amino 
acids between R and H), a novel RNase active site conserved in HEPN toxins 
(from HEPN-MNT TA system), although it lacks the polar residue immediately 
after the R (Yao et al. 2015).  
The role of Arg19 and Thr21 in toxicity is less clear. In protein–dsRNA 
interactions, hydrogen bonds occur between the nitrogen atoms of arginine side 
chain and the hydroxyl or phosphate groups from RNA backbone. Arginine 
residues also form strong interactions with guanine bases (Lustig et al. 1997) It 
could be that Arg19 is required for attracting, orientating and binding to the RNA 
substrate (Drusin et al. 2016; Pathak et al. 2013) Thr21 is the third residue in 
the loop and evidence from high resolution structures (of dsRNA with dsRBDs) 
suggests that residues in this position form sequence specific contacts. The 
carbonyl group of the peptide backbone is able form a hydrogen bond with the 
exocyclic amino group of guanine, the only base that exhibits an amino group in 
the minor groove (Blaszczyk et al. 2004; Gan et al. 2008; Gan et al. 2006; Stefl 
et al. 2010; Ryter & Schultz 1998; Yang et al. 2010). It may be that Thr21 is 
involved in recognising the RNA substrate (threonine favours bonding with 
adenosine (Lustig et al. 1997)) of BPSS0390, which would also explain why it is 
not highly conserved in BPSS0390 homologues. Alternatively, it might be 
required for stabilising configuration of side chains within the active site 
(Hamilton et al. 2014), which would explain why the relative calculated 
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concentration of protein after two hours was not significantly different to the 
toxic control. 
Unexpectedly, substitution of Ser23 with an alanine did not modify toxicity; this 
suggests that the hydroxymethyl side chain is not involved in substrate binding. 
However, it may be that the methyl side chain of the substituted alanine is also 
able to form hydrogen bonds with the substrate and future work could involve 
replacing Ser23 with a less reactive amino acid.   
Region 3 of a canonical dsRBD is located at the N-terminus of the α2 helix and 
contains the well conserved amino acid sequence KKxAK. The orientation of 
the first and third lysines are pre-organised to allow their side chains to contact 
the phosphodiester of one strand, whilst the second lysine contacts the other 
strand of the major groove. Formation of this arch is stabilised by a series of 
Van der Waals forces between the lysine side chains and residues in the 
hydrophobic core, and also by the rigid peptide backbone embedded in the 
alpha helix. Variations of the KKxAK motif include replacement of one or more 
lysines with arginine, glutamate, a negatively charged residue or glycine. In all 
cases the presence of a lysine in α1 helix compensates for these variations 
(Johnston et al. 1992; Barraud et al. 2012; Ryter & Schultz 1998; Masliah et al. 
2013). None of the residues identified as critical for function in the β3- α2 loop 
and α2 helix of BPSS0390 were lysines. This is unusual (Ramos et al. 2000; 
Nanduri et al. 1998; Patel et al. 1996; Bycroft et al. 1995).  
One pair of lysines was located on the β3- α2 loop, one pair within the α2 helix 
and one located within the α1 helix ; mutation of K42 (β3- α2 loop) and K55 (α2 
helix) did reduce toxicity but not significantly. NMR analysis of the β3- α2 loop of 
BPSS0390 was ill defined, suggesting that the loop was able to occupy multiple 
conformations (Butt et al. 2014). In Staufen protein, the individual lysine side 
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chains in the β3- α2 loop of the dsRBDs underwent a large amplitude of motion 
that lead to formation short- lived contacts to dsRNA (less than 10 picoseconds) 
before the side chains switched to new contacts within the dsRNA. This 
continuous flicking between polar interactions ensured constant association with 
dsRNA but allowed for a degree of freedom in the dsRBD-RNA complex 
(Castrignanò et al. 2002; McMillan et al. 1995; Hartman et al. 2013). It is 
possible that the β3- α2 loop and α2 helix of BPSS0390 also undergo this 
switching of polar interactions, and whilst all lysines do not contribute equally to 
binding (McMillan et al. 1995), abolishing individual lysines may not be sufficient 
to fully prevent interaction with phosphodiester backbone. For future work 
determine if these lysines are critical for dsRNA binding, it might be necessary 
to mutate all lysines to alanines within one protein and examine the mutant for 
changes in RNA binding and toxicity. RNA binding assays, where labelled RNA 
probe is mixed with mutant protein samples and then electrophoresed could 
also be used to look for changes in binding between controls and individual 
alanine mutants. 
The residues critical for toxicity in the β3- α2 loop and α2 helix may be involved 
in forming further contacts between the phophodiester backbone and 
BPSS0390, or in helping orientate the residues that do. Indeed, both lysines in 
α2 helix are succeeded in the sequence by serines (Ser52 and Ser56), which 
likely do not contribute to binding dsRNA but may be packed against the β-
sheet surface, stabilising the α2 helix and helping orientate the preceding 
lysines. Bulky side chains in this location would destabilise β-sheet surface by 
causing steric clashes (Wu et al. 2004; Ramos et al. 2000), although it is 
perhaps odd that substitution with alanine would cause this.  Ala57 has been 
187 
 
assigned to the hydrophobic core, but substitution with a glycine may have also 
destroyed the tight packing of the α2 helix against the β-sheet. 
It is not possible to definitively determine the roles of Pro41, Asp44, Leu45 and 
Thr49. The proximity of Asp44 to Lys 42 and Lys43 suggests it may be involved 
in contacting the phosphodiester backbone. However, proline residues are often 
located in turns and loops and may play an important role in chain compaction 
during early protein folding (Krieger et al. 2005; Qiu et al. 2008); suggesting that 
the role of Pro41 is structural rather than functional. 
Unlike the β1-β2 and β3- α2 loop, the β2- β3 loop of dsRBDs is unremarkable; 
its flexibility is quenched despite having no direct contact with dsRNA. It may be 
that this rigid structure is required to ensure that regions 2 and 3 are spread the 
correct distance apart to discriminate between dsRNA and dsDNA (Castrignanò 
et al. 2002; Fu et al. 2009). Alanine substitution of four residues in the β2- β3 
loop of BPSS0390 abolished toxicity (H29A, K31A, K32A and G34). It is 
possible that these four residues are required to make two γ turns in the loop 
and are responsible for stabilising the molecule. As neither these turns nor 
these residues are conserved in dsRBDs, it may also suggest that this positively 
charged region is important for antitoxin binding.  
The final region involved in recognising dsRNA is located in the α1 helix and 
consists of 4-5 residues at specific locations, although only one residue is 
conserved (Ryter & Schultz 1998; Masliah et al. 2013) . There is some debate 
as to whether the interactions of these residues with the minor groove are 
shape, such as the UUGG tetraloop, or sequence specific, for example, contact 
of methyl group of methionine 4 in ADAR2 dsRBD with the edge of an adenine 
(Chang & Ramos 2005; Stefl et al. 2010; Masliah et al. 2013). In BPSS0390, 
alanine substitution revealed three residues where mutation abolished function; 
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S3, I7 and L10. Leucine 10 was assigned to the hydrophobic core. Interestingly, 
Ser3 of dsRBD in Staufen protein interacts with the 2’OH and phosphate 
oxygen of the RNA stem loop and so Ser3 of BPSS0390 may also interact with 
the dsRNA substrate (Chang & Ramos 2005). Ile7 was assigned to the 
hydrophobic core but also corresponds to the first of the four residues involved 
in recognition of minor groove in canonical dsRBDs. In Xenopus leavis RNA 
binding protein A (Xlrbpa) the side chain of the of the bulky and hydrophobic 
reside in this position was able to make Van der Waals contacts to the ribose 
moiety of dsRNA minor groove. It also interacted with alanines in α2 to assist in 
formation of the core (Krovat & Jantsch 1996; Masliah et al. 2013). The other 
three residues that might be involved in RNA binding are Arg8, Glu11 and 
Glu12. Arg8 in Dicer-like 1 (DCL1) protein, a ribonuclease III enzyme, was able 
to form hydrogen bonds with nitrogenous bases and preferentially bound to 
mismatched base pairs within the helix, acting as an anchor (Drusin et al. 
2016). However, Arg8 is not conserved across proteins with homology to 
BPSS0390 and substitution with an alanine did not abolish toxicity.  
The final two residues that might be involved are both glutamatic acids. In 
Xlrbpa and Staufen proteins, a glutamic acid carbonyl group makes a hydrogen 
bond with the 2’OH group of ribose sugar in minor groove. The second glutamic 
acid is conserved in both proteins and its mutation abolishes function (Ramos et 
al. 2000; Krovat & Jantsch 1996). However, in BPSS0390 neither residue was 
individually required for toxicity and both were conserved in less than 75% 
homologous proteins. It may both residues and the succeeding Asp13 are 
involved binding ribose moieties in the minor groove, in a sequence specific 
manner and so a reduction in toxicity would only be observed after alanine 
substitution of all three residues in the same mutant. 
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In the α1-β1 loop, Gly14 was 97% conserved across BPSS0390 homologues 
and yet substitution with an alanine reduced but did not abolish toxicity. Trp15 
was assigned to the hydrophobic core. However,  in dsRBD of Saccharomyces 
cerevisiae RNase III, the α1-β1 loop forms a hinge that facilitates the 
conformational changes required for both α1 helix and β1-β2 loop to find the 
minor groove (Hartman et al. 2013). Substitution of the flexible glycine with 
alanine in BPSS0390 may have partially impaired movement the movement of 
this hinge.  
Masliah et al. (2013) determined that hydrophobic residues conserved in more 
than 40% of proteins in a multiple sequence alignment of various dsRBD were 
important for maintenance of a stable hydrophobic core, including but not 
limited to two leucines in the α1 helix, a proline on the α1- β1 loop, a 
phenylalanine in the β2 strand, valines in the β3 strand and alanine in the α2 
helix (Masliah et al. 2013). These residues correspond well to I7 and L10 (α1 
helix), W15 (aromatic, α1- β1 loop), F27 (β2 strand), V38 (β3 strand) and A57 
(α2 helix) in BPSS0390, validating the assignment of these residues as part of 
the hydrophobic core. Western blot analysis indicated that cells expressed 
W15A and V38A mutant proteins at levels similar to wild type BPSS0390, whilst 
cells expressed I7A, L10A, F27A and A57G mutant proteins at a statistically 
significantly higher relative calculated concentration. Organisation of residues 
within the core is important both for structure and stability of a protein  (Munson 
et al. 1996) so it might be that disruption of the W15 and V38 residues results in 
an unstable protein that degrades rapidly, whilst I7A, L10A, F27A and A57G 
proteins are more stable and non-toxic so larger quantities are produced as 
there is no cell growth arrest after expression.  
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It is hard to draw firm conclusions from expression data as Western blotting is a 
“semi-quantitative” method that relies on even transfer of protein onto 
membrane and even exposure to washing and antibodies, procedures where 
some variation is inevitable. Although use of  quantitative fluorescent Western 
blotting with a fluorescent secondary antibody and a standard curve to generate 
a linear detection profile may have improved the sensitivity and accuracy 
compared to ECL labelling (Eaton et al. 2014). Only small quantities of 
BPSS0390 are produced in response to induction of expression as the toxic 
effects of the protein causes cell growth arrest and a decrease in the number of 
culturable cells, whereas large quantities of protein are produced when the 
mutant is non-toxic, for example, H24A. Small quantities of protein might be 
produced when the mutant is as or more toxic than native BPSS0390 or when 
the mutation has completely interrupted the structure of the protein and the 
protein cannot fold properly. It is therefore very difficult to interpret the 
expression data against the toxicity data and this is an area that will require 
more thought in future work. 
The size of the BPSS0390 protein was also problematic for Western blotting; 
intact, histidine tagged BPSS0390 is 10kDa so any fragments produced due to 
instability are likely to be very small and lost from the SDS-PAGE gel. For future 
work, mutants showing increased calculated relative concentration could be 
further characterised using quantitative real-time PCR to quantify mutant gene 
expression and circular dichroism (CD) spectroscopy used to determine 
changes to secondary structure of the protein (Drusin et al. 2016; Butt 2013). 
Bibi-Triki et al. (2014) solved the structure of  the HicA3-HicB3 complex to 
determine that the interface of the complex consisted of  i) one face of the β-
sheet of HicA3 covered by α1 helix of HicB-N-terminus, occluding the catalytic 
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site at β1-β2 loop and ii) the α2 helix of HicA3 packed against the β-sheet of 
HicB3-N-terminus. This interface was stabilised by ten hydrogen bonds and five 
salt bridges. However,  it was only possible to determine this structure by 
removing the C-terminal third of the HicB protein (Bibi-Triki et al. 2014). This 
does not correlate with what has previously been observed with BPSS0390-
BPSS0391 complex formation (Butt 2013) and so it would have been interesting 
to determine which residues were involved in the binding interface of 
BPSS0390-BPSS0391complex. However, it was not possible to identify 
residues involved in BPSS0390-BPSS0391 complex formation as all of the 
BPSS0390 alanine mutants tested were neutralised as growth was observed (or 
partially neutralised, negatively charged Glu11, Glu12 and Asp13) when 
expressed with antitoxin BPSS0391. The existing co-expression assay only 
allowed for BPSS0390 mutants that retained toxicity to be tested as mutants 
that were not neutralised in the assay, were identified as they retained their 
toxic phenotype (decrease in fold change in CFU compared to toxin expression 
only). Many of the residues necessary for maintaining the structure and function 
of the β1-β2 loop and α2 helix abolished toxicity and so could not be tested. In 
future, it would be good to test these mutants for interactions with BPSS0391 
using a yeast two-hybrid system, although further work would be needed to 
demonstrate successful functional neutralisation in bacterial cells. 
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Chapter 5: Crosstalk between non-cognate 
toxin-antitoxin pairs identified in 
Burkholderia pseudomallei K96243. 
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5.0 Introduction 
Butt et al. (2013) previously designed a novel co-expression assay where 
the candidate toxin and antitoxin genes in B. pseudomallei K96243 identified by 
RASTA, could be independently or simultaneously expressed in E. coli. Over-
expression of toxin genes resulted in two toxic phenotypes; bacteriostasis or a 
rapid decrease in number of culturable cells, whilst co-expression of the toxin 
with its cognate antitoxin resulted in growth, as expected. Interestingly, when 
toxin BPSS0390 (homologous to HicA) was co-expressed with non-cognate 
antitoxin BPSL0174 (homologous to RelB)  growth, an increase in OD and CFU, 
was also observed, suggesting that an antitoxin from one system could 
neutralise a toxin from a different system (Butt 2013). 
Toxin-antitoxin systems are typically described as a gene pair where one 
gene encodes a protein toxin and the other gene encodes a cognate antitoxin 
capable of sequestering the  toxin (Yamaguchi et al. 2011; Gerdes & 
Maisonneuve 2012). In type II systems this description suggests that only one 
antitoxin may neutralise one toxin.   
The co-existence of multiple homologous and non-homologous TA 
systems within individual bacterial genomes may suggest that non-cognate 
interactions are possible (Goeders & Melderen 2014).  In pathogenic E. coli 
O157:H7 two homologues of the ccd TA system have been identified, one 
plasmid-borne, ccdF, and one located on the chromosomal backbone, ccdO157. 
Both systems co-exist and encode functional toxins, targeting DNA gyrase, and 
functional antitoxins, subject to degradation by Lon protease. Experiments to 
examine cross-interaction between the two systems revealed that the 
chromosomal toxin could be sequestered by the plasmid encoded antitoxin but 
that the toxin encoded by the plasmid could not be sequestered by the 
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chromosomal antitoxin (Wilbaux et al. 2007). Limited evidence suggests that 
non-cognate TA pairs in Mycobacterium tuberculosis can interact physically and 
functionally (Zhu et al. 2010). These functional interactions between non-
cognate systems, within and without different families, suggest that TA systems 
may operate as networks that co-operate to enable adaptation to the host cell 
environment.  
There is published data on four type II TA systems identified in B. 
pseudomallei K96243. Two systems, BPSS1060-1061 and BPSL0174-0175 are 
paralogous. Toxin BPSL0175 has 54% identity to RelE toxin from Klebsiella 
pneumoniae and antitoxin BPSS1060, 53% identity. One system, BPSS1583-
1584, is homologous to hipBA, with toxin BPSS1584 sharing 100% identity with 
HipA in B. mallei and antitoxin BPSS1584 92%. Finally, system BPSS0390-
0391, where toxin BPSS0390 has 78% identity with HicA toxin from 
Acinetobacter baumannii and antitoxin BPSS0391 43% identity with HicB 
Neisseria subflava (Butt 2013).  
An existing co-expression assay was modified to allow for co-expression 
of non-cognate TA pairs. Six non-cognate pairs were co-expressed using this 
assay and the OD and number of culturable cells monitored over time (Figure 
5.1). 
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Toxin gene 
  
BPSS0390 BPSS1584 BPSS1060 BPSL0175 
Antitoxin gene Homologous to: hicA hipA relE relE 
BPSS0391 hicB    x x  
BPSS1583 hipB  x  x   x 
BPSS1061 relB   x  x  
BPSL0174 relB  x   x  
 
Figure 5.1: Matrix to show toxin-antitoxin pairs co-expressed in this study. 
Antitoxin genes identified in B. pseudomallei are listed to the left and toxin genes 
identified are listed above. The cognate TA pair BPSS0390-BPSS0391 was used to 
optimise the co-expression assay before other non-cognate pairs were co-expressed. 
Ticks indicate gene pairs that were co-expressed. Crosses indicate gene pairs that 
were not examined.  
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5.1 Aim 
Determine if type II TA antitoxins in B. pseudomallei form a co-operative 
network through non-cognate toxin-antitoxin interactions. 
 
5.2 Results 
5.2.1 Existing method for co-expression of cognate toxin-antitoxin 
pairs   
A co-expression assay designed to determine if  antitoxin BPSS0391 could 
neutralise its cognate toxin BPSS0390 has previously been described (Butt et 
al. 2013; Butt 2013). This published expression system allowed for co-
expression of both toxin and antitoxin genes as the toxin was cloned into the 
arabinose inducible pBAD/his vector and the antitoxin gene into the IPTG 
inducible pME6032 vector (both described previously). To co-express the toxin 
and the antitoxin both arabinose (final concentration of 0.2% (w/v)) and IPTG 
(final concentration of 25mM) were added to E. coli culture harbouring 
pBAD/his-BPSS0390 and pME6032-BPSS0391 and the optical density and 
number of culturable cells monitored hourly for two hours. 
A culture of E. coli containing plasmid encoded toxin (pBAD/his-BPSS0390) and 
plasmid encoded antitoxin (pME6032-BPSS0391) was grown to early log phase 
(OD590 ~ 0.1) and split; supplemented with either arabinose  (final concentration 
of 0.2% (w/v)) to induce toxin expression, or arabinose and IPTG (final 
concentration of 25mM) to induce both toxin and antitoxin expression, or IPTG 
only added to induce antitoxin expression, or glucose (final concentration 0.2% 
(w/v)) to repress toxin expression. The optical density and number of culturable 
cells were monitored hourly for three hours (Figure 5.2). 
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  Glucose repression allowed the cells to continue growing, as did 
expression of only antitoxin BPSS0391 (25mM IPTG). Expression of BPSS0390 
only (0.2% (w/v) arabinose), reduced both the growth rate and the number of 
culturable cells after three hours. However, addition of both arabinose and IPTG 
(0.2% (w/v) arabinose and 25mM IPTG) resulted in an increase in optical 
density and number of culturable cells after three hours.  
 
 
 
 
 
 
 
198 
 
 
 
 
Figure 5.2: Co-expression of cognate toxin- antitoxin pair BPSS0390 and 
BPSS0391 in E. coli MG1655. a) Change in OD; b) number of culturable cells, after 
either: induction of toxin expression only (0.2% (w/v) arabinose), or repression of toxin 
expression (0.2% (w/v) glucose), or induction of toxin and antitoxin expression (0.2% 
(w/v) arabinose and 25mM IPTG) or induction of antitoxin only (25mM IPTG). Data 
shown represents two biological repeats and error bars represent SEM. 
 
 
 
 
a) 
b) 
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5.3 IPTG as an inhibitor of PBAD expression system  
 Kim et al. (2007) have previously indicated that IPTG can inhibit expression 
from the PBAD expression system.  Therefore it was necessary to determine if 
the cell growth observed after co-expression of toxin gene BPSS0390 with 
antitoxin BPSS0391 (as described above) was a result of IPTG-induced 
repression of the PBAD arabinose promoter or the neutralisation of toxic protein 
by the antitoxin. 
 An overnight culture of E. coli with plasmid encoded toxin HicA (pBAD/his-
BPSS0390) was supplemented with ampicillin (100 µg/ml), and glucose (2% 
(w/v)) was used to inoculate fresh LB broth supplemented with ampicillin (100 
µg/ml). The culture was grown until early log phase (OD590 ~0.1) before 
splitting; either glucose (final concentration 0.2% (w/v)) was added to repress 
toxin expression, or arabinose (final concentration 0.2% (w/v)) was added to 
induce toxin expression or the media was supplemented with IPTG (final 
concentration of 25mM) before induction of toxin expression by addition of 
arabinose (final concentration 0.2% (w/v)). The optical density and number of 
culturable cells were monitored for three hours (Figure 5.3) 
The addition of glucose allowed the cells to continue growing as evidenced by 
the increase in optical density and number of culturable cells after three hours. 
When arabinose alone was added there was a rapid decrease in culturable cells 
after three hours and a reduced growth rate when compare to the glucose 
repressed control. However, when both IPTG and arabinose were added, the 
optical density and number of culturable cells increased, similar to the glucose 
control. 
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Figure 5.3: Addition of IPTG repressed expression from the PBAD 
promoter. Supplementing media with IPTG (25mM) before induction (0.2% (w/v) 
arabinose) of toxin expression, or toxin expression only (0.2% (w/v) arabinose) or 
repression (0.2% (w/v) glucose) of toxin expression. Graphs show changes in a) optical 
density and b) number of culturable cells. Data shown is average of three biological 
repeats and error bars represent SEM. 
 
 
 
 
a) 
b) 
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5.3.1 Determining the inhibitory concentration of IPTG 
An overnight of culture of E. coli pBAD/his-BPSS0390 supplemented with 
ampicillin (100 µg/ml) and glucose (2% (w/v)) was used to inoculate fresh LB 
broth supplemented with ampicillin (100 µg/ml). The culture was grown until 
early log phase (OD590 ~0.1) before splitting. Cultures were supplemented with 
IPTG to a final concentration of either 1mM, 5mM, 10mM or 25mM IPTG before 
toxin expression was induced by addition of final concentration of 0.2% (w/v) 
arabinose. There were two controls where no IPTG was added; one where toxin 
expressed was induced by addition of final concentration of 0.2% (w/v) 
arabinose and the other where toxin expression was repressed by addition of a 
final concentration of 0.2% (w/v) glucose. The optical density and number of 
cultural cells were monitored for three hours (Figure 5.4) 
The addition of glucose allowed the cells to continue growing. When arabinose 
alone was added, there was a decrease in the number of culturable cells after 
three hours and a reduced growth rate when compared to the glucose 
repressed control. However, when media was supplemented with either 10mM 
or 25mM IPTG the number of culturable cells increased after three hours, 
despite addition of arabinose to induce toxin expression. When media was 
supplemented with arabinose and 5mM IPTG the culturable grew for the first 
hour before becoming bacteriostatic. Only when media was supplemented with 
1mM IPTG and toxin expression induced was a reduction in culturable cells 
observed. 
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Figure 5.4: Determining the inhibitory concentrations of IPTG. Media was 
supplemented with different final concentrations of IPTG ( 1mM, 5mM, 10mM or 25mM) 
and toxin expression induced (0.2% (w/v) arabinose). Changes in a) optical density and 
b) number of culturable cells for three hours. Data shown represents two biological 
repeats and error bars represent SEM 
 
 
 
a) 
b) 
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5.3.2 IPTG toxicity 
  An overnight of culture of E. coli pBAD/his-BPSS0390 supplemented with 
ampicillin (100 µg/ ml) and glucose (2% (w/v)) was diluted to an OD590nm of 0.01 
in LB broth supplemented with ampicillin (100µg/ ml)  and either no, 1mM, 5mM, 
10mM or 25mM IPTG. 100µl aliquots of the cell suspension were pipetted into 
individual wells in a 96-well plate and incubated overnight at 37°C. A Softmax 
Pro-5 Microplate Reader (VersaMax) was used to take OD590 over 24 hour 
period (Figure 5.5). 
Cultures that had been supplemented with 1, 2 or 5mM IPTG demonstrated 
similar growth profiles to the culture with no IPTG supplementation: normal 
growth. Cultures supplemented with either 10mM or 25mM IPTG showed a 
reduced growth rate.   
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Figure 5.5: Growth of cultures supplemented with different final 
concentrations of IPTG. Diluted cells were supplemented with different 
concentrations of IPTG before transference to a 96-well plate. The optical density was 
monitored for 24 hours using a plate reader. Data shows mean of two biological 
replicates and error bars represent SEM.  
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5.3.3 Optimising the co-expression assay 
The experiment shown at figure 5.4 indicated that concentrations of IPTG of 
5mM and above were able to abolish the toxic phenotype observed when toxin 
expression was induced  and so the co-expression assay was repeated as 
previously reported but using 1mM or 5mM IPTG to induce antitoxin expression 
and with E. coli MG1655 ΔhipBA as a host. This E. coli strain was chosen to 
ensure that there were no interactions between the native host TA systems and 
the B. pseudomallei TA components being ectopically expressed.  
Heat shock was used to transform pME6032-BPSS0391 into competent E. coli 
MG1655 ΔhipBA and transformants were recovered onto LB agar plates 
supplemented with tetracycline (15 µg/ml). Competent E. coli  MG1655 ΔhipBA  
pME6032-BPSS0391 cells were generated and transformed with pBAD/his-
BPSS0390 by heat shock and transformants selected by plating onto LB agar 
plates with ampicillin (100 µg/ml), tetracycline (15 µg/ml) and glucose (2% 
(w/v)).   
An E. coli ΔhipBA pBAD/his-BPSS0390 pME6032-BPSS0391 culture 
was grown to an OD590 of approximately 0.1 (early log phase) and split into four 
cultures of equal size. Either: arabinose (final concentration of 0.2% (w/v)), or 
arabinose and IPTG (final concentration of either 1 or 5mM), or glucose (final 
concentration 0.2% (w/v)) were added to repress toxin expression. The optical 
density and number of culturable cells were monitored hourly for three hours 
(Figure 5.6). 
As a control, a culture of E. coli ΔhipBA harbouring pBAD/his-BPSS0390 
pME6032 (lacking the antitoxin gene), was also grown and the culture split and 
treated as described above. 
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Addition of arabinose induced toxin expression for both strains; a decrease in 
the number of culturable cells and a reduced growth rate was observed. When 
toxin expression was repressed by addition of glucose, the number of culturable 
cells increased in both cultures. For cultures harbouring both pBAD/his-
BPSS0390 and pME6032-BPSS0391, induction of toxin and antitoxin 
expression (arabinose and either 1mM or 5mM IPTG) resulted in an increase in 
the number of culturable cells; a growth phenotype similar to glucose 
repression. For cultures harbouring pBAD/his-BPSS0390 and empty pME6032, 
addition of final concentration 0.2% (w/v) arabinose and 1mM IPTG resulted in 
a decrease in culturable cells and OD similar to arabinose only toxin 
expression. However, when a final concentration of 0.2% (w/v) arabinose and 
5mM IPTG were added to cultures harbouring pBAD/his-BPSS0390 and empty 
pME6032, the number of culturable cells did not change. 
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Figure 5.6: Optimising co-expression of cognate toxin-antitoxin pair 
BPSS0390-BPSS0391 in E. coli MG1655 ΔhipBA. E. coli MG1655 ΔhipBA 
harbouring either pBAD/his-BPSS0390 and pME6032-BPSS0391 (a,b) or BAD/his-
BPSS0390 and empty pME6032 vector (control) (c,d) was grown to early log phase 
(OD590 0.1) before cultures were split and either toxin expression induced (0.2% (w/v) 
arabinose),  or repressed  (0.2% (w/v) glucose) , or toxin and antitoxin expression 
induced (0.2% (w/v) arabinose and  1mM or 5mM IPTG) and the changes in optical 
density (a,c) and number of culturable cells (b,d)  recorded hourly.  Data shown 
represents two biological repeats and error bars represent SEM. 
 
 
 
 
a) b) 
d) c) 
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5.4 Co-expression of toxin gene BPSS0390 with antitoxin genes from 
different families  
5.4.1Co-expression of BPSS0390 with BPSL0174 (homologous to 
relB) 
E. coli MG1655 ΔhipBA  pME6032-BPSL0174 competent cells were  
transformed with pBAD/his-BPSS0390  by heat shock and transformants 
selected by plating onto LB agar plates with ampicillin (100 µg/ml), tetracycline 
(15 µg/ml) and glucose (2%(w/v)).   
A culture of E. coli MG1655 ΔhipBA  pBAD/his-BPSS0390  pME6032-
BPSL0174 was grown until early log phase (OD590 ~ 0.1) and the culture split 
and supplemented with either arabinose (final concentration of 0.2% (w/v)) or 
arabinose and IPTG (final concentration 1mM) or IPTG only (final concentration 
1mM) or glucose (final concentration of 0.2% (w/v)). The OD and number of 
culturable cells were monitored for three hours (Figure 5.7). 
Induction of toxin expression (arabinose) resulted in a decreased growth rate 
and a 100-fold decrease in the number of culturable cells. Glucose-repression 
of toxin expression resulted in growth with both the OD and number of 
culturable cells increasing. When only IPTG was added, a growth phenotype 
was observed similar to glucose-repression. However, when both toxin 
BPSS0390 and antitoxin BPSL0174 were expressed a toxic phenotype, where 
both OD and number of culturable cells decreased, was observed. This 
suggests that in this assay, antitoxin BPSL0174 was not able to neutralise toxin 
BPSS0390. 
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Figure 5.7: Co-expression of genes BPSS0390 and BPSL0174 in E. coli 
ΔhipBA pBAD/his-BPSS0390 pME6032-BPSL0174. a) Change in OD ; b)  
change in number of culturable cells after induction of either toxin expression 
(arabinose), or toxin and antitoxin expression (arabinose and IPTG), or  antitoxin 
expression (IPTG) or repression of toxin expression (glucose) in cultures of E. coli 
MG1655 ΔhipBA harbouring pBAD/his-BPSS0390 and pME6032-BPSL0174 . Data 
shown represents three biological repeats and error bars represent SEM. 
 
 
 
a) 
b) 
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5.4.2 Co-expression of BPSS0390 with BPSS1061 (homologous to 
relB) 
E. coli MG1655 ΔhipBA  pME6032-BPSS1061 competent cells were  
transformed with pBAD/his-BPSS0390 by heat shock and transformants 
selected by plating onto LB agar plates with ampicillin (100 µg/ml), tetracycline 
(15 µg/ml) and glucose (2% (w/v)).   
A culture of E. coli MG1655 ΔhipBA  pBAD/his-BPSS0390  pME6032-
BPSS1061 was grown until early log phase (OD590 ~ 0.1) and the culture split 
and supplemented with either arabinose (final concentration of 0.2% (w/v)) or 
arabinose and IPTG (final concentration 1mM) or IPTG only (final concentration 
1mM) or glucose (final concentration of 0.2% (w/v)). The OD and number of 
culturable cells were monitored for three hours (Figure 5.8). 
When BPSS0390 toxin expression was induced, there was over a 100-fold 
decrease in culturable cells, whilst glucose-repression of BPSS0390 expression 
resulted in growth with the OD and number of culturable cells increasing after 
three hours. Addition of only IPTG resulted in a growth phenotype similar to 
glucose-repression, with the number of culturable cells increasing. When both 
BPSS0390 and BPSS1061 expression was induced there was a 100-fold 
decrease in the number of culturable cells, suggesting that in this assay 
antitoxin BPSS1061 was not able to neutralise BPSS0390. 
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Figure 5.8: Co-expression of genes BPSS0390 and BPSS1061 in E. coli 
ΔhipBA pBAD/his-BPSS0390 pME6032-BPSS1061. a) Change in OD; b)  
change in number of culturable cells after induction of either toxin expression 
(arabinose), or toxin and antitoxin expression (arabinose and IPTG), or antitoxin 
expression (IPTG) or repression of toxin expression (glucose) in cultures of E. coli 
MG1655 ΔhipBA harbouring pBAD/his-BPSS0390 and pME6032-BPSS1061 . Data 
shown represents three biological repeats and error bars represent SEM. 
 
 
 
 
 
a) 
b) 
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5.4.3 Co-expression of BPSS0390 with BPSS1583 (homologous to 
hipB) 
E. coli MG1655 ΔhipBA  pME6032-BPSS1583 competent cells were  
transformed with pBAD/his-BPSS0390 by heat shock and transformants 
selected by plating onto LB agar plates with ampicillin (100 µg/ml), tetracycline 
(15 µg/ml) and glucose (2% (w/v)).   
E. coli MG1655 ΔhipBA  pBAD/his-BPSS0390  pME6032-BPSS1583 culture 
was grown until early log phase (OD590 ~ 0.1) before being split and 
supplemented with either arabinose (final concentration of 0.2% (w/v)) or 
arabinose and IPTG (final concentration 1mM) or IPTG only (final concentration 
1mM) or glucose (final concentration of 0.2% (w/v)). The OD and number of 
culturable cells were monitored for three hours (Figure 5.9) 
Induction of toxin BPSS0390 expression resulted in a rapid decrease in the 
number of culturable cells, whereas both glucose repression and antitoxin only 
expression (IPTG) resulted in an increase in culturable cells and growth rate. 
However, co-expression of BPSS0390 and BPSS1583 (arabinose and IPTG) 
resulted in a rapid decrease in the number of culturable cells, similar to the 
toxin-only control. This suggests that in this assay, antitoxin BPSS1583 was not 
able to neutralise toxin BPSS0390. 
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Figure 5.9: Co-expression of genes BPSS0390 and BPSS1583 in E. coli 
ΔhipBA pBAD/his-BPSS0390 pME6032-BPSS1583. a) Change in OD ; b)  
change in number of culturable cells after induction of either toxin expression 
(arabinose), or toxin and antitoxin expression (arabinose and IPTG), or  antitoxin 
expression (IPTG) or repression of toxin expression (glucose) in cultures of E. coli 
MG1655 ΔhipBA harbouring pBAD/his-BPSS0390 and pME6032-BPSS1583 . Data 
shown represents three biological repeats and error bars represent SEM. 
 
 
a) 
b) 
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5.5 Co-expression of antitoxin gene BPSS0391 (homologous 
with hicB) with BPSS1584 (homologous to hipA) 
E. coli MG1655 ΔhipBA  pME6032-BPSS0391 competent cells were  
transformed with pBAD/his-BPSS1584 by heat shock and transformants 
selected by plating onto LB agar plates with ampicillin (100 µg/ml), tetracycline 
(15 µg/ml) and glucose (2%(w/v)).   
E. coli MG1655 ΔhipBA  pBAD/his-BPSS1584  pME6032-BPSS0391 culture 
was grown until early log phase (OD590 ~ 0.1) before being split and 
supplemented with either arabinose (final concentration of 0.2% (w/v)) or 
arabinose and IPTG (final concentration 1mM) or IPTG only (final concentration 
1mM) or glucose (final concentration of 0.2% (w/v)). The OD and number of 
culturable cells were monitored for three hours (Figure 5.10) 
Repression of toxin BPSS1584 expression resulted in over a 10-fold increase in 
the number of culturable cells and the cells continued to grow. Induction of 
antitoxin BPSS0391 also allowed an over 10-fold increase in the number of 
culturable cells. However, induction of toxin BPSS1584 expression resulted in a 
10-fold decrease in the number of culturable cells, as did induction of both toxin 
BPSS1583 and antitoxin BPSS0391 suggesting that antitoxin BPSS0391 was 
not able to neutralise BPSS1583 in this assay. 
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Figure 5.10: Co-expression of genes BPSS1584 and BPSS0391 in E. coli 
ΔhipBA pBAD/his-BPSS1584 pME6032-BPSS0391. a) Change in OD; b) 
change in number of culturable cells after either: induction of toxin expression 
(arabinose), or toxin and antitoxin expression (arabinose and IPTG), or antitoxin 
expression (IPTG) or repression of toxin expression (glucose) in cultures of E. coli 
MG1655 ΔhipBA harbouring pBAD/his-BPSS1584 and pME6032-BPSS0391. Data 
shown represents three biological repeats and error bars represent SEM. 
 
 
 
 
a) 
b) 
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5.6 Co-expression of toxin genes from one system with 
antitoxin genes from a different system but the same family 
5.6.1. Co-expression of BPSL0175 (homologous to relE) and 
BPSS1061 (homologous to relB) 
E. coli MG1655 ΔhipBA  pME6032-BPSS1061 competent cells were  
transformed with pBAD/his-BPSL0175 by heat shock and transformants 
selected by plating onto LB agar plates with ampicillin (100 µg/ml), tetracycline 
(15 µg/ml) and glucose (2% (w/v)).  A culture of E. coli MG1655 ΔhipBA 
pBAD/his-BPSL0175 pME6032-BPSS1061 was grown until an early log phase 
(OD590 ~ 0.1) and the culture split. Cultures were supplemented with either: 
arabinose (final concentration of 0.2% (w/v)) to induce toxin expression, or 
glucose (final concentration of 0.2% (w/v)) to repress toxin expression or IPTG 
(final concentration 1mM) to induce antitoxin expression, or arabinose and IPTG 
to induce toxin and antitoxin expression. Changes in OD and culturable cells 
were monitored over three hours (Figure 5.11). 
When BPSL0175 toxin expression was repressed, there was a 10-fold increase 
in both the OD and the number of culturable cells. Addition of only IPTG 
resulted in growth similar to glucose-repression. Induction of BPSL0175 
expression resulted in a smaller increase in the number of culturable cells.  
When both BPSL0175 and BPSS1061 expression was induced there was a 
slight increase in the number of culturable cells, similar to the toxin only control. 
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Figure 5.11: Co-expression of genes BPSL0175 and BPSS1061 in E. coli 
ΔhipBA pBAD/his-BPSL0175 pME6032-BPSS1061. a) Change in OD; b)  
change in number of culturable cells after induction of either toxin expression 
(arabinose), or toxin and antitoxin expression (arabinose and IPTG), or  antitoxin 
expression (IPTG) or repression of toxin expression (glucose) in cultures of E. coli 
MG1655 ΔhipBA harbouring pBAD/his-BPSL0175 and pME6032-BPSS1061. Data 
shown represents three biological repeats and error bars represent SEM. 
 
 
a) 
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5.6.2 Co-expression of BPSL0174 (homologous to relB) and 
BPSS1060 (homologous to relE) 
E. coli MG1655 ΔhipBA  pME6032-BPSL0174 competent cells were  
transformed with pBAD/his-BPSS1060 by heat shock and transformants 
selected by plating onto LB agar plates with ampicillin (100 µg/ml), tetracycline 
(15 µg/ml) and glucose (2% (w/v)).  A culture of E. coli MG1655 ΔhipBA 
pBAD/his-BPSS1060 pME6032-BPSL0174 was grown until an early log phase 
(OD590 ~ 0.1) and the culture split and supplemented with either: arabinose 
(final concentration of 0.2% (w/v)) to induce toxin expression, or glucose (final 
concentration of 0.2% (w/v)) to repress toxin expression or IPTG (final 
concentration 1mM) to induce antitoxin expression, or arabinose and IPTG to 
induce toxin and antitoxin expression. Changes in OD and culturable cells were 
monitored over three hours (Figure 5.12). 
Repression of BPSS1060 expression resulted in 10-fold increase in culturable 
cells and increased OD as the cells continued to grow. When IPTG was added 
to induce antitoxin BPSL0174 expression, growth was also observed. Only a 
small increase in the number of culturable cells was observed when toxin 
BPSS1060 expression was induced, regardless of antitoxin BPSL0174 
expression.  
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Figure 5.12: Co-expression of genes BPSS1060 and BPSL0174 in E. coli 
ΔhipBA pBAD/his-BPSS1060 pME6032-BPSL0174. a) Change in OD; b)  
change in number of culturable cells after induction of either toxin expression 
(arabinose), or toxin and antitoxin expression (arabinose and IPTG), or  antitoxin 
expression (IPTG) or repression of toxin expression (glucose) in cultures of E. coli 
MG1655 ΔhipBA harbouring pBAD/his-BPSL0175 and pME6032-BPSS1061 . Data 
shown represents three biological repeats and error bars represent SEM. 
 
 
 
 
a) 
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5.6 Discussion 
In silico methods  are frequently used to predict new TA systems, but 
confirmation of functionality is only possible by experimental validation (Guo et 
al. 2016; Bustamante et al. 2014; Zheng et al. 2015; Makarova et al. 2009). 
Typically, this involves over-expression of candidate toxin genes in either the 
native host species or in E. coli, and monitoring for changes in bacterial growth. 
Butt et al. (2013) designed an antibiotic- free expression system that allowed for 
both independent and co-expression of predicted TA genes. In this system, 
candidate toxin genes were cloned into the arabinose- inducible pBAD vector 
and candidate antitoxin genes into the IPTG inducible pME6032 vector. Toxin 
expression was induced by arabinose (0.2% (w/v)) and/or antitoxin expression 
induced by IPTG (25mM) and number of culturable cells monitored for 2 hours. 
When a growth phenotype was observed it was assumed that the candidate 
toxin had been sequestered by the candidate antitoxin. I demonstrated that the 
toxic phenotype associated with toxin overexpression in E. coli was completely 
abolished when media was supplemented with 25mM IPTG and so I suggest 
that the growth observed in the co-expression assay of Butt et al. (2013) was a 
result of IPTG inhibiting the PBAD arabinose promoter and preventing toxin 
expression, not sequestration of the toxin by the antitoxin. 
The interaction between IPTG and the PBAD arabinose promoter is not well 
recognised and the mechanisms for this interaction are unclear. Activity from 
the PBAD promoter is reduced in the presence of even low concentrations of 
IPTG, although the reduction is dependent on the relative concentrations of the 
two inducers within the cell (Lee et al. 2007). The PBAD arabinose promoter 
system is regulated by dimeric AraC protein. In the absence of arabinose, AraC 
creates a DNA loop that prevents transcription by binding at two half sites on 
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the DNA. When arabinose is present, AraC is no longer able to bind to this site 
so releases the DNA loop, permitting transcription. The D-galactose moiety in 
IPTG has an identical ring structure to L-arabinose and so it is possible that 
IPTG could bind to AraC (Schleif 2010), although mutations in AraC that reduce 
IPTG inhibition are found both inside and outside the arabinose binding pocket 
suggesting that other parts of the IPTG molecule may also be involved (Lee et 
al. 2007).  
To overcome this interaction it was necessary to reduce the concentration of 
IPTG used for induction of expression, although other groups have reported 
success using higher concentrations of arabinose (Coray 2014) or expression 
vectors that encoded IPTG- insensitive versions of AraC (Lee et al. 2007; 
Kasari et al. 2013).  
For future work, it would be better to generate a different co-expression system 
to validate candidate genes. The optimised co-expression system did not allow 
for higher concentrations of IPTG inducer to be used to generate a greater 
amount of antitoxin, due to the interaction between IPTG and the PBAD 
arabinose promoter. It was not possible to examine crosstalk between non-
cognate pairs in vivo.  
There are many limitations to generating a new system; suitable plasmids must 
occupy different incompatibility groups, harbour different antibiotic resistant 
cassettes and there can be no crosstalk between promoters and inducers. 
Despite this other co-expression systems could be produced: firstly the toxin 
and antitoxin separately and the entire TA encoding region could be cloned into 
separate copies of same vector (Guo et al. 2016; Yao et al. 2015). This would 
not allow for separate inducement of the two candidate genes but would allow 
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for consistent transcription in response to inducer.  Secondly, both the toxin and 
antitoxin candidate genes could be cloned into different multiple cloning sites on 
a pETDuet-1 vector (Merfa et al. 2016) or into a newly generated vector 
containing two promoters on the same backbone (Zheng et al. 2015). Finally, 
existing constructs could be used to create a hybrid promoter, which would 
allow for more efficient transcription at lower concentrations of inducer 
(Comstock 1983). A reverse genetics approach, where in-frame deletions are 
created in each operon and candidate TA gene, could also be used to examine 
crosstalk between in vivo, although this method is limited if the antitoxins are 
essential to cell survival (Fiebig et al. 2010). 
In this study, crosstalk was not observed between any of the non-cognate pairs 
of TA systems tested. It is not surprising that RelB1, RelB2 antitoxin and HipB 
antitoxins were not able to neutralise toxin HicA. Structurally neither RelB nor 
HipB are similar to HicB. RelB has a ribbon-helix-helix (RHH) at its N-terminus 
and associates with RelE to form an open v-shaped heterotetramer (Overgaard 
et al. 2009; Bøggild et al. 2012), whilst HipB also forms a heterotetramer with 
HipA, it binds HipA far from its active site and its interaction with DNA is via a 
helix -turn-helix (HTH) (Schumacher et al. 2009; Chan et al. 2016).  A HicB 
homologue isolated from Y. pestis was determined to have a N-terminal domain 
that binds to the active site of HicA, forming a tetramer capable of binding two 
HicA toxin molecules, whilst the DNA binding domain was located at the C-
terminus and folded as a RHH (Bibi-Triki et al. 2014). Previously there has been 
some reported evidence of across family interactions between VapB and MazF, 
and VapC and MazE, in M. tuberculosis; pull down experiments demonstrated 
physical interactions between toxins and non-cognate antitoxins. However, 
functional confirmation relied on a co-expression system using an arabinose- 
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inducible plasmid and an IPTG-inducible plasmid and so perhaps the interaction 
observed was between IPTG and PBAD arabinose-inducible promoter rather than 
TA proteins (Zhu et al. 2010). 
More surprising is the apparent lack of crosstalk in this study between the 
RelBE systems, BPSS1060-1061 and BPSL0174-0175, two systems 
considered paralogous with 98% identity (Butt 2013). With such high similarity, 
it would be expected that an antitoxin from one system would be able to 
neutralise the toxin from a second system. Indeed, non-cognate interactions 
within the same family have previously been observed in pathogenic E. coli 
O157:H7, which has two homologues of the ccd TA system, one plasmid-borne, 
ccdF, and one located on the chromosome, ccdO157.  Experiments examining 
cross-interaction between the two systems revealed that both the 
chromosomally encoded toxin and the toxin encoded by the plasmid could be 
neutralised by the plasmid encoded antitoxin (although the chromosomal 
antitoxin could not sequester the plasmid encoded toxin) (Wilbaux et al. 2007). 
However, several studies have examined interactions between non-cognate 
pairs of VapB/VapC and found that neutralisation of the toxin was only possible 
using the cognate pair (Ramage et al. 2009; Ahidjo et al. 2011).  One study 
examining interactions between non-cognate pairs of all 14 TA systems 
identified in V. cholerae concluded that there were no cross-interactions, even 
in non-cognate pairs within the same type II family. Almost all of these TA 
systems were located on a superintegron, and so the group theorised that the 
main role of the systems was stabilising the superintegron (Iqbal, Krin, et al. 
2015). Within the B. pseudomallei genome, BPSS0390-0391 is located on 
genomic island (GI) 15, BPSL0174-0175 on GI2 and BPSS1060-1061 on GI13 
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(Holden et al. 2004). One of the roles these TA systems may be to stabilise the 
B. pseudomallei genome.  
Potential negative effects have also been linked to cross-interaction between 
different systems. Interaction between one antitoxin and multiple toxins from 
different systems would change the ratio of toxin: antitoxin leading to an excess 
of free toxin capable of inducing growth arrest (Park et al. 2013; Goeders & 
Melderen 2014).  Cross-interactions have also been linked to TA system 
degradation (Goeders & Melderen 2014).  
Alternatively, the lack of crosstalk observed between all the non-cognate pairs 
tested in this study might indicate that the non-cognate antitoxin was not 
expressed in the co-expression assay. The co-expression assay used for this 
study was optimised to the cognate TA system BPSS0390-BPSS0391 and 
concentrations of inducer could not exceed 1mM, without potentially inhibiting 
toxin expression. Whilst induction of toxin expression in response to the addition 
of arabinose was not definitively confirmed, a toxic phenotype was always 
observed. However, the toxic phenotype observed after co-expression of the 
non-cognate pair coupled with the lack of definitive confirmation of expression 
of the antitoxin (after addition of IPTG) undermines this study; it may be that 
there was no neutralisation because there was no antitoxin protein present in 
the assay. To validate these results, this co-expression assay should be tested 
using the cognate TA pairs BPSS1583-BPSS1584, BPSS1060-BPSS1061 and 
BPSL0174-BPSL0175. If a neutralisation phenotype (or absence of a toxic 
phenotype) is observed using the other cognate pairs, then it is likely that 
antitoxin is expressed in response to 1mM IPTG and these results are a true 
negative. Confirmation of expression of both the toxin and antitoxin proteins 
should also be sought, perhaps using quantitative real-time PCR to quantify 
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expression.  A poly-histidine tag could also be incorporated into the antitoxin 
protein to allow for Western blotting but this would also require confirmation that 
the tag did not alter protein structures or interfere with binding affinities. 
Although there is currently no evidence for protein cross-interactions between 
chromosomal non-cognate pairs in B. pseudomallei K96423, there is evidence 
to suggest that TA systems may form networks that facilitate adaption to the 
host environment. In Enterococcus faecalis, MazE and MazEF (type II system) 
function as autorepressors and activate RatA, the antitoxin in the type I TA 
system txpS-ratA (Wessner et al. 2015). Type II TA toxins can trans-activate 
other TA systems by relieving transcriptional regulation and degrading freshly 
generated antitoxin encoding mRNA (Wang et al. 2014; Kasari et al. 2013). 
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Chapter 6: Summary 
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This study had three broad aims: to evaluate B. pseudomallei toxin BPSS0390 
as a potential antimicrobial compound, to identify residues in BPSS0390 
involved in toxicity and BPSS0390-BPSS0391 complex formation and to 
determine if TA antitoxins in B. pseudomallei can neutralise non-cognate toxins 
from different type II systems to form a co-operative network. 
Induction of expression of toxin BPSS0390 in all of the species tested resulted 
in a decrease in the number of culturable cells. Even in species with partial 
antitoxin homologues this decrease was remarkable (2 log and 3 log). In B. 
thailandensis, the activity of BPSS0390 was lowered, likely due to the presence 
of a homologue with 99% identity. Induction of expression of BPSS0390 in E. 
coli resulted in the formation of escape mutants, unless expression was actively 
repressed. 
Site-directed mutagenesis of BPSS0390 identified 20 residues required for 
toxicity in E. coli. Most of these residues are undoubtedly critical for maintaining 
correct folding of the protein. The structure of the dsRBD like fold of BPSS0390 
closely resembled the canonical dsRBD of many other proteins. It was 
interesting that none of the lysines in the BPSS0390 molecule were critical for 
function. It was disappointing that no residues involved in TA complex formation 
could be identified, but not unexpected. BPSS0390 is a small molecule and 
typically TA antitoxins bind toxins at the active site (M. a Schumacher et al. 
2009) so any molecules required for toxicity may be required for antitoxin 
binding also. 
Finally, there was no interaction between BPSS0390 and any non-cognate 
antitoxin. No interactions were observed between any of the non-cognate pairs 
tested. This is no surprising as TA systems rely on specificity for many of their 
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biological putative functions. However, this study did highlight the need for 
improved tools for examining interactions between TA components. 
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Table to show sequences of primers used for site-directed mutagenesis of HicA: 
 
Primer name Sequence 
H29A_FOR ggcttcttgggggctttgaaatgatgatggctgcctg 
H29A_REV caggcagccatcatcatttcaaagcccccaagaagcc 
H40A_FOR aggtccttcttcggggcgggaaccgtcacaag 
H40A_REV cttgtgacggttcccgccccgaagaaggacct 
W15A_FOR cactcgaaccaacctcgcgccatcttcctcaagc 
W15A_REV gcttgaggaagatggcgcgaggttggttcgagtg 
P46A_FOR cagtcccaatcgctaggtccttcttcggg 
P46A_REV cccgaagaaggacctagcgattgggactg 
S3A_FOR cggatcagcttcgatgcgttcatgagctcggatcc 
S3A_REV ggatccgagctcatgaacgcatcgaagctgatccg 
H25A_FOR ggggtgtttgaaatgagcatggctgcctgtcactcgaac 
H25A_REV gttcgagtgacaggcagccatgctcatttcaaacacccc 
S23A_FOR gttggttcgagtgacaggcgcccatcatcatttcaaacac 
S23A_REV gtgtttgaaatgatgatgggcgcctgtcactcgaaccaac 
G34A_FOR gaaccgtcacaagggctggcttcttgggg 
G34A_REV ccccaagaagccagcccttgtgacggttc 
V36A_FOR gtggggaaccgtcgcaaggcctggctt 
V36A_REV aagccaggccttgcgacggttccccac 
D44_FOR gtcccaatcggtagggccttcttcgggtgg 
D44_REV ccacccgaagaaggccctaccgattgggac 
T49A_FOR ctggatgctttttacagccccaatcggtaggtcc 
T49A_REV ggacctaccgattggggctgtaaaaagcatccag 
I53A_FOR ggccggcggatttctgggcgctttttacagtcccaatc 
I53A_REV gattgggactgtaaaaagcgcccagaaatccgccggcc 
T37A_FOR ggtggggaaccgccacaaggcctgg 
T37A_REV ccaggccttgtggcggttccccacc 
P46A_FOR cagtcccaatcgctaggtccttcttcggg 
P46A_REV cccgaagaaggacctagcgattgggactg 
G22A_FOR gaaatgatgatggctggctgtcactcgaaccaac 
G22A_REV gttggttcgagtgacagccagccatcatcatttc 
P41A_FOR gtaggtccttcttcgcgtggggaaccgtc 
P41A_REV gacggttccccacgcgaagaaggacctac 
G14A_FOR cgaaccaacctccaggcatcttcctcaagcatc 
G14A_REV gatgcttgaggaagatgcctggaggttggttcg 
H24A_FOR gggtgtttgaaatgatgagcgctgcctgtcactcgaac 
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H24A_REV gttcgagtgacaggcagcgctcatcatttcaaacaccc 
A57G_FOR cgaattctcacaggccgccggatttctggatgc 
A57G_REV gcatccagaaatccggcggcctgtgagaattcg 
G58A_FOR cgaattctcacagggcggcggatttctgg 
G58A_REV ccagaaatccgccgccctgtgagaattcg 
N2A_FOR ggatcagcttcgatgaggccatgagctcggatcccc 
N2A_REV ggggatccgagctcatggcctcatcgaagctgatcc 
S4A_FOR gatcagcttcgctgagttcatgagctcggatcc 
S4A_REV ggatccgagctcatgaactcagcgaagctgatc 
K5A_FOR caagcatccggatcagcgccgatgagttcatgagctc 
K5A_REV gagctcatgaactcatcggcgctgatccggatgcttg 
L6A_FOR cctcaagcatccggatcgccttcgatgagttcatgag 
L6A_REV ctcatgaactcatcgaaggcgatccggatgcttgagg 
I7A_FOR cttcctcaagcatccgggccagcttcgatgagttcatg 
I7A_REV catgaactcatcgaagctggcccggatgcttgaggaag 
R8A_FOR ccatcttcctcaagcatcgcgatcagcttcgatgag 
R8A_REV ctcatcgaagctgatcgcgatgcttgaggaagatgg 
M9A_FOR gccatcttcctcaagcgcccggatcagcttcgatg 
M9A_REV catcgaagctgatccgggcgcttgaggaagatggc 
L10A_FOR ccagccatcttcctcagccatccggatcagcttc- 
L10A_REV gaagctgatccggatggctgaggaagatggctgg 
E11A_FOR ctccagccatcttccgcaagcatccggatc 
E11A_REV gatccggatgcttgcggaagatggctggag 
E12A_FOR cctccagccatctgcctcaagcatccgg 
E12A_REV ccggatgcttgaggcagatggctggagg 
D13A_FOR ggatgcttgaggaagctggctggaggttgg 
D13A_REV ccaacctccagccagcttcctcaagcatcc 
R16A_FOR ctgtcactcgaaccaacgcccagccatcttcctc 
R16A_REV gaggaagatggctgggcgttggttcgagtgacag 
L17_FOR gcctgtcactcgaaccgccctccagccatcttcc 
L17_REV ggaagatggctggagggcggttcgagtgacaggc 
V18A_FOR gcctgtcactcgagccaacctccagcc 
V18A_REV ggctggaggttggctcgagtgacaggc 
R19_FOR ctgcctgtcactgcaaccaacctccagccatc 
R19_REV gatggctggaggttggttgcagtgacaggcag 
V20A_FOR gatggctgcctgtcgctcgaaccaacctc 
V20A_REV gaggttggttcgagcgacaggcagccatc 
T21A_FOR gatgatggctgcctgccactcgaaccaacc 
T21A_REV ggttggttcgagtggcaggcagccatcatc 
H26A_FOR cttcttggggtgtttgaaagcatgatggctgcctgtcac 
H26A_REV gtgacaggcagccatcatgctttcaaacaccccaagaag 
F27A_FOR ggcttcttggggtgtttggcatgatgatggctgcctg 
F27A_REV caggcagccatcatcatgccaaacaccccaagaagcc 
K28A_FOR ggcttcttggggtgtgcgaaatgatgatggctgcctg 
K28A_REV caggcagccatcatcatttcgcacaccccaagaagcc 
P30A_FOR caaggcctggcttcttggcgtgtttgaaatgatgatgg 
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P30A_REV ccatcatcatttcaaacacgccaagaagccaggccttg 
K31A_FOR catcatttcaaacaccccgcgaagccaggccttgtgac 
K31A_REV gtcacaaggcctggcttcgcggggtgtttgaaatgatg 
K32A_FOR ccgtcacaaggcctggcgccttggggtgtttgaaatg 
K32A_REV catttcaaacaccccaaggcgccaggccttgtgacgg 
P33A_FOR cgtcacaaggcctgccttcttggggtg 
P33A_REV caccccaagaaggcaggccttgtgacg 
L35A_FOR ggggaaccgtcacagcgcctggcttcttgg 
L35A_REV ccaagaagccaggcgctgtgacggttcccc 
V38A_FOR cttcgggtggggagccgtcacaaggcc 
V38A_REV ggccttgtgacggctccccacccgaag 
P39A_FOR cttcgggtgggcaaccgtcacaaggcc 
P39A_REV ggccttgtgacggttgcccacccgaag 
K42A_FOR cggtaggtccttcgccgggtggggaaccg 
K42A_REV cggttccccacccggcgaaggacctaccg 
K43A_FOR ccaatcggtaggtccgccttcgggtggggaac 
K43A_REV gttccccacccgaaggcggacctaccgattgg 
L45A_FOR cagtcccaatcggtgcgtccttcttcgggtgg 
L45A_REV ccacccgaagaaggacgcaccgattgggactg 
I47A_FOR gatgctttttacagtcccagccggtaggtccttcttcggg 
I47A_REV cccgaagaaggacctaccggctgggactgtaaaaagcatc 
G48A_FOR ggatgctttttacagtcgcaatcggtaggtccttc 
G48A_REV gaaggacctaccgattgcgactgtaaaaagcatcc 
V50A_FOR gatttctggatgctttttgcagtcccaatcggtagg 
V50A_REV cctaccgattgggactgcaaaaagcatccagaaatc 
K51A_FOR ggatttctggatgcttgctacagtcccaatcggtaggtccttc 
K51A_REV gaaggacctaccgattgggactgtagcaagcatccagaaatcc 
S52A_FOR cggatttctggatggcttttacagtcccaatcggtaggtcc 
S52A_REV ggacctaccgattgggactgtaaaagccatccagaaatccg 
Q54A_FOR ggccggcggatttcgcgatgctttttacagtccc 
Q54A_REV gggactgtaaaaagcatcgcgaaatccgccggcc 
K55A_FOR ctcacaggccggcggatgcctggatgctttttacag 
K55A_REV ctgtaaaaagcatccaggcatccgccggcctgtgag 
S56A_FOR caggccggcggctttctggatgctttttacag 
S56A_REV ctgtaaaaagcatccagaaagccgccggcctg 
L59A_FOR ccagaaatccgccggcgcgtgagaattcgaagc 
L59A_REV gcttcgaattctcacgcgccggcggatttctgg 
Q54G_FOR ggccggcggatttcccgatgctttttacagtccc 
Q54G_REV gggactgtaaaaagcatcgggaaatccgccggcc 
 
 
 
 
269 
 
 
 
